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Cardiovascular	   disease	   (CVD),	  which	   include	  hypertension,	   coronary	   heart	  
disease	   (CHD),	   stroke,	   and	   congestive	   heart	   failure	   (CHF),	   are	   the	   leading	  
and	   most	   common	   causes	   of	   mortality	   in	   both	   developing	   and	  
industrialized	  countries,	  accounting	  for	  one	  third	  of	  all	  deaths	  globally.	  
Cardiomyocyte	   regeneration	   is	   limited	   in	   adult	   life	   and	   therefore	   the	  
identification	   of	   a	   putative	   source	   of	   progenitors	   is	   of	   great	   interest	   to	  
provide	   usable	   in	   vitro	   models	   and	   new	   perspectives	   for	   regenerative	  
therapies.	  This	  appears	  to	  be	  a	  challenge	  due	  to	  the	  peculiar	  functional	  and	  
anatomical	   heart	   properties.	   The	   goal	   of	   this	   project	  was	   to	   differentiate	  
adult	   human	   Adipose	   tissue-­‐derived	   multipotent	   Stem	   Cells	   (ASCs)	   into	  
cardiomyocytes	   or	   their	   close	   progenitors.	   Thus,	   the	   ultimate	   aim	   is	   to	  
develop	   stem	   cell-­‐based	   therapies	   for	   the	   cure	   of	   cardiovascular	   disease.	  
More	   specifically,	   we	   investigated	   the	   application	   of	   two	   innovative	  
approaches:	  the	  use	  of	  human	  growth	  factors	  in	  a	  well	  defined	  serum-­‐free	  
culture	  medium	  and	  the	  application	  of	  electrical	  and	  mechanical	  stimuli	  to	  
mimic	  the	  physiological	  environment	  of	  the	  heart.	  	  
First	  of	  all,	  we	  developed	  a	  new	  protocol	  for	  the	  isolation	  of	  ASCs	  according	  
with	   the	   standard	   GMP-­‐procedure,	   which	   allows	   to	   extract	   a	   substantial	  
number	  of	  cells	  for	  clinical	  application.	  The	  starting	  material	  was	  obtained	  
from	  subcutaneous	  adipose	   tissue	   collected	  during	  an	  elective	   liposuction	  
procedure.	   The	   isolated	   ASCs	   were	   characterized	   by	   flow	   cytometry	   and	  
expanded	   until	   second	   passage.	   Several	   different	   cocktails	   of	   growth	  
factors,	   cytokines	   and	   several	   culture	   conditions	   were	   tested	   for	   their	  
ability	   to	   induce	   cardiomyogenesis.	   The	   goal	   was	   to	   identify	   the	   right	  
combination	   of	   those	   factors	   and	   their	   time	   of	   application.	   One	   of	   the	  
cardiogenic	   cocktails	   tested	   was	   indeed	   very	   effective	   in	   inducing	   the	  
selected	  cardiac	  markers	  (e.g.	  NKX2-­‐5	  and	  MEF2C)	  and	  was	  chosen	  for	  the	  
second	  part	  of	  this	  research	  work.	  The	  differentiation	  obtained	  was	  highly	  
reproducible,	   as	   it	   was	   observed	   in	   15	   out	   of	   15	   samples	   from	   different	  
patients.	   Interestingly,	   non	   induced	   ASCs	   expressed	   half	   of	   the	   selected	  




intrinsic	  potential	  and	  the	  inherent	  propensity	  of	  ASCs	  to	  differentiate	  into	  
cardiac	   precursors.	   We	   further	   analysed	   the	   morphological	   changes	   that	  
ASCs	  underwent	  during	  their	  differentiation	  by	  use	  of	  electron	  microscopy	  
and	   immunofluorescence	   staining.	   By	   treating	   the	   cells	   with	   our	   selected	  
induction	   cocktail,	   clear	   changes	   in	   their	  morphology	  were	   observed:	   the	  
cells	  assumed	  a	  fusiform	  shape	  and	  became	  oriented.	  	  
The	   last	   milestone	   was	   to	   understand	   if	   the	   combination	   of	   the	   cardiac	  
induction	  cocktail	  with	  a	  mechanical	  (and	  eventually	  electrical)	  stimulation	  
on	   a	   scaffold	  would	   increase	   the	   efficiency	   of	   cardiogenic	   differentiation.	  
For	   this,	   a	   customized	  device	   has	   been	  developed	  by	   the	   Swiss	   Stem	  Cell	  
Foundation	   in	   collaboration	   with	   Scuola	   Universitaria	   Professionale	   della	  
Svizzera	  Italiana	  (SUPSI)	  for	  the	  application	  of	  controlled	  mechanical	  and/or	  
electrical	  stimuli	  to	  a	  scaffold	  over	  a	  desired	  lap	  of	  time.	  The	  scaffolds	  used	  
were	   developed	   and	   characterized	   by	   Prof.	   Ciardelli’s	   Research	   Group	  
(Materials	   in	   Bionanotechnology,	   Department	   of	   Mechanical	   and	  
Aerospace	   Engineering,	   Politecnico	   di	   Torino).	   The	   preliminary	   results	  
showed	  that	  the	  combination	  of	  growth	  factors,	  cytokines	  and	  mechanical	  
stimulation	   for	   10	   days	   led	   to	   an	   at	   least	   2	   fold	   increase	   in	   mRNA	  
expression	   of	   NKX2-­‐5,	   MEF2C,	   HAND2	   and	   MHC	   when	   compared	   to	   the	  
induction	  with	  cardiogenic	  cocktail	  alone	  on	  a	  simple	  2D	  culture	  condition.	  
In	  conclusion,	  in	  this	  work	  we	  present	  a	  new	  protocol	  for	  the	  extraction	  of	  
ASCs	   starting	   from	   adipose	   lipoaspirates,	   a	   new	   serum-­‐free	   based	  
cardiogenic	   induction	   cocktail	   for	   ASCs	   and	   preliminary	   data	   about	   the	  
differentiation	   in	   scaffold	   enhanced	   by	  mechanical	   stimulation	   opening	   a	  







5-­‐AZA:	  	   5-­‐azacytidine	  
ACTC1:	  	   Cardiac	  α-­‐actin	  
ASCs:	  	   Adipose	  derived	  stem	  cells	  
AT:	  	   Adipose	  tissue	  
βFGFR:	  	   Basic	  fibroblast	  growth	  factor	  receptor	  
BM:	  	   Bone	  marrow	  
BMPs:	  	   Bone	  morphogenetic	  proteins	  
BV:	  	   Blood	  vessel	  
CAL:	  	   Cell-­‐assisted	  lipotransfer	  
CAMTA:	  	  Calmodulin	  binding	  transcription	  activator	  2	  
CDs:	  	   Clusters	  of	  differentiation	  
CFU-­‐Fs:	  	  Colony-­‐forming	  unit-­‐fibroblasts	  
CHD:	  	   Coronary	  heart	  disease	  
CHF:	  	   Congestive	  heart	  failure	  
CPCs:	  	   Cardiac	  progenitors	  cells	  
CSCs:	  	   Cardiac	  stem	  cells	  
CVD:	  	   Cardiovascular	  diseases	  
DAPI:	  	   4’,	  6-­‐diamidino-­‐2-­‐phenylindole,	  dihydrochloride	  
DC:	  	   Differentiated	  support	  cells	  
DKK1:	  	   Divkkopf-­‐1	  	  	  
ECM:	  	   Extracellular	  matrix	  
EGFR:	  	   Epidermal	  growth	  factor	  receptor	  
ESCs:	  	   Embryonic	  stem	  cells	  
FACS:	  	   Fluorescence-­‐Activated	  Cell	  Sorter	  
FGFs:	  	   Fibroblast	  growth	  factors	  
FOG:	  	   Friend	  of	  Gata	  
G-­‐CSF:	  	  	  	  Granulocyte	  colony	  stimulating	  factor	  
Glu:	  	   Glutamine	  
GvHD:	  	   Graft-­‐versus-­‐host	  disease	  
HLA:	  	   Human	  leukocytes	  antigen	  
HSCs:	  	   Hematopoietic	  stem	  cells	  
ICM:	  	   Inner	  cell	  mass	  
IFNγ: 	  	   Interferon-­‐γ 
IGF:	  	   Insulin	  like	  growth	  factor	  	  
IL:	  	   Interleukin	  
iPS:	  	   Induced	  pluripotent	  stem	  cells	  
ITS:	  	   Insulin,	  Transferrin	  and	  Selenium	  




klf4:	  	   Krupple-­‐like	  family	  transcription	  factor	  4	  
LIF:	  	   Leukemia	  inhibitory	  factor	  
LVEF:	  	   LV	  ejection	  fraction	  
LVR:	  	   Left	  ventricle	  remodelling	  
MEF2C:	  	  Myocyte	  enhancer	  factor	  2	  c	  
MI:	  	   Myocardial	  infarction	  
MNCs:	  	   Mononucleated	  cells	  
MSCs:	  	   mesenchymal	  stem	  cells	  
MYL2:	  	   Myosin	  light	  chains	  
MYL6:	  	   α-­‐myosin	  heavy	  chain	  
Nanog:	  	   Nanog	  homeobox	  
NCX:	  	   Sodium-­‐Calcium	  Exchanger	  
NOD:	  	   Non-­‐obese	  diabetic	  
Oct4:	  	   Octamer-­‐4	  
PCL:	  	   Polye	  caprolactone	  
PDGF:	  	   Platelet	  –derived	  growth	  factor	  
PGA:	  	   Polyglycolide	  
PLA:	  	   Polylactide	  
PURs:	  	   Polyurethanes	  
RT:	  	   Room	  temperature	  
SEM:	  	   Scanning	  electron	  microscopy	   	  
SERCA-­‐2:	  Sarco/Endoplasmic	  Reticulum	  Ca2+-­‐ATPase	  
Sox2:	  	   Sox	  determining	  region	  Y-­‐box	  2	  
SR:	  	   Sarcoplasmic	  reticulum	  
SSEA-­‐4:	  	  Stage	  specific	  embryonic	  antigen	  4	  
SVF:	  	   Stromal	  vascular	  fraction	  
TBX:	  	   T-­‐box	  
TEM:	  	   Transmission	  electron	  microscopy	  
TERM:	  	   Tissue	  engineering/regenerative	  medicine	  
TGF-­‐β: 	  	   Transforming	  growth	  factors	  b	  
TGFR1:	  	   Trasforming	  growth	  factor	  receptor	  
TNFa:	  	   Tumor	  necrosis	  factor-­‐a	  
TNNI3:	  	   Cardiac	  Troponin	  III	  
UCB:	  	   Umbelican	  cord	  blood	  
VEGF:	  	   Vascular	  endothelial	  growth	  factor	  
Wnt:	  	   Wingless-­‐related	  protein	  
α-­‐SA:	  	   α-­‐sarcomeric	  actin	  






1.1	  Stem	  Cells	  
Stem	  cells	  are	  defined	  as	  unspecialized	  cells	  with	   the	  ability	   to	   self-­‐renew	  
through	  cell	  division	  or	   to	  differentiate	  to	  become	  tissue	  or	  organ	  specific	  
cells	  with	   specialized	   functions	   (Stanford	   and	   Julie,	   2009).	   To	   ensure	   self-­‐
renewal,	  stem	  cells	  undergo	  two	  types	  of	  division.	  Symmetric	  division	  gives	  
rise	   to	   two	   identical	   daughter	   cells,	   both	   endowed	   with	   stem	   cell	  
properties,	  whereas	  asymmetric	  division	  produces	  only	  one	  stem	  cell	  and	  a	  
progenitor	   cell	   with	   limited	   self-­‐renewal	   potential.	   Progenitors	   can	   go	  
through	   several	   rounds	  of	   cell	   division	  before	   finally	  differentiating	   into	   a	  
mature	  cell.	  It	  is	  believed	  that	  the	  molecular	  distinction	  between	  symmetric	  
and	   asymmetric	   division	   lies	   in	   differential	   segregation	   of	   cell	  membrane	  
proteins	  between	  the	  daughter	  cells.	  A	  classification	  of	  stem	  cells	  has	  been	  
compiled	  by	   the	  National	   Institute	  of	  Health	   (National	   Institutes	  of	  Health	  
(U.S.),	   2001).	   Until	   the	   8-­‐cell	   morula	   stage,	   the	   cells	   in	   the	   embryo	   are	  
totipotent	   because	   they	   can	   give	   rise	   to	   all	   the	   tissue	   of	   the	   organism,	  
including	  extra-­‐embryonic	  tissues,	  such	  as	  the	  placenta,	  the	  umbilical	  cord	  
and	   the	   yolk	   sac	   [Fig.	   1].	   The	   cells	   from	   inner	   cell	   mass	   (ICM)	   of	   the	  
blastocyst	   are	   pluripotent,	   with	   the	   capacity	   to	   differentiate	   into	   all	   cell	  
types	   of	   the	   body	   but	   not	   in	   the	   cells	   that	   compose	   the	   extra-­‐embryonic	  
tissue.	  Multipotent	  stem	  cells	  are	  able	  to	  specialize	  only	  in	  certain	  cell	  types	  
and	  the	  unipotent	  stem	  cells	  can	  generate	  only	  one	  type	  of	  specialized	  cell	  
[Fig.	  1].	  The	  progress	   in	   stem	  cell	   research	  has	   raised	  hopes	   for	  novel	   cell	  
therapy	   treatments	   of	   severe	   diseases	   such	   as	   diabetes,	   neurological	  
disorders	  and	  cardiac	  failure.	  	  
1.2	  Pluripotent	  Stem	  Cells	  
1.2.1	  Human	  embryonic	  stem	  cells	  
Embryonic	   stem	   cells	   (ESCs)	   are	   derived	   from	   the	   inner	   cell	   mass	   of	  
mammalian	  blastocysts,	  and	  mouse	  ESCs	  were	  first	  isolated	  in	  1981.	  Human	  
ES	  cells	  derived	  from	  human	  blastocysts	  were	  first	  established	  by	  Thomson	  
and	  co-­‐workers	  in	  1998	  (Thomson	  et	  al.,	  1998).	  




outermost	   cell	   layer	   called	   trophoblast	   surrounds	   the	   blastocyst	   and	   will	  
give	   rise	   to	   the	   extra-­‐embryonic	   tissues,	   the	   internal	   cavity	   or	   blastocoel	  
and	   the	   inner	   cell	   mass,	   a	   group	   of	   approximately	   30	   cells	   within	   the	  
blastocoel,	   destined	   to	   differentiate	   and	   give	   rise	   to	   the	   embryo	   or	   to	  
become	   source	   of	   ESCs.	   Therefore	   ESCs	   are	   pluripotent	   cells	   capable	   of	  
generating	   all	   the	   different	   cell	   types	   of	   the	   body;	   ESCs	   are	   unspecialized	  
cells	   and	   can	   replicate	   indefinitely,	   if	   kept	   under	   appropriate	   conditions.	  
ESCs	   have	   been	   also	   genetically	   manipulated.	   Thanks	   to	   these	  
characteristics,	  these	  cells	  could	  be	  particularly	  useful	  for	  therapeutic	  use	  in	  
an	  attempt	  to	  treat	  certain	  human	  diseases	  in	  which	  cellular	  functions	  are	  
altered	  or	  destroyed.	  
When	   undifferentiated	   hESCs	   are	   capable	   of	   proliferating	   extensively	   in	  
vitro,	   they	   have	   the	   ability	   to	   differentiate	   towards	   all	   three	   germ	   layers	  
and	   they	   can	   give	   rise	   to	   all	   cell	   types	   of	   the	   body.	   Furthermore,	   hESC	  
express	   several	   transcription	   factors	   and	   surface	  markers	   associated	  with	  
the	   non-­‐differentiated	   phenotype,	   such	   as	   Octamer-­‐4	   (Oct4),	   Nanog	  
homeobox	   (Nanog),	   Sox	   determining	   region	   Y-­‐box	   2	   (Sox2)	   and	   Stage	  
specific	  embryonic	  antigen	  4	  (SSEA-­‐4)	  (Boyer	  et	  al.,	  2005).	  Telomerase	  and	  
alkaline	  phosphatase	  activities	  of	  hESCs	  are	  high	  and	  the	  karyotype	  should	  
be	  normal	  and	  remain	  unaltered	  during	  extended	  culture	  periods	  (Hoffman	  








Figure	  1.	  Hierarchy	  of	  Stem	  Cells.	  A	  schematic	  representation	  of	  the	  levels	  of	  staminality	  of	  
stem	  cells.	  The	  cells	  in	  the	  embryo	  until	  the	  8-­‐cell	  morula	  stage	  are	  totipotent;	  the	  cells	  from	  
inner	   cell	  mass	   (ICM)	  of	   the	  blastocyst	   are	  pluripotent;	  multipotent	   stem	  cells	   are	   able	   to	  
specialize	  only	  in	  certain	  cell	  types	  and	  the	  unipotent	  stem	  cells	  can	  generate	  only	  one	  type	  




1.2.2	  Induced	  pluripotent	  stem	  cells	  (iPS	  cells)	  
The	  induced	  pluripotent	  stem	  cells	  (iPS	  cells)	  were	  first	  established	  in	  2006	  
by	   Takahashi	   and	   Yamanaka	   by	   retrovirus-­‐mediated	   transduction	   of	   four	  
transcription	   factors	   (Oct4,	   Sox2,	   c-­‐myc	   and	   Krupple-­‐like	   family	  
transcription	   factor	   4	   -­‐	   klf4)	   into	   mouse	   fibroblasts	   (Takahashi	   and	  
Yamanaka,	  2006).	   These	   reprogrammed	  cells,	  which	  were	   selected	  by	   the	  
expression	   of	   a	   beta-­‐geo	   cassette	   (a	   fusion	   of	   beta-­‐galactosidase	   and	  
neomycin	  resistance	  genes)	  driven	  by	  the	  mouse	  Fbx15	  promoter,	  failed	  to	  
contribute	   to	   adult	   chimeras.	   To	   obtain	   high-­‐quality	   iPS	   cells,	  
reprogrammed	  cells	  were	  selected	  for	   their	  expression	  of	  either	  Nanog	  or	  
Oct3/4	  expression,	  both	  of	  which	  are	   involved	   in	  pluripotency.	  These	  cells	  
successfully	   contributed	   to	   adult	   chimeras	   and	   also	   showed	   germline	  
transmission	  (Fukuda	  and	  Yuasa,	  2013).	  	  
Human	   iPS	   cells	  were	   established	   in	   2007	   (Takahashi	   et	   al.,	   2007)	   by	   the	  
transduction	  of	  either	  the	  same	  set	  of	  transcription	  factors	  or	  another	  set	  
of	   transcription	   factors	   (i.e.	   Oct3/4,	   SOX2,	   Nanog,	   Lin28)	   into	   human	  
fibroblasts	  (Yu	  et	  al.,	  2007).	  These	  human	  iPS	  cells	  are	  similar	  to	  human	  ES	  
cells	   in	   their	   morphology,	   gene	   expression	   and	   epigenetic	   status	   of	  
pluripotent	  cell-­‐specific	  genes.	  Furthermore	  they	  can	  differentiate	  into	  the	  
cell	   types	   of	   the	   three	   germ	   layers	   in	   vitro	   and	   in	   vivo	   (Takahashi	   et	   al.,	  
2007).	  Human	  iPS	  cells	  have	  been	  established	  from	  skin	  fibroblasts	  (Park	  et	  
al.,	   2008),	   keratinocytes	   (Aasen	   et	   al.,	   2008),	   mobilized	   CD34+	  
hematopoietic	  stem-­‐progenitor	  cells	  (Loh	  et	  al.,	  2009)	  and	  differentiated	  T	  
cells	   from	   peripheral	   blood	   (Loh	   et	   al.,	   2010).	   Human	   iPS	   cells	   provide	   a	  
chance	   to	   develop	   new	   treatment	  modalities	   in	   the	   field	   of	   regenerative	  
medicine	  (Yoshida	  and	  Yamanaka,	  2011).	  
	  
1.3	  Multipotent	  stem	  cells	  
1.3.1	  Fetal	  stem	  cells	  	  
Fetal	  stem	  cells	  can	  be	  obtained	  either	  from	  fetus	  or	  from	  extra-­‐embryonic	  
structures	   such	   as	   the	   umbilical	   cord	   blood,	   the	   amniotic	   fluid,	   the	  
Wharton’s	   Jelly,	   the	  amniotic	  membrane	  and	   the	  placenta.	  Umbilical	   cord	  




like	   stem	   cells.	   Transplantation	   of	   UCB	   has	   been	   clinically	   successful	   for	  
hematopoietic	   stem	   applications	   resulting	   in	   high	   degree	   of	   engraftment,	  
favourable	   immunotolerance	   and	   limited	   evidence	   for	   graft-­‐versus-­‐host	  
disease	   compared	   to	   adult	   bone	   marrow	   stem	   cell	   transplantation.	  
Reconstruction	  of	  the	  adult	  hematopoietic	  system	  was	  the	  initial	  rationale	  
for	  UCB-­‐based	  applications.	  
1.3.2	  Adult	  stem	  cells	  	  
Adult	   stem	   cells	   are	   multipotent	   undifferentiated	   cells,	   characterized	   by	  
continuous	   self-­‐renewal	   and	   located,	   together	   with	   the	   specialized	   cells	  
typical	  of	  a	  tissue,	  within	  the	  same	  organ.	  Adult	  stem	  cells	  comprise	  a	  wide	  
range	  of	  progenitors	  derived	  from	  non-­‐embryonic,	  non-­‐fetal	  tissue	  such	  as	  
bone	   marrow,	   adipose	   tissue	   and	   resident	   stem	   cell	   pools.	   Scientific	  
interest	  in	  adult	  stem	  cells	  is	  focused	  on	  their	  ability	  to	  generate	  all	  the	  cell	  
types	   of	   the	   organ	   from	   which	   they	   originate,	   potentially	   being	   able	   to	  
regenerate	  an	  entire	  organ	  starting	  from	  a	  few	  cells.	  Unlike	  embryonic	  stem	  
cells,	  the	  use	  of	  adult	  stem	  cells	  in	  research	  and	  therapy	  is	  not	  considered	  
to	   be	   controversial,	   as	   they	   are	   derived	   from	   adult	   tissue	   samples	   rather	  
than	   left	   over	   human	   embryos.	   Adult	   stem	   cells	   are	   therefore	   a	   leading	  
candidate	   for	   clinical	   application	   in	   regenerative	  medicine	   based	   on	   their	  
accessibility,	   autologous	   status	   and	   favourable	   proliferative	   potential.	   In	  
addition,	   adult	   stem	   cells	   have	   no	   ethical	   reservations	   and	   are	   easy	   to	  
isolate.	  	  
Adult	   stem	   cells	   have	   been	   known	   since	   the	   sixties,	   when	   two	   different	  
types	  of	  stem	  cells	  in	  the	  bone	  marrow	  were	  discovered:	  the	  hematopoietic	  
stem	  cells	  (HSCs),	  that	  give	  rise	  to	  all	  types	  of	  blood	  and	  the	  mesenchymal	  
stem	   cells	   (MSCs)	   or	   stromal	   cells	   that	   can	   differentiate	   into	   multiple	  
mesenchymal	  tissue	  cell	  types	  such	  as	  bone,	  cartilage,	  adipose	  and	  muscle	  
cells	  [Fig.	  2].	  	  
Bone	   marrow-­‐derived	   hematopoietic	   stem	   cells	   represent	   the	   earliest	  
example	   of	   cell-­‐based	   regenerative	   medicine,	   pioneered	   to	   address	   the	  
needs	  of	  patients	  treated	  with	  total	  body	  irradiation	  against	  leukemia	  that	  
developed	   life-­‐threatening	   infections	   and	   irreversible	   tissue	   destruction.	  
Those	  stem	  cells	  are	  defined	  by	  the	  expression	  of	  the	  CD34	  surface	  marker	  




engraftment	  (Nelson	  et	  al.,	  2009).	  Hematopoietic	  stem	  cells	  did	  provide	  the	  
basis	   for	   autologous	   and	   allogeneic	   stem	   cell	   transplantation	   and	   offer	  
novel	   treatments	   for	   patients	  with	   cancer,	   autoimmune	   diseases,	   genetic	  
diseases	   such	   as	   severe	   combined	   immunodeficiency	   and	   thalassemia,	  
spinal	  cord	   injury	  (Mackay-­‐Sim	  and	  Féron,	  2013),	   liver	  cirrhosis	  (Takami	  et	  
al.,	   2012)	   and	   peripheral	   vascular	   disease	   (Subrammaniyan	   et	   al.,	   2011).	  
Transplant	   studies	   have	   also	   revealed	   engraftment	   of	   non-­‐hematopoietic	  
cell	   lineages	  derived	  from	  donor	  bone	  marrow,	  unmasking	  subpopulations	  
























Figure	  2.	  Adult	   stem	  cells.	  Adult	  stem	  cell	  are	  considered	  multipotent,	  as	  illustrated	  for	  
bone	  marrow-­‐derived	  stem	  cells	  that	  contain	  both	  hematopoietic	  progenitors	  (HSCs)	  and	  
mesenchymal	   stem	   cells	   (MSCs);	   HSCs	   give	   rise	   to	   lymphoid-­‐derived	   T	   cells,	   B	   cells,	  
natural	  killer	  cells	  and	  myeloid-­‐derived	  red	  blood	  cells,	  platelets	  and	  macrophages.	  HSCs	  
provide	  the	  standard	  of	  care	  for	  bone	  marrow	  reconstruction.	  MSCs	  also	  have	  a	  diverse	  
spectrum	   of	   differentiation	   that	   includes	   bone,	   muscle,	   cartilage,	   cardiomyocytes,	  




1.3.3	  Cardiac	  stem	  cells	  (CSCs)	  	  
Recent	   evidence	   suggests	   that	   the	   heart	   contains	   a	   small	   population	   of	  
endogenous	  stem	  cells	  that	  most	  likely	  facilitate	  minor	  repair	  and	  turnover-­‐
mediated	   cell	   replacement.	   These	   cells	   have	   been	   isolated	   and	  
characterized	  in	  the	  hearts	  of	  rats,	  mice,	  dogs	  and	  humans	  (Beltrami	  et	  al.,	  
2003).	   Thus,	   the	   heart’s	   own	   regenerative	   potential	   opens	   up	   a	   new	  
paradigm	  in	  cardiology.	  
The	  cells	  can	  be	  harvested	  in	  limited	  quantity	  from	  human	  endomyocardial	  
biopsy	  specimens	  and	  can	  be	  injected	  into	  the	  site	  of	  infarction	  to	  promote	  
cardiomyocyte	   formation	   and	   improvements	   in	   systolic	   function	   (Messina	  
et	  al.,	  2004).	  Separation	  and	  expansion	  ex	  vivo	  over	  a	  period	  of	  weeks	  are	  
necessary	   to	   obtain	   sufficient	   quantities	   of	   these	   cells	   for	   experimental	  
purposes.	  
Experimental	   results	   suggested	   that	   CSCs	   are	   able	   to	   differentiate	   into	  
three	   major	   cardiac	   cell	   populations,	   including	   cardiomyocytes,	   smooth	  
muscle	   cells	   and	  endothelial	   cells	   (Beltrami	   et	   al.,	   2003;	   Zhao	  and	  Huang,	  
2013).	   All	   together,	   CSCs	   may	   be	   the	   optimal	   stem	   cells	   to	   use	   in	   the	  
regeneration	   of	   the	   myocardium	   for	   the	   treatment	   of	   heart	   failure	  
(Messina	  et	  al.,	  2004).	  
	  
1.4	  Cells	  of	  our	  interest:	  Adult	  stem	  cells	  
Adult	  stem	  cells	  have	  been	  found	  in	  almost	  all	  organs:	  brain,	  bone	  marrow,	  
blood	  vessels,	  skeletal	  muscle,	  skin	  and	  liver	  but	  their	  number	  is	  very	   low.	  
Stem	   cells	   reside	   in	   specific	   niches	   in	   each	   organ,	   remain	   quiescent	   for	   a	  
long	   time	  and,	  when	  activated	   in	   case	  of	   injury,	   they	  begin	   to	  proliferate,	  
migrate	  out	  of	   the	  niche	  and	  undergo	  differentiation.	  Such	  niches	  contain	  
also	   specialized	   cells	   that	   secrete	   several	   growth	   factors	  and	  organize	   the	  
extracellular	  matrix	  for	  the	  maintenance	  of	  the	  ability	  of	  stem	  cells	  to	  self-­‐
renewal.	  
Adult	  stem	  cells	  include	  a	  large	  population	  of	  progenitor	  cells	  derived	  from	  
non-­‐embryonic	   tissues	   such	   as	   bone	  marrow,	   adipose	   tissue	   as	   well	   as	   a	  
variety	  of	  other	  organs.	  Stem	  cells	  exhibit	  three	  main	  properties.	  First,	  they	  




abilities,	   which	   allow	   them	   to	   preserve	   a	   population	   of	   undifferentiated	  
stem	   cells	   while	   proliferating	   and	   differentiating.	   Third,	   they	   are	   able	   to	  
differentiate	  towards	  multiple	  lineages	  and	  to	  repair	  damaged	  tissues.	  Our	  
body	  harbours	   a	   limited	  number	  of	   stem	   cells	   that	  may	  differentiate	   into	  
one	  or	  several	  mature	  cell	  types	  when	  the	  surrounding	  tissue	  is	  damaged	  or	  
lost	   (Ong	  and	  Sugii,	  2013).	  However,	   in	  many	  clinically	   relevant	  cases,	   the	  
tissue	  damages	  exceeds	   the	  body's	  natural	   repair	  potential,	   requiring	  cell-­‐
based	   medical	   intervention	   involving	   sufficient	   amounts	   of	   repair-­‐
competent	   cells.	   In	   this	   regard,	   due	   to	   their	   accessibility	   and	   to	   their	  
differentiation	  and	  proliferative	  potential,	  adipose	  derived	  adult	  stem	  cells	  
(ASCs)	   are	   currently	   the	   best	   candidates	   for	   clinical	   applications	   in	  
regenerative	  medicine	  involving	  autologous	  cells.	  	  
	  
1.5	  Adipose	  Tissue	  
Almost	  every	  animal	  species	  has	  a	  way	  to	  store	  excess	  energy	  in	  the	  form	  of	  
fat.	  This	  is	  mainly	  achieved	  in	  a	  mesodermal	  tissue	  termed	  “white	  adipose	  
tissue”	   in	   which	   mass	   triglyceride	   storage	   takes	   place	   under	   hormonal	  
control	  (Cousin	  et	  al.,	  2006).	  However,	  white	  adipose	  tissue	  not	  only	  acts	  as	  
a	   fat	   reservoir	   tissue,	   but	   is	   also	   responsible	   for	  mechanical	   support	   and	  
thermal	  insulation,	  and	  it	  works	  as	  the	  largest	  and	  most	  efficient	  endocrine	  
organ,	   releasing	   a	   wide	   range	   of	   hormones	   and	   cytokines	   capable	   of	  
regulating	   immune	   response,	   blood	   pressure,	   angiogenesis	   or	   bone	  mass	  
(Cousin	  et	  al.,	  2006).	  At	  the	  histological	  level,	  adipose	  tissue	  (AT)	  appears	  to	  
be	   mostly	   composed	   of	   adipocytes	   (large	   cells	   with	   a	   peripheral	   nucleus	  
and	  a	  cytoplasm	  occupied	  by	  a	  single	  drop	  of	  lipid	  that	  are	  held	  together	  in	  
a	  framework	  of	  collagen	  fibres	  (Mazo	  et	  al.,	  2011).	  The	  white	  adipose	  tissue	  
makes	  up	  most	  of	  the	  fat	  in	  humans	  and	  can	  be	  classified	  into	  visceral	  and	  
subcutaneous	  AT	  (Oedayrajsingh-­‐Varma	  et	  al.,	  2006).	  Several	  studies	  have	  
pointed	   out	   that	   subcutaneous	   AT	   contains	   a	   greater	   number	   of	  
multipotent	   cells	   than	   visceral	   tissue.	   Although	   the	   subcutaneous	   fat	   is	  
present	  in	  all	  parts	  of	  the	  body,	  selected	  anatomical	  sites	  appear	  to	  harbour	  
larger	  numbers	  of	   stem	  cells.	   In	   fact,	  higher	  quantities	  of	   stem	  cells	  were	  
isolated	   from	   subcutaneous	   abdominal	   region	   as	   compared	   to	   thighs	   and	  




From	  an	  embryological	  point	  of	  view,	  human	  adipose	  tissue	  is	  derived	  from	  
the	   mesodermal	   germ	   layer	   and	   contains	   a	   supportive	   stromal	   vascular	  
fraction	   (SVF)	   that	   can	   be	   easily	   separated	   from	   the	   surrounding	   tissue	  
(Baer	  and	  Geiger,	  2012).	  The	  SVF	  is	  composed	  of	  a	  heterogeneous	  mixture	  
of	   cells	   that	   can	   be	   isolated	   by	   enzymatic	   digestion	   or	   density	   gradient	  
centrifugation	   among	   which	   are	   cells	   interesting	   for	   adipogenesis	   and	  
regenerative	   medicine,	   including	   the	   precursors	   of	   adipocytes,	  
endothelium,	  pericytes	  and	  adipose-­‐derived	  stromal	  cells.	  Hence,	  the	  SVF	  is	  
not	  homogeneous,	  but	  rather	  a	  mixture	  of	  several	  cell	  populations	  that	  can	  
be	   characterized	   by	   flow	   cytometric	   analysis	   of	   cell-­‐surface	   clusters	   of	  
differentiation	   (CDs).	   We	   previously	   demonstrated	   that	   the	   SVF	   includes	  
not	   only	   multipotent	   stem	   cells	   (CD44,	   CD73	   and	   CD90),	   but	   also	  
hematopoietic	   (CD11b,	   CD34	   and	   CD45)	   and	   endothelial	   cells	   (CD31,	  
CD133)	  (Tallone	  et	  al.,	  2011).	  
Adipose	   Stem	   Cells	   (ASCs)	   are	   a	   subpopulation	   of	   stromal	   cells	   found	   in	  
subcutaneous	   and	   visceral	   fat	   tissues.	   The	   main	   advantage	   in	   using	   AT	  
compared	   to	   bone	   marrow,	   is	   that	   AT	   can	   be	   obtained	   in	   much	   larger	  
amounts	   and	   with	   a	   far	   less-­‐invasive	   surgical	   operation	   (i.e.	   liposuction).	  
More	   importantly,	   the	   number	   of	   ASCs	   in	   harvested	   fat	   is	   approximately	  
40-­‐times	  higher	   than	   that	  of	  bone	  marrow	  MSCs.	  Furthermore	   these	  cells	  
exhibit	   a	   high	   proliferation	   capacity,	   self-­‐renewal	   and	   the	   ability	   to	  
differentiate	   into	  different	   cell	   types	  and	   repair	  damaged	   tissue.	  All	   these	  
features	   have	   attracted	   the	   attention	   of	   many	   researchers	   involved	   in	  
regenerative	   medicine,	   particularly	   in	   the	   field	   devoted	   to	   restoring	  
function	  of	  the	  damaged	  heart.	  	  
Furthermore,	  many	  groups	  have	  shown	  that	  adult	  stem	  cells	  derived	  from	  
white	  adipose	  tissue	  can	  differentiate	  along	  multiple	  pathways	  raising	  great	  
hope	   in	   regenerative	   medicine	   as	   AT	   can	   be	   an	   abundant	   source	   of	  
therapeutic	   cells	   (Schäffler	   and	   Büchler,	   2007).	   Recently,	   human	   adipose	  
derived	   stem	   cells	   were	   reprogrammed	   successfully	   into	   embryonic	   stem	  
cell-­‐like	   colonies	   (induced	   pluripotent	   stem	   cell,	   iPS)	   faster	   and	   more	  
efficiently	   than	   adult	   human	   fibroblasts	   using	   the	   strategy	   developed	   by	  




As	   a	   result,	   ASCs	   represent	   major	   candidates	   for	   tissue	   engineering	  
application.	  
ASCs	   are	   very	   appreciated	   in	   the	   plastic	   and	   reconstructive	   surgical	  
procedures,	   where	   it	   is	   apparent	   a	   shift	   toward	   tissue-­‐engineering	  
strategies	  using	  stem	  cells	  (Tanzi	  and	  Farè,	  2009).	  
Available	  reconstructive	  surgery	  using	  synthetic	  materials	  or	  autologous	  fat	  
transplants	   is	   often	   unsatisfactory,	   due	   to	   the	   unpredictability	   of	   volume	  
maintenance	  at	  long	  term.	  Transplanted	  ASCs	  may	  overcome	  the	  problems.	  
Similar	  applications	  of	  ASCs	  are	  also	  widely	  desired	  for	  cosmetic	  purposes.	  
So,	  the	  clinical	  use	  of	  autologous	  ASCs	  has	  been	  reported	  across	  the	  globe.	  
For	   example	   a	   novel	   transplantation	   strategy,	   termed	   cell-­‐assisted	  
lipotransfer	  (CAL),	  which	  involve	  the	  enrichment	  of	  ASCs	  in	  graft,	  has	  been	  
used	  with	  promising	  results	  by	  Yoshimura	  and	  co-­‐workers	  (Yoshimura	  et	  al.,	  
2008,	  2009).	  In	  Europe,	  Rigotti	  and	  co-­‐workers	  reported	  the	  use	  of	  ASCs	  to	  
treat	   the	   late	  side	  effects	  of	   radiotherapy	  (Rigotti	  et	  al.,	  2007)	  and	   in	  USA	  
Coleman	   and	   co-­‐workers	   reported	   the	   use	   of	   fat	   grafting	   for	   soft	   tissue	  
repair	  (Coleman	  and	  Saboeiro,	  2007).	  
	  
1.6	  Mesenchymal	  Stromal	  Cells	  (MSCs)	  
More	   than	   40	   years	   ago	   Friedenstein	   and	   colleagues	   demonstrated	   that	  
bone	   marrow	   (BM)	   contains	   a	   population	   of	   hematopoietic	   stem	   cells	  
(HSCs)	  and	  a	  rare	  population	  of	  plastic-­‐adherent	  cells	  (1	  in	  10000	  nucleated	  
cells	   in	   BM),	   initially	   referred	   to	   as	   stromal	   cells	   and	   are	   now	   called	  
mesenchymal	  stromal	  cells	  (MSCs).	  MSCs	  are	  spindle-­‐shaped,	  fibroblast-­‐like	  
multipotent	   stem	   cells.	   MSCs	   are	   a	   subpopulation	   of	   SVF	   and	   can	   be	  
identified	   by	   the	   criteria	   proposed	   by	   The	   International	   Society	   for	   Cell	  
Therapy.	  They	  include:	  
1. the	   ability	   to	   adhere	   to	   plastic	   in	   standard	   culture	   condition	   and	  
proliferate	  in	  vitro;	  
2. the	  expression	  of	  the	  surface	  molecules	  CD73,	  CD90	  and	  CD105	  in	  
the	   absence	   of	   CD34,	   CD45,	   HLA-­‐DR,	   CD14	   or	   CD11b,	   CD79a,	   or	  





3. the	   ability	   to	   form	   quantifiable	   colony-­‐forming	   unit-­‐fibroblasts	  
(CFU-­‐Fs),	  round	  colonies	  resembling	  fibroblastoid	  cells;	  
4. the	  capacity	  for	  in	  vitro	  differentiation	  into	  osteoblasts,	  adipocytes,	  




















MSCs	  are	  distributed	  throughout	  the	  body.	  The	  major	  limitation	  in	  their	  use	  
is	   the	   difficulty	   to	   identify	   them.	   In	   the	   literature	   there	   are	   papers	   that	  
describe	  MSCs	  growth	  characteristics	  and	  their	  ability	   to	  differentiate	   into	  
different	   cell	   types	   (Dominici	   et	   al.,	   2006),	   but	   this	   functional	  
characterization	   is	   not	   sufficient	   to	  uniquely	   identify	  MSCs	  as	   required	  by	  
the	  protocols	  used	   in	  the	  medical	   field.	  Furthermore,	  several	  studies	  have	  
attempted	  to	  determine	  the	  expression	  of	  specific	  markers	  (CDs:	  clusters	  of	  
differentiation)	  on	  MSCs	  (Dominici	  et	  al.,	  2006).	  Despite	  conflicting	  data,	  it	  
Figure	   3.	   Mesenchymal	   Stem	   cells.	   A	   representation	   of	   the	   ability	   of	   these	   cells	   to	  




is	  interesting	  to	  note	  that	  the	  MSCs	  isolated	  from	  various	  tissues	  have	  all	  a	  
similar	   immunophenotype:	   MSCs	   do	   not	   express	   CD11	   (i.e.	   marker	   of	  
immune	   cells)	   or	   CD45	   (i.e.	   marker	   for	   cells	   of	   erytropoietic	   lineage).	  
Similarly,	  CD31,	  expressed	  by	  endothelial	  cells,	  is	  not	  expressed	  by	  MSCs.	  	  
Several	   markers	   have	   been	   reported	   in	   the	   literature	   and	   different	  
combinations	   have	   been	   used	   by	   each	   research	   group	   to	   identify	   MSCs	  
populations.	   Stro-­‐1	  has	  been	   the	  best	   known	  marker	   to	   identify	  MSCs	   for	  
several	  years;	   cells	  negative	   for	   this	  marker	  were	  unable	   to	   form	  colonies	  
and	   a	   preparation	   of	   bone	  marrow	   enriched	   with	   a	   population	   of	   Stro-­‐1	  
positive	   cells,	   increased	   the	   frequency	   of	   CFU-­‐F.	   Despite	   this,	   it	   is	   not	  
possible	   to	   use	   Stro-­‐1	   as	   a	   general	  marker	   for	   the	   identification	   of	  MSCs	  
anymore,	  as	  it	  has	  been	  shown	  that	  it	  is	  not	  expressed	  by	  this	  cell	  type	  and	  
is	   lost	   during	   in	   vitro	   expansion.	   Presently	   CD73,	   a	   protein	   involved	   in	  
vascular	  adhesion,	  seems	  to	  be	  a	  promising	  marker	  for	  MSC.	  	  
The	  MSCs	  were	   found	   in	   a	   variety	  of	   tissues:	  mesodermal	   tissues	   such	   as	  
adipose	   tissue	   and	   bone	   marrow,	   and	   more	   recently	   also	   in	   non-­‐
mesodermal	   tissues	   such	   as	   brain,	   synovial	   tissue,	   umbilical	   cord	   blood,	  
peripheral	  blood,	  kidney	  and	  lungs.	  It	  is	  important	  to	  note	  that	  MSCs	  have	  
variable	   growth	   potential,	   but	   all	   have	   similar	   surface	   and	   mesodermal	  
differentiation	   potential.	   Many	   attempts	   have	   been	   made	   to	   determine	  
specific	  cell-­‐surface	  antigen	  profiles	   (immunophenotype)	   for	  more	  specific	  
identification	   of	   MSCs.	   Particularly	   relevant	   is	   the	   question	   of	   whether	  
MSCs	   isolated	   from	   different	   tissues	   can	   be	   identified	   by	   the	   same	  
immunophenotype,	   i.e.	  whether	  all	   these	  cells	  have	  common	  ancestors	  or	  
at	  least	  share	  similar	  properties.	  Researchers	  showed	  that	  the	  morphology	  
and	   the	   phenotype	   of	   MSCs	   from	   different	   sources	   are	   in	   fact	   rather	  
similar.	  This	  has	  led	  to	  develop	  a	  theory	  according	  to	  which	  in	  every	  tissue	  
there	  are	  microenvironments	  (niches)	  sharing	  similar	  characteristics.	  These	  
niches	   are	   isolated	   from	   the	   surrounding	  environment	   and	  harbour	  MSCs	  
that	  are	  kept	  in	  an	  undifferentiated	  state	  until	  they	  are	  required	  to	  exit	  the	  
niche.	   The	   niche	   consists	   of	   various	   extracellular	   matrix	   elements	   and	  
additional	   cells	   that	   surround	   the	   MSCs	   and	   keep	   them	   in	   their	  
undifferentiated	  stage,	  until	  a	  stimulus	  occurring	  at	  the	  level	  of	  niche	  drives	  




schematically	   a	   hypothetical	   stem	   cell	   niche.	   A	   niche	   is	   constituted	   by	   a	  
precise	   number	   of	   mesenchymal	   cells	   that	   are	   located	   in	   a	   specific	  
perivascular	   microenvironment.	   These	   cells	   are	   closely	   associated	   with	  
differentiated	   support	   cells	   (DC)	   and	   an	   extracellular	   matrix	   (ECM).	   The	  
supporting	   cells	   communicate	   with	   mesenchymal	   cells	   through	   cell-­‐cell	  
interactions	  and	  secrete	  paracrine	  factors.	  It	  seem	  that	  also	  a	  slight	  hypoxia	  
















Again,	  MSCs	  are	  not	  a	  homogenous	  population,	  but	  rather	  a	  heterogeneous	  
mixture	   of	   cells	   with	   variable	   proliferation	   and	   differentiation	   potentials	  
and	   with	   different	   morphology	   and	   expression	   of	   surface	   antigens	  
correlates	  with	  their	  functions.	  
The	   identification	   of	   specific	   signalling	   networks	   and	   “master”	   regulatory	  
genes	   that	   govern	   unique	  MSCs	   differentiation	   lineages	   remains	   a	   major	  
challenge.	  The	  ability	   to	  modulate	  biological	  effectors	   that	  drive	  a	  desired	  
differentiation	  program,	  or	  that	  possibly	  prevent	  spurious	  differentiation	  of	  
Figure	  4.	  Mesenchymal	  Stem	  cell	  Niche.	  A	  niche	  is	  constituted	  by	  a	  precise	  number	  of	  MSCs	  
located	   in	   a	   specific	   perivascular	   microenvironment	   (BV,	   blood	   vessel).	   These	   cells	   are	  




MSCs,	  is	  needed	  for	  effective	  clinical	  applications,	  as	  for	  tissue	  engineering	  
and	  regeneration.	  
MSCs	  can	  be	  influenced	  via	  a	  multitude	  of	  growth	  factors	  and,	  accordingly,	  
a	  number	  of	  growth	  factor	  receptors	  have	  been	  identified	  on	  their	  surface.	  
Indeed,	  membrane	  receptors	  and	  their	  ligands	  are	  relevant	  for	  a	  number	  of	  
metabolic	  cell	   functions.	  EGFR,	  βFGFR,	  TGFRI	  and	  TGFRII	  were	  reported	  to	  
be	   important	   for	   MSCs	   self-­‐renewal	   and	   differentiation.	   MSCs	   express	   a	  
wide	  set	  of	  cytokine	  receptors:	  IL-­‐1R,	  IL-­‐3R,	  IL-­‐4R,	  IL-­‐6R,	  IFNgR	  and	  TNFI	  and	  
IIR.	  Recent	  evidence	  demonstrates	  that	  MSCs	  stimulated	  by	  TNFa	  and	  IL-­‐6	  
are	  able	  to	  invade	  and	  migrate	  through	  basement	  membrane-­‐like	  matrigel.	  
Furthermore,	  some	  researchers	  reported	  expression	  of	  Notch	  1,	  2	  and	  3	  in	  
MSCs.	  The	  Notch	  pathway	  is	  particularly	  relevant	  in	  this	  context	  because	  it	  
is	  considered	  the	  gatekeeper	  of	  stemness.	  	  Activation	  of	  Notch	  by	  its	  ligand,	  
triggers	  proteolytic	  cleavage	  and	  release	  of	  the	  Notch	  intracellular	  domain,	  
which	   enters	   the	   cell	   nucleus	   and	   alters	   gene	   expression	   (Niessen	   and	  
Karsan,	  2007).	  
Experimental	   evidence	   suggests	   that	   ASCs	   are	   located	   at	   the	   level	   of	  
vascular	  precursors.	  It	   is	  well	  known	  that	  the	  SVF	  contains	  progenitor	  cells	  
that	  can	  differentiate	  in	  endothelial	  cells	  thus	  participating	  in	  the	  formation	  
of	  blood	  vessels.	  
Immunohistochemical	   studies	   have	   shown	   that	   CD34	   positive	   cells	   are	  
predominantly	  associated	  with	  blood	  vessels	  of	   small	  and	  medium	  caliber	  
(50-­‐150	   μm)	   present	   in	   adipose	   tissue;	   the	   expression	   of	   this	   marker	  
remains	   the	   same	   along	   the	   section	   of	   the	   vessel	   from	   intima	   tunica	   to	  
inside	   of	   the	   adventitia	   tunica,	   while	   the	   expression	   of	   CD31	   decreases.	  
Many	   papers	   have	   shown	   that	   the	   very	   high	   CD34	   expression	   in	   SVF	  
decreases	  rapidly	  during	  the	  first	  passages	  of	  cell	  culture.	  However,	  this	  loss	  
of	  expression	   is	  due	  to	  a	  negative	  regulation	  of	  the	  expression,	  not	  to	  the	  
death	  of	  CD34	  cells	  (Tallone	  et	  al.,	  2011).	  
	  
Human	  MSCs	  express	  moderate	   levels	  of	  human	   leukocytes	  antigen	   (HLA)	  
major	   histocompatibility	   complex	   class	   I,	   lack	   major	   histocompatibility	  
complex	  class	  II	  expression	  and	  do	  not	  express	  co-­‐stimulatory	  molecules	  B7	  




this	  unique	  immune-­‐phenotype	  coupled	  with	  powerful	  immunosuppressive	  
activity	   via	   cell-­‐cell	   contact	   with	   target	   immune	   cells	   and	   secretion	   of	  
soluble	   factors,	   such	   as	   nitric	   oxide	   and	   heme	   oxygenase-­‐1.	   MSCs	   have	  
immune-­‐modulatory	  functions	  by	  interacting	  with	  both	  innate	  and	  adaptive	  
immunity.	   The	   innate	   immune	   cells	   (neutrophils,	   dendritic	   cells,	   natural	  
killer	  cells,	  eosinophils,	  mast	  cells	  and	  macrophages)	  are	   responsible	   for	  a	  
nonspecific	  defence	   to	   infarction	  and	  MSCs	  have	  been	  shown	  to	  suppress	  
most	  of	  these	  inflammatory	  cells.	  
A	   remarkable	   property	   of	   MSCs	   is	   their	   powerful	   ability	   of	   regulating	  
immune	   response.	   As	   a	   result,	   current	   MSCs-­‐based	   therapy	   has	   mainly	  
been	  applied	  to	  alleviate	  immune	  disorders.	  Various	  studies	  have	  evaluated	  
the	   therapeutic	   effect	   of	   MSCs	   in	   preclinical	   animal	   models	   and	  
demonstrated	  great	  clinical	  potential	  (Ren	  et	  al.,	  2012).	  
	  
Graft-­‐versus-­‐host	   disease	   (GvHD)	   is	   a	   severe	   complication	   following	   bone	  
marrow	  and	  HSC	   transplantation.	   It	   has	  been	   shown	   that	  more	   than	  40%	  
recipients	   of	   bone	   marrow	   transplantation	   develop	   GvHD	   and	   many	   of	  
them	  are	  hard	   to	   treat	  even	  with	   steroids	   (Kernan	  et	  al.,	   1993).	   In	   recent	  
years,	  MSCs	  have	  been	  successfully	  applied	  to	  treat	  GvHD	  in	  mouse	  models.	  
One	  or	  two	  infusions	  of	  MSCs	  after	  bone	  marrow	  transplantation	  improved	  
the	   survival	   rate	   of	   GvHD	   mice	   and	   dramatically	   reduced	   immune	   cell	  
infiltration	   in	   various	   organs.	   These	   studies	   also	   demonstrated	   that	   pro-­‐
inflammatory	   cytokines	  are	   critical	   in	  MSCs-­‐mediated	   immunosuppression	  
in	   vivo,	   as	   elimination	   of	   interferon-­‐γ	   (IFNγ)	   signalling	   diminishes	   the	  
therapeutic	  effect	  of	  MSCs	  (Polchert	  et	  al.,	  2008;	  Ren	  et	  al.,	  2008).	  
	  
In	  the	  treatment	  of	  autoimmune	  type	  I	  diabetes,	  MSCs	  significantly	  delayed	  
diabetes	  onset	  in	  non-­‐obese	  diabetic	  (NOD)	  mice.	  MSCs	  infusion	  protected	  
islets	   from	   destruction,	   as	   evidenced	   by	   insulin	   staining,	   lymphocyte	  






1.7	  Cardiovascular	  disease	  (CVD)	  
Cardiovascular	   disease	   (CVD),	  which	   include	   hypertension,	   coronary	   heart	  
disease	   (CHD),	   stroke,	   and	   congestive	   heart	   failure	   (CHF),	   are	   the	   leading	  
and	   most	   common	   causes	   of	   mortality	   in	   many	   developing	   and	  
industrialized	   countries,	   accounting	   for	   one	   third	   of	   all	   deaths	   globally	  
(Thom	  et	  al.,	  2006).	  The	  American	  Heart	  Association	  reported	  that	  cardiac	  
failure	  was	  responsible	  for	  38%	  of	  all	  deaths	  in	  recent	  years.	  Nearly	  half	  of	  
all	   deaths	   associated	   with	   CVD	   are	   the	   result	   of	   heart	   failure	   due	   to	  
ischemic	   cardiomyopathy	   events	   such	   as	   myocardial	   infarction	   (MI),	   a	  
pathology	  characterized	  by	  clot	   formation	  within	  a	  coronary	  artery,	  which	  
prevents	  blood	  flow	  to	  the	  region	  of	  the	  heart	  distal	  to	  the	  site	  of	  occlusion.	  
Acute	   myocardium	   infarction	   (MI)	   and	   all	   heart	   injuries	   can	   lead	   to	  
immediate	  death,	  due	  to	  loss	  of	  oxygenation	  in	  ventricular	  muscle,	  usually	  
by	   occlusion	   of	   a	   coronary	   artery,	   which	   quickly	   results	   in	  
ischemia/reperfusion	   injury	   and	   necrosis	   of	   the	   tissue.	   In	   the	   best	   case,	  
living	  patients	  face	  progressive	  deterioration	  of	  their	  condition	  over	  several	  
years,	  ultimately	  resulting	  in	  heart	  failure.	  This	  failure	  stems	  from	  a	  lack	  of	  
intrinsic	  regenerative	  responses	  able	  to	  replenish	  the	  vast	  amounts	  of	   lost	  
cardiomyocytes	   and	   results	   in	   scar	   formation	   and	   rapidly	   compromised	  
heart	  function	  (Rosenthal	  and	  Harvey,	  2010).	  	  
The	  prevalence	  of	  CVD	  is	  expected	  to	  increase	  to	  three	  fourths	  of	  all	  deaths	  
by	   2020	   in	   part	   due	   to	   an	   increasing	   prevalence	  of	   risk	   factors	   related	   to	  
coronary	   disease,	   such	   as	   obesity	   and	   sedentary	   lifestyle	   (metabolic	  
syndrome),	   making	   CVD	   an	   even	   greater	   public	   health	   concern.	   Both	   of	  
these	   conditions	   result	   in	   death	   of	   cardiomyocytes	   by	   apoptosis	   and/or	  
necrosis.	   Since	   cardiomyocytes	   rarely	   divide,	   contractile	   cells	   cannot	  
repopulate	  the	  infarct	  area,	  while	  non-­‐contractile	  cells	  (fibroblast)	  gradually	  
replace	  them	  (Holmes	  et	  al.,	  2005;	  Leor	  and	  Cohen,	  2004;	  Sun	  and	  Weber,	  
2000).	  Moreover	  healthy	  myocytes	  close	  to	  the	  infarcted	  area	  may	  also	  die,	  
causing	   an	   increase	   of	   the	   necrotic	   tissue	   area.	   Dead	   cardiomyocytes	   are	  
replaced	  by	   fibroblasts	   that	   divide	   and	  migrate	   into	   the	  damaged	  area	   to	  
form	   scar	   tissue	   [Fig.	   5].	   This	   process	   involves	   the	   left	   ventricle	   and	   it	   is	  
called	   left	   ventricle	   remodelling	   (LVR).	   During	   LVR,	   the	   ventricle	   wall	  




and	   Cohen,	   2004)(Zhu	   et	   al.,	   2009).	   Changes	   in	   size	   and	   shape	   of	   left	  
ventricle	   can	   be	   observed:	   an	   enlargement	   of	   the	   heart	   chamber	   takes	  
place	  and	   the	   sphericity	   index	   (ratio	  of	   the	   long-­‐axis	   length	  divided	  by	   LV	  
short-­‐axis	   length,	  both	  during	  systole	  and	  diastole)	   increases.	  LVR	  renders	  
the	   heart	   more	   inclined	   to	   dysfunctions	   and	   to	   failure.	   LVR	   may	   also	   be	  
associated	   with	   an	   increased	   risk	   of	   ventricular	   arhythmias	   (Zamilpa	   and	  
Lindsey,	  2010).	  	  
The	  persistence	  of	  scar	  tissue	  following	  myocardial	  infarction	  suggests	  that	  





















The	   design	   of	   future	   cell	   based	   therapies	   for	   CVDs	   appears	   to	   be	   a	  
challenge	  due	   to	   the	  peculiar	   functional	   and	  anatomical	  properties	  of	   the	  
heart.	   Cardiomyocytes	   merely	   represent	   approximately	   30%	   of	   the	  
ventricular	  cell	  population.	  Transmission	  and	  scanning	  electron	  microscopy	  
have	  identified	  five	  types	  of	  non-­‐muscle	  cells	  within	  the	  adult	  myocardium:	  
Figure	   5.	   Normal	   vs	   Infarcted	   Heart.	  
The	   left	   ventricle	   has	   a	   thick	   muscular	  
wall,	  shown	  in	  cross-­‐section	  in	  A.	  After	  a	  
myocardial	   infarction	   (heart	   attack),	  
heart	   muscle	   cells	   in	   the	   left	   ventricle	  
are	   deprived	   of	   oxygen	   and	   die	   (B),	  
causing	   the	   ventricular	  wall	   to	   become	  






endothelial	   cells,	   fibroblasts,	   pericytes,	   smooth	   cells,	   and	   macrophages,	  
which	   comprise	   approximately	   65-­‐70%	   of	   ventricular	   cells.	   In	   addition	   to	  
these	   cells	   types,	   the	   3D	   extracellular	   matrix	   (ECM)	   of	   the	   myocardium	  
plays	   an	   important	   role	   in	   its	   function.	   The	  myocardium	   ECM	   consists	   of	  
collagen,	  fibronectin,	  elastin	  and	  laminin	  as	  well	  as	  various	  growth	  factors,	  
proteoglycans	  and	  glycosaminoglycans.	  Collagen	  is	  the	  most	  abundant	  ECM	  
component	   in	   the	   heart	   and	   contributes	   to	   structural	   stability	   and	   the	  
integration	   of	   cardiomyocytes	   and	   myofibrillar	   bundles.	   The	   various	  
components	  of	  the	  myocardium,	  cells	  and	  matrix,	  play	  important	  and	  very	  
complex	  roles	  in	  both	  the	  healthy	  and	  diseased	  heart.	  
Unlike	  most	  other	  cell	  types,	  cardiomyocytes,	  the	  functional	  components	  of	  
the	   heart	   muscle,	   are	   incapable	   of	   replication,	   or	   do	   so	   on	   a	   very	   small	  
scale.	  As	  a	  result,	  when	  the	  heart	  is	  damaged,	  as	  in	  the	  case	  of	  a	  myocardial	  
infarction,	  there	  is	  a	  limited	  internal	  mechanism	  for	  repair	  and	  the	  patient	  
is	  left	  with	  decreased	  cardiac	  function	  that	  rarely	  improves	  over	  time.	  
The	  adult	  heart	  has	  been	  generally	  considered	  as	  a	  terminally	  differentiated	  
organ	  (Beltrami	  et	  al.,	  2001).	  Cardiomyocytes	  were	  assumed	  to	  be	  fully	  post	  
mitotic	  cells.	  They	  possess	  a	  very	  complex	  and	  well-­‐developed	  cytoskeleton	  
consisting	   of	   hundreds	   of	   sarcomeres,	   which	   physically	   impede	   mitotic	  
spindle	   formation	   and	   tight	   cell-­‐cell	   junctions	   necessary	   for	   synchronous	  
beating	  (GAP	  junction).	  Adult	  cardiomyocytes	  are	  often	  multinucleated	  and	  
polyploid.	  Beltrami	  an	  co-­‐workers	  in	  2001	  demostrated	  that	  the	  adult	  heart	  
possesses	   a	   population	   of	   cardiomyocytes	   with	   proliferative	   potential	  
(Beltrami	  et	  al.,	  2001).	  This	  pool	  of	  cells	  was	  clearly	  insufficient	  to	  heal	  the	  
heart	  after	  myocardial	  infarction	  and	  seemed	  to	  be	  more	  relevant	  for	  long-­‐
term	  homeostatic	  maintenance	  of	  heart	  function.	  These	  observations	  gave	  
impetus	   to	   the	   efforts	   focusing	   on	   finding	   and	   activating	   cardiac-­‐resident	  
stem	   cells,	   on	   the	   transplantation	   of	   in	   vitro	   stem	   cell-­‐derived	  
cardiomyocytes,	  and	  on	  the	  administration	  of	  growth	  factors	  and	  cytokines,	  
aimed	  at	  improving	  vascularization,	  preventing	  scar	  formation	  and	  inducing	  
cardiomyocytes	  proliferation.	  	  
	  
Conventional	   therapies	   are	   largely	   palliative	   in	   nature	   and	   do	   not	  




prevent	   additional	   damage	   by	   factors	   that	   contributed	   to	   the	   initial	  
damage,	   such	   as	   hypercholesterolemia	   and	   atherosclerosis	   (Palpant	   and	  
Metzger,	   2010).	   An	   alternative	   for	   cardiac	   diseases	   is	   total	   heart	  
replacement	   or	   mechanical	   implants.	   Heart	   transplantation	   and	   artificial	  
hearts	  are	  effective	  treatments	  for	   loss	  of	  organ	  and	  tissue	  function.	  They	  
are	  associated,	  however,	  with	  serious	  problems	  such	  as	  a	  critical	  shortage	  
of	  donor	  organs,	  rejection,	  the	  need	  for	   life-­‐long	  immunosuppression,	  and	  
incomplete	  biocompatibility.	  These	   limitations	  have	   led	   to	   the	  exploration	  
of	  alternative	  biological	  options	  through	  stem	  cell-­‐based	  therapy	  for	  repair	  
of	  the	  damaged	  cardiac	  tissue.	  	  
One	  of	  the	  main	  long-­‐term	  goals	   is	  the	  de	  novo	  cardiomyocyte	  production	  
to	  provide	  a	   source	  of	   autologous	   cardiomyocytes	   for	   cell	   replacement	   in	  
damaged	  heart.	  Many	  forms	  of	  heart	  disease,	   including	  congenital	  defects	  
and	  acquired	  injuries,	  are	  irreversible	  because	  they	  are	  associated	  with	  the	  
loss	  of	  non-­‐regenerating,	  terminally	  differentiated	  cardiomyocytes.	  	  
	  
Developmental	   biology	   and	   available	   data	   on	   the	   differentiation	   of	  
embryonic	  and	  adult	  stem	  cells	  clearly	  indicate	  that	  the	  process	  of	  forming	  
a	   heart	   requires	   many	   carefully	   orchestrated	   signals,	   some	   of	   which	  
originate	  outside	  the	  pre-­‐cardiac	  mesoderm	  and	  some	  of	  which	  originate	  in	  
the	   developing	   heart.	   During	   gastrulation	   the	   heart	   is	   generated	   from	   a	  
small	  number	  of	  mesodermal	  progenitor	   cells.	   These	  progenitors	  undergo	  
complex	  and	  dynamic	  processes:	  they	  migrate,	  proliferate	  and	  differentiate	  
to	  form	  a	  linear	  heart	  tube,	  the	  primitive	  form	  of	  a	  functional	  heart.	  During	  
these	   processes,	   cells	   initially	   acquire	   generic	   cardiogenic	   phenotypes	  
typical	   of	   cardiac	   progenitors	   and	   later	   exhibit	   more	   specific	   properties	  
reflecting	   their	   final	   differentiation	   into	   for	   instance	   atrial	   and	   ventricular	  
cells.	  
Cardiomyocytes	   regeneration	   is	   limited	   in	   adult	   life	   and	   therefore	   the	  
identification	  of	  a	  putative	  source	  of	  cardiomyocyte	  progenitors	  is	  of	  great	  
interest	   to	   provide	   usable	   in	   vitro	   models	   and	   new	   perspectives	   for	  





1.8	  Clinical	  Trials	  based	  on	  the	  use	  of	  stem	  cells	  
The	   use	   of	   stem	   cells	   to	   improve	   recovery	   of	   the	   injured	   heart	   after	  
myocardial	  infarction	  (MI)	  is	  an	  important	  emerging	  therapeutic	  strategy.	  In	  
recent	  years,	  several	  clinical	  trials	  that	  use	  stem	  cells	  have	  been	  developed	  
using	  different	  approaches.	  	  
The	  majority	  of	  clinical	   trials	  based	  on	  stem	  cell	   therapy	   for	  heart	  disease	  
used	  Bone	  Marrow	  cells	  (BM),	  in	  particular	  mononucleated	  cells	  (MNCs).	  In	  
other	  trials	  other	  types	  of	  stem	  cells	  were	  tested	  and	  used	  as	  source	  to	  be	  
delivered	  by	  intracoronary	  infusion,	  including	  specific	  bone	  marrow	  CD34+	  
or	  CD133+	  and	  umbilical	  cord	  blood	  cells	  (Hoover-­‐Plow	  and	  Gong,	  2012).	  
	  
Another	  approach	   is	  based	  on	  the	  use	  of	  “induced	  pluripotent	  stem”	  (iPS)	  
cells.	   This	   source	   relies	   on	   in	   vitro	   de-­‐differentiation	   of	   adult	   cells	   to	  
embryonic-­‐like	   stem	   cells	   and	   their	   reprogramming	   using	   specific	   culture	  
conditions	   to	   induce	   cardiac	   lineage	   cells	   including	   cardiomyocytes,	  
smooth-­‐muscle	  cells	  and	  endothelial	  cells.	  In	  the	  past,	  the	  most	  commonly	  
used	   adult	   cells	   for	   iPS	  were	   fibroblasts	   derived	   from	   a	   variety	   of	   tissues	  
such	   as	   epidermis,	   liver,	   stomach,	   pancreas	   and	   neural	   as	   well	   as	  
hematopoietic	   cells.	   Nowadays,	   in	   the	   new	   trials,	   instead,	   other	   types	   of	  
stem	   cells	   are	   tested,	   including	   mesenchymal	   stem	   cells,	   adipose	   tissue	  
derived	  stem	  cells	  and	  cardiac	  progenitors	  stem	  cells.	  	  
	  
There	  are	   two	   clinical	   trials	   that	  use	   freshly	   isolated	  adipose-­‐derived	   cells	  
(ADCs)	   in	  patients	  with	   ischemic	  heart	   failure:	   the	  PRECISE	   study	   (Barnett	  
and	  Van	  den	  Hoff,	  2011)	  and,	  in	  patients	  with	  acute	  myocardial	   infarction,	  
the	  APOLLO	  Trials	  (Mazo	  et	  al.,	  2012).	  Preliminary	  data	  obtained	  from	  these	  
studies	  showed	  an	  improvement	  in	  LVEF,	  reduced	  infarct	  size	  and	  improved	  
myocardial	  perfusion.	  
A	   step	   ahead	   of	   these	   trials	   is	   MyStromalCellTrial	   that	   uses	   culture-­‐
expanded-­‐adipose-­‐derived	   stromal	   cells	   	   (ASCs)	   in	   patients	   with	   chronic	  
ischemic	  heart	  disease	  and	  refractory	  angina	  (Qayyum	  et	  al.,	  2012).	  
	  
Although	   it	  has	  been	  believed	   for	  a	   long	   time	  that	  cardiac	  myocytes	  were	  




there	   are	   resident	   or	   non-­‐cardiac	   cardiomyocytes	   progenitor	   cells.	   There	  
have	   been	   intensive	   efforts	   to	   identify	   the	   cardiomyocyte	   stem	   and	  
progenitor	   cells	   in	   the	   last	   10	   years.	   At	   present,	   there	   are	   four	   ongoing	  
clinical	  trials	  to	  test	  autologous	  cardiac	  progenitors	  cells	  (CPCs):	  one	  study	  
(ALCADIA)	  uses	   cardiac-­‐derived	  SCs	   to	   treat	   ischemic	   cardiomyopathy	  and	  
two	   studies	   take	   advantage	   of	   the	   cardiosphere-­‐derived	   stem/progenitor	  
cells	  (derived	  from	  cell	  outgrowth	  of	  autologous	  cardiac	  biopsy)	  for	  patient	  
with	   a	   recent	  MI	   (CADUCEUS)	  or	   heart	   failure	   (TICAP).	   In	   the	   SCIPIO	   trial,	  
patients	   with	   ischemic	   cardiomyopathy	   are	   treated	   with	   c-­‐kit+lin-­‐	   CPCs	  
derived	  from	  the	  right	  atrial	  appendage.	  
	  
It	  is	  thus	  clear	  that	  there	  are	  many	  ongoing	  clinical	  trials	  that	  use	  different	  
methods	   [Fig.	   6].	   Although	   the	   use	   of	   cardiac	   progenitor	   cells	   (CPCs)	   and	  
bone	  marrow	  derived	  stem	  cells	  represent	  a	  good	  therapeutic	  choice,	  their	  
retrieval	  requires	  an	  invasive	  surgical	  intervention.	  
Due	  to	  easily	  accessible	  anatomical	  location	  and	  the	  abundant	  existence	  of	  
subcutaneous	   adipose	   tissue	   in	   the	   abdominal	   region,	   ASCs	   hold	   the	  
advantage	   of	   a	   simple	   and	   less	   invasive	   harvesting	   technique.	   Adipose	  
tissue	   normally	   allows	   the	   extraction	   of	   a	   large	   volume	   of	   tissue	   with	   a	  
limited	   morbidity	   under	   local	   anesthesia.	   Moreover	   preclinical	   studies	  
indicate	   that	  ASCs	   can	  differentiate	   into	   endothelial	   cells,	   thus	  promoting	  
angiogenesis,	   or	   into	   cardiomyocytes,	   thus	   replacing	   the	   injured	  
myocardium.	  	  
Beside	   the	   hypothesis	   of	   replacement	   and	   regeneration	   by	   trans-­‐
differentiation	   of	   freshly	   ASCs	   into	   tissue	   specific	   cells,	   the	   paracrine	  
hypothesis	  has	  gradually	  gained	  credibility,	  where	  paracrine	  stimuli	  of	  stem	  
cells	  lead	  to	  the	  replacement	  of	  injured	  tissue.	  	  
	  
We	  believe	  that	  a	  viable	  approach	  to	  myocyte	  regeneration	  has	  to	  be	  safe	  
and	   feasible	   and	   could	   use	   expanded	   ASCs	   already	   committed	   to	  
cardiomyogenic	   fate.	   This	   strategy	   using	   committed	   stem	   cells	   could	   also	  
























	   	  
Figure	  6.	   Clinical	   Trials.	  The	   timeline	  describes	  the	  main	   cells	   source	  used	   in	   clinical	  




1.9	  Embryonic	  cardiac	  development	  
The	  heart	  is	  generated	  from	  a	  number	  of	  progenitors	  cells	  that	  are	  derived	  
from	   mesoderm	   during	   gastrulation.	   These	   cells	   undergo	   complex	   and	  
dynamic	   processes,	   migrating,	   expanding	   and	   diversifying	   to	   acquire	   a	  
linear	  heart	  tube	  that	  is	  the	  primitive	  form	  of	  functional	  heart.	  During	  this	  
process,	   progenitors	   acquire	   cardiogenic	   phenotypes.	   There	   are	   a	   lot	   of	  
















The	  picture	  in	  figure	  7	  shows	  the	  crucial	  biochemical	  pathways	  involved	  in	  
cardiac	   muscle	   formation	   during	   embryogenesis	   and	   stem	   cell	  
differentiation.	   Indeed,	   this	   chart	   helps	   to	   identify	   growth	   factors	   and	  
cytokines	   that,	  acting	  on	   the	  main	  cardiac	  differentiation	  pathways,	   could	  
be	   used	   in	   the	   induction	   cocktail	   to	   obtain	   functional	   cardiomyocytes	  
physiologically	  indistinguishable	  from	  cardiomyocytes	  derived	  from	  cardiac	  
tissue.	  
Figure	   7.	   Crucial	   biochemical	   pathways	   involved	   in	   cardiac	  muscle	   formation.	   Signaling	  
pathways	   involved	   in	   cardiogenesis	   were	   identified	   using	   the	   power	   of	   experimental	  
embryology.	   This	   picture	   underlines	   the	   pioneering	   work	   performed	   identifying	   the	  




In	  the	  developing	  embryo,	  the	  cardiac	  precursors	  are	  specified	  by	  a	  tightly	  
controlled	  environmental	  signalling.	  Understanding	  how	  different	  signalling	  
pathways	   dictate	   cardiac	   precursor	   specification	   is	   critical	   for	   the	   in	   vitro	  
generation	  of	  such	  cells	  and	  for	  the	  prediction	  of	  how	  they	  will	  behave	  after	  
transplant.	   In	   many	   developmental	   systems,	   Nodal,	   Activin,	   TGF-­‐β,	   bone	  
morphogenetic	   proteins	   (BMPs)	   and	   fibroblast	   growth	   factors	   (FGFs)	  
promote	  cardiogenesis	  (Behfar	  et	  al.,	  2008).	  	  
Three	  main	   families	   of	   peptide	   growth	   factors	   have	  been	   identified	   to	  be	  
essential	  for	  heart	  development	  and	  speciation.	  They	  are	  equally	  important	  
in	  the	  mammalian	  heart	  development,	  acting	  either	  as	  positive	  or	  negative	  
regulators.	   These	   factors	   are	   the	   bone	   morphogenetic	   proteins	   (BMPs),	  
members	  of	   the	   transforming	   growth	   factors	  b	   superfamily,	   the	  wingless-­‐
related	   proteins	   (Wnt)	   and	   the	   fibroblast	   growth	   factors	   (FGFs).	   In	   fact,	  
several	  members	  of	  all	  of	  these	  families	  or	  their	  inhibitors	  are	  expressed	  in	  
the	  endoderm.	  A	  disrupted	  expression	  of	   these	   ligands,	  of	   their	   receptors	  
or	  of	  their	  downstream	  target	  genes	  has	  a	  dramatic	  and	  distinct	  effect	  on	  
cardiac	  development.	  	  
	  
BMPs	  control	  several	  major	  cardiac	  specific	  transcription	  factors,	   including	  
NKX2-­‐5.	   BMP2	   and	   BMP4	   are	   co-­‐expressed	   spatially	   and	   temporally	   with	  
GATA4	   and	   NKX2-­‐5	   in	   the	   pre-­‐cardiac	   mesoderm,	   suggesting	   again	   that	  
they	  may	  control	  the	  expression	  of	  cardiac	  transcription	  factors.	  	  
Fibroblast	  growth	  factors	  (FGFs)	  signalling	  are	  involved	  in	  the	  induction	  and	  
formation	   of	   the	   mesoderm	   in	   all	   vertebrate	   species.	   FGF1,	   2	   and	   4	   are	  
secreted	   by	   the	   portion	   of	   the	   developing	   embryo	   that	   is	   necessary	   for	  
cardiac	  development,	  although	   their	  exact	   role	   is	  not	  clear.	  However,	   it	   is	  
clear	  that	  they	  cooperate	  with	  BMPs	  to	  induce	  cardiomyogenesis.	  
Another	   family	   member,	   FGF8,	   is	   expressed	   in	   the	   cardiac	   mesoderm.	  
Again,	   BMPs	   seem	   to	   cooperate	   with	   FGF8	   in	   heart	   induction	   and	  
morphogenesis.	  	  
Wingless	   (Wnt)	   proteins	   in	   vertebrates	   are	   involved	   in	   highly	   complex	  
networks	   of	   developmental	   pathways	   that	   include	   cardiac	   specification.	  
Wnt	  were	   initially	  considered	  as	  suppressors	  of	  heart	   formation,	  but	  both	  




upon	   inhibition	   of	   GSK3,	   thereby	   allowing	   the	   nuclear	   localization	   of	   β-­‐
catenin,	   and	   appears	   to	   inhibit	   the	   cardiac	   differentiation.	   Instead,	   the	  
“non-­‐canonical”	  Wnt	   involves	  protein	  kinase	  C	  and	  seems	   to	  enhance	   the	  
cardiac	   differentiation.	   Supporting	   this,	   the	   inhibition	   of	   the	   “canonical”	  
Wnt	  signaling	  increases	  the	  cardiac	  differentiation	  and	  conditional	  deletion	  
of	   β-­‐catenin	   from	   the	   definitive	   endoderm	   of	   the	   mouse	   results	   in	   the	  
formation	   of	   multiple	   ectopic	   hearts.	   The	   presence	   of	   Wnt	   antagonists	  
induces	   cardiomyocyte	   differentiation	   in	   non-­‐heart-­‐producing	  mesoderm.	  
Wnts	   3a	   and	   8	   block	   NKX2-­‐5	   and	   TBX	   expression	   and	   therefore	  
cardiomyocyte	   differentiation.	   Recent	   findings	   showing	   that	   β-­‐catenin	  
signalling	   must	   be	   blocked	   for	   heart	   valve	   formation	   in	   zebrafish	   also	  
demonstrate	  a	  negative	  role	  for	  Wnt	  in	  the	  development	  of	  the	  heart.	  
Recent	   findings	   have	   demonstrated	   that	   canonical	   Wnt	   signalling	   plays	  
distinct	   time-­‐specific	   roles	   during	   cardiogenesis,	   regulating	   the	  
specification,	  maintenance	   and	   differentiation	   of	   cardiac	   progenitors	   cells	  
(CPCs)	   distinctly.	   According	   to	   one	   study,	   a	   canonical	  Wnt	   activity	   blocks	  
the	   specification	   of	   CPCs,	   promote	   CPCs	   proliferation	   and	   stops	   the	  
differentiation	   of	   CPCs	   into	   cardiomyocytes	   during	   ESCs	   differentiation.	  
Taken	  together	  these	  informations	  demonstrate	  divergent	  time-­‐dependent	  
roles	  for	  canonical	  Wnt	  signaling.	  
Multiple	   signalling	   pathways	   are	   integrated	   and	   cross-­‐regulated	   during	  
cardiac	  differentiation.	  By	  specifically	  activating	  and	  blocking	  their	  activity,	  
Activin,	   Nodal	   and	  Wnt	   activities	   were	   shown	   to	   be	   essential	   for	   cardiac	  
specification	  of	  mesoderm,	  whereas	  BMPs	  (bone	  morphogenetic	  proteins)	  
promote	   mesoderm	   formation	   through	   a	   Wnt/Activin/Nodal-­‐dependent	  
mechanism(Alexander	  and	  Bruneau,	  2010;	  Willems	  et	  al.,	  2011a).	  
	  
1.10	  Main	  growth	  factors	  and	  molecules	  that	  controls	  cardiogenic	  
cell	  fate	  	  
Development	  is	  defined	  as	  a	  process	  by	  which	  a	  body	  is	  formed	  from	  a	  cell	  
by	  repeated	  cell	  divisions,	  called	  mitoses,	  and	  by	  the	  differentiation	  of	  the	  
cells	  derived	  therefrom,	  that	  acquire	  the	  typical	  structures	  of	  their	  species	  
(Noseda	  et	   al.,	   2011).	   The	  development	  depends	  at	   a	   large	  extent	  on	   the	  




during	   embryonic	   induction,	   which	   involves	   the	   release	   of	   a	   factor	   that	  
induces	   a	   signalling	   centre	   and	   that	   acts	   on	   a	   group	   of	   responding	   cells.	  
There	   are	   several	   families	   of	   such	   molecular	   factors	   that	   are	   known	   as	  
important	  growth	  factors,	  cytokines	  or	  hormones.	  
	  
To	   direct	   the	   differentiation	   of	   MSCs	   to	   the	   cardiac	   lineage	   we	   have	   to	  
follow	  two	  specific	  steps:	  
1-­‐ induction	  and	  specification	  of	  cardiac	  mesoderm	  	  
2-­‐ expansion	  of	  the	  cardiovascular	  lineages	  
To	   achieve	   this,	  we	   selected	   and	   used	   a	   specific	   combination	   of	   different	  
factors	   that	   are	   known	   to	   play	   a	   role	   in	   the	   development	   steps	   and	  
examined	   several	   components	   of	   Transforming	   Growth	   Factors-­‐β 	   family	  
(TGF-­‐β)	   for	   their	   ability	   to	   promote	   expression	   of	   the	   principal	   cardiac	  
transcription	  factors.	  This	  family	  includes:	  
ü TGF-­‐β	  
ü Activin/Nodal	  
ü BMP	  (bone	  morphogenetic	  proteins)	  
	  
TGF-­‐β	   starts	   the	   signal	   transmission	   by	   binding	   to	   receptor	  
serine/threonine	   kinases	   type	   I	   and	   type	   II	   on	   the	   cell	   surface.	   Signalling	  
propagates	   through	   intracellular	   Smad	   protein	   phosphorylation.	   Smad	   is	  
translocated	  into	  the	  nucleus	  where	  it	  regulates	  the	  transcription	  of	  target	  
genes.	   TGF-­‐β	   family	   play	   evolutionarily	   conserved	   roles	   in	   inducing	  
mesoderm	  and	  ectoderm	  (Yang	  et	  al.,	  2008).	  	  
Nodal	   has	   a	   graded	   influence	   at	   this	   time:	   high	   levels	   induce	   definitive	  
endoderm	   and	   anterior	   mesoderm,	   including	   cardiac	   mesoderm,	   while	  
lower	   levels	   favour	   more	   lateral	   and	   posterior	   derivatives.	   Thus,	  
specification	   of	   cardiogenic	   cells	   requires	   a	   particular	   dose	   in	   a	   temporal	  
window	   (Brennan	   et	   al.,	   2001)(Mercola	   et	   al.,	   2011).	   Similarly,	   biphasic	  
effects	  exist	  for	  BMPs	  and	  Wnts.	  	  
BMPs,	   in	   particular	   BMP2	   and	   BMP4,	   are	   needed	   during	   mesodermal	  
patterning	   but	   not	   subsequently	   for	   differentiation	   of	   committed	  




Recent	   studies	   have	   shown	   that	   the	   combination	   of	   BMP4	   and	   Activin	   A	  
promotes	  cardiac	  development	  in	  human	  ESCs	  (Kattman	  et	  al.,	  2011;	  Teo	  et	  
al.,	  2012).	  
Extracellular	   inhibitors	   of	   BMPs	   and	  Wnts	   are	   the	   principal	   inducers	   that	  
commit	   multipotent	   progenitors	   to	   a	   cardiac	   fate,	   as	   marked	   by	   heart-­‐
forming	  transcription	  factors	  NKX2-­‐5	  and	  MEF2C.	  	  
Because	  studies	  have	  shown	  that	  stage-­‐specific	  inhibition	  of	  canonical	  Wnt	  
signalling	   is	   required	   for	   cardiac	   development	   (Marvin	   et	   al.,	   2001),	   we	  
investigated	   the	   role	   of	   this	   pathway	   in	   the	   emergence	   of	   the	   cardiac	  
lineage	  from	  MSCs.	  
	  
Willens	   and	   co-­‐workers,	   by	   screening	   approximately	   550	   pathway	  
modulators,	   identified	   a	   small-­‐molecule	   inhibitor	   of	   the	   β-­‐catenin-­‐
dependent	   canonical	   Wnt	   pathway	   and	   showed	   that	   Wnt	   inhibition	   was	  
sufficient	   to	   drive	   the	   hESCs-­‐derived	   mesoderm	   to	   a	   cardiac	   fate	   in	   the	  
absence	   of	   other	   signalling	   modulators	   (Willems	   et	   al.,	   2011b).	  
Furthermore,	  Wnt	  inhibition	  drove	  cardiomyocytes	  specifically	  and	  did	  not	  
increase	   other	   mesoderm	   lineages,	   which	   suggests	   that	   Wnt	   inhibition	  
specifically	  drives	  a	  mesoderm	  progenitor	  toward	  cardiomyocytes.	  Willens	  
and	   co-­‐workers	   investigated	   also	   diverse	   Wnt	   inhibitors	   that	   target	  
different	   cellular	   components	   of	   the	   pathway.	   All	   of	   the	   small	   molecules	  
were	   much	   more	   cardiogenic	   than	   the	   natural	   inhibitors	   Divkkopf-­‐1	  	  
(DKK1).	  
In	   particular,	   they	   tested	   IWP,	   an	   inhibitor	   that	   prevents	   cells	   from	  
producing	  Wnt	   and	   IWR-­‐1	   a	   recently	   published	   inhibitor	   of	   the	   canonical	  
Wnt	  signalling	  response.	  	  
	  
Once	   the	   heart	   compartment	   is	   defined,	   proliferation	   and	   fate	   of	   cardiac	  
progenitors	  are	  controlled	  by	  signals	  such	  as	  FGFs	  and	  Notch.	  The	  latter	   is	  
particularly	  fascinating	  because	  it	  acts	  at	  different	  times	  in	  nearly	  all	  tissues	  
within	   the	   developing	   cardiovascular	   system.	   During	   specification	   of	  
cardiogenic	  cells,	  Notch	  suppresses	  cardiogenesis,	  as	  seen	  in	  ESCs	  cultures	  
(Mercola	  et	  al.,	  2011;	  Rones	  et	  al.,	  2000).	  Members	  of	  the	  fibroblast	  growth	  




germ	  layer	  during	  the	  early	  stages	  of	  embryogenesis.	  FGFs	  are	  also	  required	  
for	  the	  development	  of	  certain	  dorsal	  types	  of	  mesoderm.	  Therefore,	  bFGF	  
could	   be	   added	   to	   support	   the	   continued	   expansion	   of	   the	   developing	  
cardiovascular	  lineages.	  	  
A	  diaminopyrimidine	  (i.e.	  Cardiogenol	  C)	  could	  also	  be	  tested	  in	  the	  cocktail	  
because	   it	   is	   the	  most	  potent	   inducer	  of	  MHC	  expression.	  To	  confirm	  that	  
this	   compound	   is	   also	   a	   cardiomyogenesis	   inducting	   agent,	   Wu	   and	   co-­‐
workers	   analysed	   its	   effect	   on	   undifferentiated	   R1	   mouse	   ESCs	   that	   are	  
maintained	   in	  a	  pluripotent	   state	  with	   the	  addition	  of	   leukemia	   inhibitory	  
factor	   (LIF)	   in	   the	   culture	   medium	   (Wu	   et	   al.,	   2004).	   After	   7	   days,	   the	  
presence	   of	   beating	   cardiac	   muscle	   was	   visible	   under	   a	   microscope	   and	  
cells	  expressed	  the	  cardiac	  muscle	  cell	  specific	  transcription	  factors	  MEF2C	  
and	  NKX2-­‐5.	  	  
	  
1.11	  Markers	  for	  cardiogenic	  differentiation	  
1.11.1	  Transcription	  factors	  
Cardiomyocyte-­‐specific	  transcription	  factors	  are	  relevant	  tools	  to	  assess	  the	  
degree	  of	  differentiation	  achieved	  in	  our	  in	  vitro	  system.	  	  
Members	   of	   the	   Nk	   family	   of	   transcription	   factors	   are	   expressed	   in	   all	  
animals	  with	  contractile	  vascular	  cells	  and	  hence	  are	  crucial	  for	  myocardial	  
development	   (Bartlett	  et	  al.,	  2010);	  NKX2-­‐5	   is	   specifically	   required	   for	   left	  
ventricular	  chamber	  development	  (Zhao	  et	  al.,	  2012).	  	  
Gata	  is	  another	  family	  of	  transcription	  factors	  that	  interacts	  with	  Nk	  factors	  
to	   promote	   differentiation	   of	   cardiomyocytes,	   smooth	   muscle	   cells	   and	  
endoderm,	   and	   plays	   an	   important	   role	   in	   cardiac	   development.	  
Furthermore,	   GATA4	   regulates	   myocardial	   expression	   and	   is	   required	   for	  
fusion	   of	   the	   heart	   tubes	   in	   the	   ventral	   midline.	   GATA4	   gene	   knockout	  
studies	  demonstrate	  the	  essential	  role	  of	  this	  factor	  in	  cardiac	  development	  
and	  coordination	  of	  the	  expression	  of	  downstream	  cardiac	  genes	  (Armiñán	  
et	  al.,	  2010).	  Gata5	  is	  required	  for	  endocardial	  differentiation.	  	  
The	   implication	   of	   NKX2-­‐5	   and	   GATA4	   transcription	   factors	   is	   well	  
documented	   (Armiñán	   et	   al.,	   2009).	   These	   factors	   trigger	   the	   cardiac	  




recapitulating	   the	   molecular	   mechanism	   that	   operates	   during	   embryonic	  
heart	  development.	  During	  embryonic	  heart	  development,	   the	  expression	  
and	  activity	  of	  the	  transcription	  factor	  NKX2-­‐5	  is	  regulated	  by	  members	  of	  
the	  BMPs	  and	  TGF-­‐β signalling	  molecule	  families.	  This	  signalling	  mechanism	  
is	  reproduced	  when	  stem	  cells	  are	  treated	  with	  a	  cocktail	  of	  differentiated	  
factors.	  The	  outcome	  of	  this	  signalling	  machinery	  is	  the	  activation	  of	  several	  
terminal	   cardiac	   differentiation	   genes,	   including	   gap	   junction,	   the	   α-­‐
sarcomeric	  actin	  (α-­‐SA),	  the	  β	  myosin	  heavy	  chain	  (β-­‐MHC).	  	  	  	  
T-­‐box	  genes	  also	  play	  an	  important	  role	  in	  cardiac	  morphogenesis	  and	  TBX5	  
is	  required	  for	  atrial	  septation.	  Another	  important	  transcription	  factor	  that	  
should	   be	   considered	   is	   BAF60C	   a	   subunit	   of	   the	   BAF	   complex.	   It	   is	  
expressed	   in	   the	   developing	   heart	   and	   it	   is	   required	   for	   cardiac	  
morphogenesis	  and	  establishment	  of	  left-­‐right	  asymmetry.	  The	  addition	  of	  
BAF60C	   to	   a	   cocktail	   of	   cardiac	   transcription	   factors	   (GATA4,	   NKX2-­‐5	   and	  
TBX5)	   resulted	   in	   induction	   of	   beating	   cardiomyocytes	   from	   non-­‐
cardiogenic	   mesoderm	   (Ohtani	   and	   Dimmeler,	   2011;	   Takeuchi	   and	  
Bruneau,	   2009).	   Finally,	   BAF60C	   reinforces	   the	   function	   of	   cardiac	  
transcription	  factors	  such	  as	  GATA4	  and	  TBX5	  by	  acting	  as	  a	  bridge	  between	  
transcription	  factors	  and	  target	  genes.	  	  
The	  myocyte-­‐specific	  enhancer	  factor	  2C	  (MEF2C)	  is	  also	  involved	  in	  cardiac	  
morphogenesis,	   myogenesis	   and	   vascular	   development.	   Mice	   without	   a	  
functional	  copy	  of	  the	  MEF2C	  gene	  die	  before	  birth	  and	  have	  abnormalities	  
in	   the	   heart	   and	   vascular	   system	   (Bi	   et	   al.,	   1999).	  Other	   important	   genes	  
are	   (1)	  Mesp1	   (Bondue	   et	   al.,	   2008),	   	   which	   has	   been	   described	   as	   “the	  
master	   regulator”	   of	   cardiac	   progenitor	   specification,	   (2)	   FOG2	   (Friend	   of	  
GATA4),	  a	  basic	  helix-­‐loop-­‐helix	  transcription	  factor	  transiently	  expressed	  in	  
mesodermal	   populations	   that	   is	   physiologically	   associated	   with	   the	   N-­‐
terminal	  zinc	  finger	  of	  GATA4	  and	  modulates	  its	  transcriptional	  activity	  and	  
last	  (3)	  CAMTA	  (Calmodulin	  binding	  transcription	  activator	  2),	  that	   is	  a	  co-­‐






1.11.2	  Structural	  and	  functional	  genes	  
Contractility	   is	   a	   hallmark	   of	   cardiac	  myocytes.	  Many	   contractile	   proteins	  
are	   uniquely	   or	   predominantly	   expressed	   in	   cardiac	  myocytes	   and	   not	   in	  
other	  muscle	  cells.	  These	  proteins	  include	  several	  troponins,	  cardiac	  actins	  
and	  myosins.	  Troponin	   is	  a	  complex	  of	   three	   regulatory	  protein	   (Troponin	  
C,	  T	  and	  I)	  that	  is	  integral	  to	  contraction	  in	  myocardium.	  Cardiac	  troponin	  I	  
(TNNI3)	   and	   II	   are	   very	   sensitive	   and	   specific	   indicators	   of	   damage	   to	   the	  
heart	  muscle.	   Actins	   and	  myosins	   constitute	   contractile	   fibres.	   Cardiac	  α-­‐
actin	  (ACTC1),	  myosin	  light	  chains	  (MYL2)	  and	  α-­‐myosin	  heavy	  chain	  (MYL6)	  
are	  predominantly	  expressed	  in	  the	  heart	  but	  not	  in	  others	  muscles.	  	  
	  
1.12	  Tissue	  Engineering	  
Tissue	  engineering	  is	  a	  field	  that	  combines	  principles	  of	  engineering	  and	  of	  
life	   sciences	   for	   the	   development	   of	   biological	   substitutes	   that	   restore,	  
maintain	   or	   improve	   the	   function	   of	   damaged	   tissues	   and	   organs.	   Langer	  
and	  Vacanti	  were	  the	  first	  to	  promote	  the	  concept	  that	  cells	  may	  be	  seeded	  
on	   artificial	   matrices	   to	   support	   formation	   of	   functional	   tissue-­‐like	  
structures	  that	  may	  be	  used	  to	  repair	  diseased	  organs	  (Langer	  and	  Vacanti,	  
1993).	  
The	  goal	  of	  this	  technology	  is	  therefore	  to	  expand	  cells	  ex	  vivo	  on	  polymeric	  
biocompatible	  three-­‐dimensional	  matrices	  (named	  scaffolds)	  for	  the	  repair	  
of	   injury	  and	   for	   tissue	  regeneration;	   the	   full	   colonization	  of	   such	  scaffold	  
will	  give	  rise	  to	  a	  pseudo-­‐tissutal	  construct	  in	  vitro,	  which	  can	  be	  implanted	  
in	  vivo	  in	  humans.	  	  
Particularly,	   the	   perspective	   to	   use	   engineered	   tissues	   as	   organ	  
replacements	   in	   patients	   has	   intrigued	   scientists	   and	   clinicians.	   There	   is	   a	  
great	   medical	   necessity	   to	   develop	   alternatives	   to	   current	   organ	  
transplantation,	   given	   the	  worldwide	  mismatch	   between	   patients	  waiting	  
for	  organ	  transplants	  and	  the	  availability	  of	  donor	  organs	  (Zimmermann	  et	  
al.,	  2006).	  
The	   standard	   engineering	   methodology	   for	   the	   engineering	   for	  
implantations	  in	  humans	  involves	  the	  isolation	  of	  a	  specific	  cell	  line	  using	  a	  
biopsy,	   performed	   directly	   on	   a	   patient	   or	   on	   a	   compatible	   donor,	   and	   a	  




construct	   in	   specific	   and	   reproducible	   conditions.	   Finally,	   the	   construct	  
(scaffold	  and	  cells)	  will	  be	  placed	   in	   the	  patient	   in	  order	   to	   reconstruct	  or	  
repair	   the	   damaged	   tissue.	   These	   structures	   represent	   the	   second	  
bioartificial	  generation	  of	   replacement	  systems	  of	  organs	  and	   tissues.	   It	   is	  
very	  important	  to	  understand	  and	  characterized	  the	  interaction	  of	  the	  cell	  
with	   the	   substrate,	   the	   biomolecules	   transport	  within	   the	  matrix	   and	   the	  
development	   of	   technologies	   for	   the	   control	   of	   chemical-­‐physical	   and	  
mechanical	  parameter	  (bioreactors).	  Furthermore,	  it	  is	  important	  to	  have	  a	  
biodegradable	  and	  bioresorbable	  scaffold	  to	  allow	  a	  gradual	  absorption	  of	  
the	   support	   after	   a	   period	   of	   time	   from	   its	   contact	   with	   the	   biological	  
environment	   during	   the	   formation	   of	   new	   tissue	   engineered	   (Dutta	   and	  
Dutta,	  2009;	  Kawakami,	  2008;	  Rezwan	  et	  al.,	  2006).	  
Tissue	   engineering/regenerative	   medicine	   (TERM)	   approach	   could	   be	   a	  
really	   promising	   tool	   to	   induce	   cardiac	   infarcted	   tissue	   repair,	   avoiding	  
heart	   transplantation	   drawbacks	   and	   risks.	   One	   of	   the	   most	   promising	  
approaches	   in	  myocardial	  TERM	   is	   the	  design	  and	   fabrication	  of	   scaffolds,	  
which	  are	   realized	  with	   synthetic	   and	  natural	  materials.	   TERM	  techniques	  
based	  on	  scaffold	   implantation	  are	  more	  appropriate	  for	  the	  regeneration	  
of	  tissues	  that	  require	  a	  mechanical	  support	  to	  the	  reparative	  process,	  such	  
as	   the	   cardiac	   one,	   while	   cell	   therapy	   is	  more	   suitable	   for	   tissues	   with	   a	  
relatively	   simple	   structure	   and	   in	   case	   of	   small	   injuries	   (Leor	   and	   Cohen,	  
2004;	   Obradovic	   et	   al.,	   2010).	   The	   use	   of	   3D	   scaffolds	   provides	   some	  
advantages	   over	   cell	   injection	   into	   damaged	   area:	   such	   a	   scaffold	  
temporarily	   replaces	   the	   injured	   tissue,	   provides	   a	   transitional	   support	   to	  
cell	  colonization,	  migration	  and	  proliferation	  and	  degrades	  with	  time	  as	  the	  
need	  of	  an	  artificial	  aid	  decreases;	  scaffold	  implantation	  allows	  control	  over	  
graft	   dimension,	   shape,	   mechanical	   properties	   and	   composition;	   since	   a	  
myocardial	   infarct	   (MI)	   generally	   causes	   the	   loss	  of	  more	   than	  one	  billion	  
cells,	   cell	   therapy	  would	   require	   the	   injection	   of	   a	   large	   number	   of	   cells.	  
When	  cells	  are	   injected	   intra-­‐coronary,	  about	  90%	  of	   them	  are	   lost	   in	   the	  
blood	   circulation	   and	   90%	   of	   the	   successfully	   injected	   ones	   dies	  within	   a	  
week	   (Leor	   and	   Cohen,	   2004)(Curtis	   and	   Russell,	   2009).	   Several	   studies	  
have	   demonstrated	   the	   capability	   of	   heart	   patches	   to	   alleviate	   LV	  




region	   immediately	   or	   within	   two	   weeks	   after	   the	   MI	   (Fujimoto	   et	   al.,	  
2007).	  More	  recently	  Liao	  and	  co-­‐workers	  (Liao	  et	  al.,	  2010)	  demonstrated	  
the	   capability	   of	   heart	   patches	   to	   attenuate	   LVR	   and	   improve	   cardiac	  
performances	   (LV	   ejection	   fraction	   improvement)	   even	   if	   implanted	   in	  
chronic	   conditions	   (eight	   weeks	   after	   the	   MI).	   Scaffolds	   can	   be	   used	   as	  
heart	   patches,	   in	   order	   to	   create	   the	   optimal	   platform	   for	   living	   cells	   to	  
grow	   and	   then	   degrade	   over	   time	   as	   the	   cell	   form	   their	   own	   external	  
support	   structures.	   These	   substrates	   can	   be	   designed	   to	   enhance	  
recruitment	   and	   differentiation	   of	   cardiac	   progenitors	   cells	   (CPC),	   by	  
introducing	   bioactive	   molecules	   such	   as	   growth	   factors	   and	   extracellular	  
matrix	   (ECM)	  molecules.	   Patches	   can	   be	   pre-­‐seeded	   with	   cells	   or	   not,	   in	  
approaches	   that	   can	   be	   classified	   in	   vitro	   or	   in	   vivo.	   To	   guide	  myocardial	  
regeneration	   and	   give	   a	   mechanical	   support,	   the	   scaffold	   must	   have	   the	  
following	  characteristics:	   long-­‐term	  elasticity	   that	  matches	  the	  mechanical	  
demands	   of	   force-­‐generating	   contractile	   tissue;	   biodegradation	   at	   rates	  
compatible	   with	   tissue	   regeneration;	   ability	   to	   support	   cell	   proliferation,	  
migration	  and	  differentiation;	  porous	  structures	  to	  attain	  the	  desired	  mass	  
transport	   (Engelmayr	   et	   al.,	   2008;	   de	  Mulder	   et	   al.,	   2009;	   Silvestri	   et	   al.,	  
2013).	  
	  
Biomaterials	   for	   TERM	   must	   satisfy	   requirements	   from	   a	   biological,	  
chemical	  and	  mechanical	  point	  of	  view.	  These	  materials	  not	  only	  need	  to	  be	  
cell	   and	   tissue	   compatible,	   with	   no	   inflammatory	   response	   after	  
implantation,	  but	  also	  need	  to	  support	  cell	  attachment,	  differentiation	  and	  
proliferation. One	  of	  the	  main	  physical	  requirements	  that	  a	  biomaterial	  has	  
to	  meet	   is	   the	  biodegradability.	  Materials	  have	  to	  degrade	   in	  vivo	  at	  rates	  
compatible	  with	   tissue	   regeneration,	  with	   the	   release	   of	   non-­‐toxic,	   easily	  
metabolized,	   and	   secreted	   products	   from	   the	   body,	   not	   inducing	  
inflammatory	  response.	  
They	  have	  also	  the	  possibility	  to	  be	  processed	  into	  porous	  scaffolds	  for	  cell	  
penetration,	  tissue	  growth,	  vascularization	  and	  nutriment	  delivery.	  Also	  the	  
mechanical	   characteristics	   are	   important,	   since	   the	   heart	   patch	   should	  
restore	   heart	   geometry,	   provide	   a	  mechanical	   support	   and	   accommodate	  




failure	   (Christman	   and	   Lee,	   2006).	   Since	   the	  most	   abundant	   cardiac	   ECM	  
protein	  is	  collagen,	  Chen	  and	  co-­‐workers	  (Chen	  et	  al.,	  2009)	  supposed	  that	  
cells	  could	  find	  the	  most	  suitable	  microenvironment	  for	  their	  proliferation	  
into	  a	  matrix	  with	  analogue	  mechanical	  properties	   to	   those	  of	  myocardial	  
collagen.	  
1.12.1	  Biomaterials	  and	  polymers	  in	  regenerative	  medicine	  
Biomaterials	  should	  respond	  to	  the	  need	  of	   functionally	  and	  metabolically	  
replacing	  a	  no	  more	  active	  human	  tissue	  or	  organ,	  damaged	  by	  pathological	  
or	   traumatic	   events.	   The	   number	   of	   their	   applications	   has	   grown	  
significantly	  in	  recent	  years.	  	  
The	  performance	  of	  materials	  used	   in	  medical	   field	   is	  evaluated	  according	  
to	   their	  bio-­‐functionality	  and	  biocompatibility.	   The	  bio-­‐functionality	   refers	  
to	   the	   property	   that	   a	   device	   must	   have	   to	   play	   a	   specific	   physical	   and	  
mechanical	   function.	   The	   biocompatibility	   is	   the	   ability	   of	   the	   device	   to	  
perform	  the	  same	  function	  during	  the	  useful	  life	  of	  the	  system	  and	  refers	  to	  
the	   interactions	   between	   the	   biomaterials	   and	   the	   tissues.	   The	   starting	  
parameters	   include:	   cytotoxicity,	   cytostasis,	   lysis	   of	   the	   cell	   membrane,	  
mutagenesis	  and	  carcinogenesis.	  	  
Secondary	   tests	   are	   designed	   to	   analyse	   the	   inflammatory	   and	   immune	  
response.	  The	  materials	  are	  implanted	  for	  a	  defined	  period	  (i.e.	  from	  weeks	  
to	  years)	  and,	  at	  the	  end	  of	  the	  established	  time	  any	  possible	  damage	  has	  
to	  be	  evaluated.	  The	  materials	  are	  implanted	  in	  large	  animals	  and	  only	  after	  
animal	  testing	  are	  approved	  for	  humans.	  
Polymers	   consist	   of	   very	   long	   and	   flexible	   molecules,	   composed	   by	   the	  
repetition	  of	  simple	  units	  (called	  monomeric	  units)	  linked	  together	  through	  
covalent	  bonds.	  Long	  chains	  are	   joined	  together	  by	  Van	  der	  Waals	   forces,	  
by	  hydrogen	  bonds	  or	  by	  covalent	  bonds.	  A	  fundamental	  parameter	  of	  the	  
polymer	   is	   the	   degree	   of	   polymerization	   (average	   number	   of	   repetitive	  
units	  within	  a	  molecule),	  that	  determines	  the	  relative	  mobility	  of	  the	  chains	  





1.12.1.1	  Natural	  Polymers	  
Natural	   Polymers	   are	   highly	   biocompatible,	   stimulating	   low	   in	   vivo	  
inflammatory	   response	   and	   providing	   a	   natural	   substrate	   for	   cell	  
attachment,	   proliferation	   and	   differentiation	   in	   their	   native	   state.	   They	  
favour	  cell	  attachment	  and	  proliferation	  due	  to	  their	  adhesion	  specific	  sites	  
(Jawad	  et	  al.,	  2007).	  Despite	  these	  positive	  features,	  natural	  polymers	  have	  
poor	   mechanical	   properties,	   poor	   workability	   and	   rapid	   degradation	  
kinetics,	  which	  limit	  their	  clinical	  application.	  To	  overcome	  these	  problems	  
a	   strategy	   consists	   in	   blending	   them	   with	   synthetic	   polymers	   (Sui	   et	   al.,	  
2011).	  Among	  natural	  polymers,	  collagen,	  gelatin,	  fibrin	  alginate	  have	  been	  
mainly	  investigated	  (Silvestri	  et	  al.,	  2013)	  
1.12.1.2	  Synthetic	  Polymers	  
Synthetic	  materials	  are	  widely	  used	  in	  myocardial	  tissue	  regeneration,	  due	  
to	   some	   excellent	   characteristics.	   First	   they	   show	   superior	   mechanical	  
properties	   than	  natural	  polymers	   that	  make	   them	  suitable	   for	  mechanical	  
support	   (Jawad	   et	   al.,	   2008;	   Sui	   et	   al.,	   2011).	   These	   properties,	   together	  
with	   hydrophilicity	   and	   degradability,	   can	   be	   controlled	   in	   a	   reproducible	  
manner.	   Drawbacks	   regard	   their	   poor	   interaction	   with	   the	   cells	   and	   the	  
biological	   environment.	   The	   main	   synthetic	   polymers	   are:	   polyesters,	  
polylactide	   PLA,	   polyglycolide	   PGA,	   PLGA	   that	   is	   a	   combination	   of	  
polylactide	   PLA	   and	   polyglycolide	   PGA,	   polye	   caprolactone	   PCL	   and	  
polyurethanes	  PURs	  (Silvestri	  et	  al.,	  2013).	  
1.12.1.3	  Polyurethanes	  (PURs)	  
Polyurethanes	  are	  a	  large	  group	  of	  polymers	  widely	  used	  in	  the	  biomedical	  
and	  industrial	  field.	  Materials	  with	  varying	  chemical,	  mechanical,	  biological	  
and	   degradation	   properties	   can	   be	   achieved	   (Li	   et	   al.,	   2013)	   by	   proper	  
selection	  of	  different	  starting	   reagents	   (polydiols,	  diidocyanates	  and	  chain	  
extenders).	  In	  cardiac	  TERM,	  degradable	  PURs,	  based	  on	  polyester	  polyols,	  
have	   been	   studied	   for	   a	   long	   time	   because	   of	   their	   biocompatibility	   and	  
elastomeric	   properties	   that	   fit	   the	   requirements	   of	   materials	   for	  




1.13	  Aim	  of	  the	  project	  	  
The	   goal	   of	   this	   project	   is	   to	   differentiate	   adult	   adipose	   tissue-­‐derived	  
mesenchymal	   stem	   cells	   into	   cardiomyocytes	   progenitors.	   On	   the	   long	  
term,	  these	  studies	  could	  contribute	  to	  the	  development	  of	  stem	  cell-­‐based	  
therapies	   for	   the	   cure	  of	   cardiovascular	  diseases.	   The	   first	  part	   is	   focused	  
on	  developing	  protocols	  for	   isolation,	  characterization,	   in	  vitro	  culture	  and	  
identification	  of	  optimal	  conditions	  for	  long-­‐term	  storage	  of	  Adipose	  Tissue-­‐
Derived	  Multipotent	  Stromal	  Cells	  (ACSs).	  For	  that,	   isolated	  ACSs	  has	  been	  
extensively	   characterized	  by	   flow	  cytometry,	   and	  genetically	  profiled	  by	  a	  









After	   the	   achievement	   of	   this	   initial	   phase,	  we	  have	   tried	   to	   differentiate	  
ASCs	  into	  cardiac	  progenitor	  cells	  following	  two	  innovative	  approaches:	  the	  
use	   of	   human	   growth	   factors	   in	   a	   defined	   serum-­‐free	   culture	   induction	  
medium	   and	   the	   application	   of	   mechanical	   stimuli	   to	   mimic	   the	   heart	  
environment	   [Fig.	   9].	   Since	   these	   protocols	   are	   ultimately	   aimed	   at	  
producing	   cells	   for	   applications	   in	   humans,	   we	   developed	   protocols	  
compliant	   with	   the	   strict	   European	   regulations	   concerning	   the	   Advanced	  
Figure	  8.	  Aim	  and	  strategy	  of	  the	  project.	  The	  first	  aim	  focused	  on	  developing	  protocols	  for	  





Therapy	   Medicinal	   Product.	   Therefore,	   from	   the	   very	   first	   steps	   of	   the	  
project	  (i.e.	  the	  isolation	  of	  ASCs),	  we	  focused	  on	  the	  use	  of	  “clinical	  grade”	  




1.14	  Our	  approach	  
We	  are	  particularly	   interested	   in	   investigating	  the	  cardiogenic	  potential	  of	  
ASCs.	   In	   the	   past,	   different	   approaches	   have	   been	   used	   to	   induce	   the	  
differentiation	  of	  ASCs	   toward	  the	  cardiac	   lineage	  such	  as	  methylcellulose	  
media	  (Sliwa	  et	  al.,	  2009),	  culturing	  the	  cells	  with	  nuclear	  and	  cytoplasmic	  
extracts	   from	   rat	   cardiomyocytes	   (Gaustad	  et	   al.,	   2004),	   co-­‐culturing	  with	  
neonatal	   rat	   cardiomyocytes	   (Madonna	   et	   al.,	   2008)(Zhu	   et	   al.,	   2009),	   or	  
using	   of	   the	   chemical	   agent	   5-­‐azacytidine	   (5-­‐AZA).	   Because	   the	   use	   of	  
animal	   derivatives	   or	   chemical	   agents	  may	   affect	   the	   genomic	   stability	   of	  
Figure	  9.	  Aim	  and	  strategy	  of	  the	  project.	  The	  second	  goal	  is	  to	  find	  strategies	  for	  cardiogenic	  
differentiation.	  We	   tested	  three	  different	  approaches,	   the	   first	  based	  on	   the	  use	  of	   growth	  
factors	  and	  cytokines,	  the	  second	  based	  on	  the	  application	  of	  an	  mechanical	  stimuli,	  and	  the	  





the	  cells	   (5-­‐AZA)	   (Madonna	  et	  al.,	  2008;	  Palpant	  et	  al.,	  2007),	  none	  of	   the	  
above	   cited	   methods	   is	   compatible	   with	   the	   use	   of	   ASCs	   in	   the	   clinical	  
practice.	  Moreover	  the	  heart	  should	  be	  considered	  as	  a	  complex	  structure	  
organ	  in	  which	  the	  electrical	  conduction	  and	  mechanical	  stimuli	  play	  a	  very	  
important	  role.	  This	  particular	  aspect	  has	  been	  poorly	  investigated	  and	  may	  
significantly	   contribute	   to	   the	   differentiation	   of	   the	   cardiac	   progenitors	  
during	  embryonic	  development.	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2.	  Materials	  and	  Methods	  
2.1	  Isolation	  of	  Stromal	  Vascular	  Fraction	  (SVF)	  
	  
We	   designed	   the	   isolation	   protocol	   around	   the	   use	   of	   a	   100ml	   syringe	  
(Omnifix	  100ml	  with	  Luer	  Adaptor,	  B.	  Braun	  AG,	  Melsungen,	  Germany)	  as	  a	  
separation	  funnel	  (Patent	  pending;	  Minonzio	  et	  al.,	  submitted	  manuscript).	  
The	  protocol	  is	  based	  on	  the	  fact	  that	  adipose	  tissue	  and	  hydrophilic	  fluids	  
spontaneously	  separate	  in	  two	  phases	  without	  need	  of	  centrifugation.	  The	  
piston	   of	   the	   syringe	   is	   used	   to	   take	   in	   or	   to	   expel	   the	   solutions	   used	   to	  
wash	   the	   sample,	   to	   dissociate	   the	   suctioned	   fat,	   or	   to	   extract	   the	   cells	  
from	  the	  dissociated	  adipose	  tissue.	  The	  syringe	  is	  hold	  in	  a	  vertical	  position	  
using	   a	   laboratory	   support	   stand	   with	   support	   rings.	   Therefore,	   all	   the	  
necessary	  manipulations	   for	   the	   extraction	   of	   ASCs	   are	   performed	   inside	  
the	  syringe	  and	  last	  about	  70	  minutes.	  The	  first	  step	  is	  to	  wash	  the	  sample	  
with	   40	   ml	   Dulbecco’s	   PBS	   (PBS,	   with	   Ca2+	   &	   Mg2+,	   PAA	   Laboratories,	  
Pasching,	  Austria)	   by	   gentle	   agitation.	   The	   syringe	   is	   hold	   vertically	   in	   the	  
support	   stand	   for	   few	  minutes	   to	   allow	   the	   separation	  of	   the	  phases	   and	  
the	  lower	  aqueous	  phase	  is	  discarded	  by	  pushing	  the	  piston.	  The	  sample	  is	  
washed	  twice.	  To	  free	  the	  cells	   in	  the	  aqueous	  phase	  the	  washed	  adipose	  
tissue	   is	   digested	  with	   the	   appropriate	   amount	   of	   Liberase	  MTF-­‐S	   (Roche	  
Applied	  Science,	  Basel,	  Switzerland)	  at	  a	  final	  concentration	  of	  0.28	  Wünsch	  
U/ml	  [10]	  diluted	  in	  10	  ml	  DPBS	  (with	  Ca2+	  &	  Mg2+).	  The	  sample	  is	  incubated	  
45	  minutes	  at	  37°C	  under	  constant	  but	  gentle	  agitation.	  Enzymatic	  reaction	  
is	  stopped	  by	  aspiration	  of	  30	  ml	  of	  injectable	  5%	  human	  albumin	  solution	  
(CSL	  Behring	  AG,	  Bern,	  Switzerland)	   in	  the	  syringe.	  The	  syringe	   is	  then	  put	  
back	   in	   vertical	   position	   to	   allow	   the	   separation	  of	   the	  phases.	   The	   lower	  
layer,	   which	   contains	   now	   the	   SVF	   cells,	   is	   carefully	   poured	   out	   into	   a	  
conical	   50	   ml	   centrifuge	   tube	   (TPP,	   Trasadingen,	   Switzerland).	   Extracted	  
adipose	   tissue	   is	  washed	  again	  with	  40	  ml	  5%	  human	  albumin	  solution	   to	  
increase	   cell	   yield.	   Finally,	   after	   filtration	   through	   100	   and	   a	   40	  μm	   sieve	  
(Cell	  Strainer,	  BD	  Falcon,	  Basel,	  Switzerland),	  SVF	  is	  centrifuged	  400g	  5	  min	  
RT	   and	   the	   pellet	   resuspended	   in	   DPBS	   (without	   Ca2+	   &	   Mg2+,	   PAA	  
Laboratories,	  Pasching,	  Austria)	  or	   in	   tissue	   culture	  medium.	  The	  SVF	  was	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analysed	  for	  cell	  count	  and	  the	  number	  of	  nucleated	  cells	  was	  established	  
using	  an	  electronic	  cell	  counter	  (Hemocytometer	  –	  AxonLab	  ABX	  Micros60).	  
2.2	   Cellular	   characterization	   by	   Fluorescence-­‐Activated	   Cell	   Sorter	  
(FACS)	  analysis.	  
	  
The	   Fluorescence-­‐Activated	   Cell	   Sorter	   (FACS)	   allows	   the	   measurement,	  
characterization	  and	  separation	  of	  cells	  suspended	  in	  a	  fluid	  medium,	  based	  
on	   the	   physical	   characteristics	   of	   the	   cell	   and	   on	   the	   presence	   of	  
fluorescent	  molecules	  bound	  to	  the	  cell.	  	  
In	  this	  work	  cytometric	  analysis	  was	  performed	  using	  a	  Navios	  machine,	  10	  
channel	  flow	  cytometer	  (Navios,	  Beckman	  and	  Coulter,	  Nyon,	  Switzerland),	  
and	  the	  data	  were	  analysed	  with	  a	  Kaluza	  software.	  	  	  
2.2.1	  Stromal	  Vascular	  Fraction	  characterization	  
Fresh	  SVF	  cells	  were	  characterized	  by	  FACS	  	  following	  standard	  procedures.	  
All	   antibodies	   and	   reagents	   mentioned	   below	   have	   been	   provided	   by	  
Beckman	  and	  Coulter.	  
Briefly,	   550.000	   cells	   from	   fresh	   SVF	   preparation	   were	   taken	   and	  
centrifuged	  5	  min	  400	  g	  at	  RT.	  The	  pellet	  was	  resuspended	  in	  220	  μl	  of	  FACS	  
buffer	   (i.e.	   PBS	  without	  Ca2+/Mg2+	  with	   1%	  human	   converted	  AB	   serum).	  
Two	  test	  tubes	  were	  prepared	  for	  staining	  with	  the	  following	  antibodies:	  
	  
1)	  control	  tube	  
ü IgG2a-­‐PE	  -­‐	  A12695	  
ü IgG1-­‐KRO	  -­‐	  A96415	  	  
ü IgG1-­‐APC-­‐A750	  -­‐	  A71120	  	  
ü Syto	  40	  -­‐	  S11351	  (Invitrogen)	  
2)	  sample	  tube:	  
ü CD146-­‐PE	  	  -­‐	  A07483	  
ü CD45-­‐KRO	  -­‐	  A96416	  	  
ü CD34-­‐APC-­‐A750	  -­‐	  A89309	  	  
ü 7-­‐AAD	  -­‐	  A07704	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100	  μl	  of	   the	   resuspended	   cells	  were	   then	  added	   to	   the	   tubes	   containing	  
the	  antibodies	  and	  incubated	  for	  25	  min	  at	  RT	  in	  the	  dark.	  1	  ml	  of	  Versalyse	  
Lysing	  solution	  was	  added	  to	  both	  tubes	  that	  were	  thereafter	  incubated	  for	  
10	  min	  at	  RT	  in	  the	  dark.	  100	  μl	  of	  flow	  count	  Fluorospheres	  were	  added	  to	  
the	  sample	  tube	  just	  before	  the	  measurement.	  
2.2.2	  Characterization	  of	  cultured	  ASCs	  cells	  
At	  the	  second	  passage	  all	  cells	  were	  characterized	  for	  the	  expression	  of	  cell	  
surface	  molecules	  and	  mesenchymal	   stem	  cell	  markers	  with	   the	   following	  
anti-­‐human	  monoclonal	  antibodies:	  	  
ü CD105-­‐PE	  	  (A07414)	  Beckman	  Coulter	  
ü CD73-­‐FITC	  (561254)	  BD	  
ü CD90-­‐PC5	  (IM3703)	  Beckman	  Coulter	  
ü CD31-­‐FITC	  (IM1431U)	  Beckman	  Coulter	  
ü CD45-­‐KRO	  (A96416)	  Beckman	  Coulter	  
ü CD34-­‐APC-­‐A750	  (A89309)	  Beckman	  Coulter	  
And	  the	  proper	  controls:	  
ü IgG1-­‐FITC	  (A07795)	  Beckman	  Coulter	  
ü IgG1-­‐PE	  (400113)	  BioLegend	  
ü IgG1-­‐PC5	  (A07798)	  Beckman	  Coulter	  
ü IgG-­‐APC	  AF750	  (A71120)	  Beckman	  Coulter	  
ü IgG1-­‐KRO	  (A96415)	  Beckman	  Coulter	  
	  
2.3	  Colony-­‐Forming	  Unit	  (CFU-­‐F)	  Assay.	  	  
	  
The	  CFU-­‐F	  assay	  was	  performed	  as	  already	  described	  elsewhere	   (Casteilla	  
et	  al.,	  2011;	  Pittenger	  et	  al.,	  1999)	  and	  used	   to	  evaluate	   the	   frequency	  of	  
mesenchymal	  progenitors	   in	   the	  SVF	   fraction.	  Freshly	  extracted	  nucleated	  
cells	   were	   plated	   at	   two	   cell	   concentrations	   (5000	   and	   10000	   cells)	   in	  
standard	   100	   x	   20	  mm	   tissue	   culture	   dishes	   (growth	   area	   58.95	   cm2,	   BD	  
Falcon,	   Basel,	   Switzerland)	   and	   cultured	   in	   MEM/5%	   converted	   human	  
serum/1%	  antibiotics	  for	  14	  days.	  The	  plates	  were	  then	  washed	  with	  DPBS,	  
fixed	   in	   2%	   formaldehyde	   (Sigma-­‐Aldrich,	   Buchs,	   Switzerland)/0.2%	  
Glutaraldehyde	   (AppliChem,	   Darmstadt,	   Germany)	   for	   5	   minutes	   and	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stained	  with	   crystal	   violet	   solution	   (Sigma-­‐Aldrich,	   Buchs,	   Switzerland)	   for	  
10	  minutes.	  After	  washing	  the	  plates	  with	  water,	  the	  number	  of	  colonies	  in	  
each	   dish	   was	   counted.	   A	   colony	   consisting	   of	   more	   than	   50	   cells	   was	  
defined	  as	  a	  CFU-­‐F.	  
2.4	  Cryopreservation	  and	  thawing	  of	  SVF.	  
	  
Fresh	  SVF	  cells	  were	  centrifuged	  for	  5	  min	  at	  400g,	  resuspended	  in	  ice-­‐cold	  
solution	  of	   injectable	  5%	  human	  albumin	   solution	  with	  10%	  DMSO	   (WAK-­‐
Chemie	   Medical	   GmbH,	   Steinbach,	   Germany),	   and	   transferred	   into	   a	  
freezing	   cryovial.	   The	   cells	   were	   frozen	   using	   a	   programmable	   freezer	  
(Consartic	   GmbH,	   Schoellkrippen,	   Germany)	   under	   standard	   “controlled-­‐
rate”	   conditions	   from	   4°C	   to	   -­‐100°C	   and	   then	   finally	   stored	   in	   liquid	  
nitrogen.	  For	  thawing,	  the	  cryovial	  was	  put	  in	  ice	  for	  5	  min	  and	  immersed	  in	  
a	  37°C	  water	  bath	  usually	  2-­‐3	  min.	  Immediately	  after	  being	  thawed	  the	  cells	  
were	   carefully	   aspirated,	   mixed	   with	   an	   equal	   volume	   of	   injectable	   5%	  
human	   albumin	   solution	   in	   a	   15	   ml	   TPP	   conical	   tube	   and	   centrifuged	   at	  
400g	  for	  5	  min.	  The	  supernatant	  was	  discarded,	  the	  pellet	  resuspended	   in	  
fresh	  tissue	  culture	  medium	  and	  used	  for	  the	  subsequent	  analyses.	  
	  
2.5	  Cell	  culture	  and	  standard	  differentiations.	  
	  
Cells	  were	  cultured	  until	  passage	  2	  in	  basal	  Ham’s	  F12/IMDM	  (1:1)	  medium	  
supplemented	  with	   various	   growth	   factors	   and	   referred	   to	   as	   serum	   free	  
control	  medium	  (Patent	  pending).	  For	  osteogenic	  differentiation	  cells	  were	  
then	   plated	   at	   a	   density	   of	   3	   x	   103/cm2	   onto	  multi	   well	   plates	   (PureCoat	  
ECM	   Mimetic	   Cultureware,	   BD	   Biosciences,	   Bedford,	   USA)	   and	   put	   in	  
osteogenic	   differentiation	   medium	   for	   21	   days.	   Non-­‐induced	   cells	   were	  
incubated	   in	  serum	  free	  control	  medium.	  Osteoinductive	  medium	  was	  the	  
serum	  free	  control	  medium	  supplemented	  with	  Sr2+	  and	  Vitamin	  D	  (Patent	  
pending).	   Morphological	   changes	   appeared	   during	   the	   second	   week	   of	  
culture	   and	   cell	   differentiation	   was	   confirmed	   at	   day	   21	   by	   Alizarin	   Red	  
staining	  (see	  2.5.2).	  Briefly,	  the	  cells	  were	  fixed	  in	  10%	  formalin	  for	  30	  min	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at	  RT	  and	  incubated	  30	  min	  at	  RT	  in	  Alizarin	  Red	  staining.	  The	  formation	  of	  
red	  calcium	  deposits	  is	  a	  marker	  of	  osteogenic	  differentiation.	  	  
The	   adipogenic	   potential	  was	   assessed	  by	  plating	   cells	   at	   a	   density	   of	   3	   x	  
103/cm2	   onto	  multi	  wells	   plates	   (BD	   PureCoat	   ECM	  Mimetic	   Cultureware,	  
BD	   Biosciences,	   Bedford,	   USA)	   in	   serum	   free	   control	   medium	   or	   in	  
adipogenic	   induction	   medium	   for	   21	   days.	   Adipogenic	   induction	   medium	  
was	   the	   serum	   free	   control	   medium	   supplemented	   with	   EGF	   (cyt-­‐217,	  
ProSpec-­‐Tany	   Technogene	   Ltd.,	   East	   Brunswick,	   USA)	   and	   Rosiglitazone	  
(Sigma-­‐Aldrich,	   Buchs,	   Switzerland)	   (Patent	   pending).	   Adipogenesis	   was	  
assessed	  by	  Oil	  Red	  staining	  (see	  2.5.1	  for	  details).	  Briefly,	  cells	  fixed	  in	  10%	  
formalin	  for	  30	  min	  at	  RT	  were	  incubated	  in	  fresh	  Oil	  O	  Red	  water	  solution	  
for	  5	  min	  at	  RT.	  Induced	  cells	  should	  be	  visible	  as	  cells	  containing	  consistent	  
red	  deposits	  in	  vacuoles.	  	  
Chondrogenic	  differentiation	  was	  assessed	  by	   induction	  of	  ASCs	  using	   the	  
micromass	  method.	  Briefly,	  ASCs	  were	  gently	  centrifuged	   in	  15	  ml	  conical	  
tube	   to	   form	   small	   pellets	   and	   cultured	   for	   21	   days	   in	   the	   serum	   free	  
control	  medium	   supplemented	  with	   sodium	   pyruvate,	   BMP-­‐6,	   TGF-­‐beta3,	  
beta-­‐FGF	   and	   PGE2	   (Patent	   pending).	   Chondrogenic	   pellets	   were	   fixed	   in	  
10%	   formalin	   for	   30	  min	   at	  RT.	   Samples	  were	   then	  embedded	   in	  paraffin	  
and	  sections	  stained	  with	  Alcian	  Blue.	  	  
2.5.1	  Oil-­‐Red	  O	  staining	  
The	   presence	   of	   lipid	   granules	   in	   cell	   cultures	   induced	   to	   adipogenic	  
differentiation	  was	  determined	  with	  Oil-­‐Red-­‐O.	  The	  cells	  were	  fixed	  in	  fixing	  
solution	  and	  washed	  in	  H20	  and	  incubated	  for	  15	  minutes	  with	  a	  solution	  of	  
isopropanol	  0.5%	  Oil-­‐Red-­‐O	  (Sigma),	  filtered	  and	  diluted	  to	  60%	  in	  distilled	  
H20.	  Subsequently	  the	  cells	  were	  washed	  in	  H20.	  
2.5.2	  Alizarin	  Red	  Staining	  
The	   formation	   of	   red	   calcium	   deposits	   is	   a	   marker	   of	   osteogenic	  
differentiation	  and	  it	  is	  shown	  by	  the	  use	  of	  Alizarin	  Red	  staining.	  	  
After	   the	   induction	   the	   medium	   was	   discarded,	   cells	   were	   then	   washed	  
with	  PBS	  without	  Ca	  and	  Mg	  and	  fixed	  in	  formalin	  10%	  for	  30	  minutes.	  The	  
plate	  was	  washed	  again	  with	  distilled	  water,	  Alizarin	  Red	  O	  solution	  added	  
and	  the	  plate	   incubated	   in	  a	  gentle	  agitation	   for	  20	  minutes.	  The	  samples	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were	  washed	  3	  times	  with	  distilled	  water	  to	  remove	  the	  excess	  of	  Alizarin	  
Red	  O.	  Calcium	  deposits	  were	  observed	  at	  the	  microscope.	  
2.6	  Cardiac	  Induction	  -­‐	  cell	  culture	  	  
	  
Cells	  were	  cultured	  until	  passage	  2	  in	  basal	  Ham’s	  F12/IMDM	  (1:1)	  medium	  
supplemented	  with	   various	   growth	   factors	   and	   referred	   as	   to	   serum	   free	  
control	   medium	   (Patent	   pending).	   Cells	   were	   then	   detached	   with	   Tryple	  
Select	  (Gibco,	  Switzeland)	  and	  then	  replated	  at	  a	  concentration	  of	  15	  x	  103	  
Cells/cm2	  and	  maintained	  with	  serum	  free	  culture	  medium	  in	  6-­‐well	  plates	  
(PureCoat	   ECM	  Mimetic	   Cultureware,	   BD	   Biosciences,	   Bedford,	   USA)	   in	   a	  
controlled	  CO2	  cell	  incubator.	  
Twenty-­‐four	  hours	  later,	  the	  culture	  media	  was	  removed,	  the	  cells	  washed	  
with	  PBS	  solution,	  and	  each	  well	  submitted	  to	  a	  specific	  protocol	  aimed	  at	  
obtaining	   cardiogenic	   differentiation,	   as	   shown	   in	   Table	   2.	   Plates	   were	  
incubated	   in	   5%	   CO2	   incubator	   at	   37°C	   for	   21	   days.	   During	   this	   period,	  
cultures	   were	   observed	   and	   evaluated	   regarding	   their	   morphological	  
changes	  on	  an	  inverted	  optical	  microscope.	  
2.7	  Cardiogenic	  Differentiation	  Analysis	  
2.7.1	  RNA	  extraction	  and	  PCR	  reaction	  
Total	  mRNA	  was	  extracted	   from	  ASCs	  cultivated	   in	   serum	  free	  medium	  at	  
passage	   1	   or	   from	   human	   heart	   biopsies	   (positive	   control,	   see	   section	  
2.7.1.1),	   using	   TRI	   Reagent	   (Sigma)	   and	   following	   manifacturer’s	  
instructions.	   Total	   mRNA	   was	   then	   reverse-­‐transcribed	   using	   Maxima	   H	  
Minus	   First	   Strand	   cDNA	   Synzhesis	   Kit	   Reverse	   Transcriptase	   (Thermo	  
Scientific).	  The	  resulting	  cDNA	  was	  used	  as	  a	  template	  for	  PCR	  amplification	  
with	  Taq	  DNA	  Polymerase	  (Qiagen),	  using	  primer	  pairs	  specific	  for	  cardiac-­‐
specific	  genes	  and	  transcription	  factors	  [Tab.	  1].	  All	  primer	  sequences	  were	  
original	  and	  determined	  through	  established	  mRNA	  GenBank	  sequences.	  β	  
actin	  was	  used	  as	  a	  control	  for	  PCR	  efficiency.	  Reactions	  were	  performed	  in	  
a	  CFX	  Connect	  Real	  Time	  System	  (BIO-­‐RAD)	  for	  35	  cycles,	  consisting	  of	  94°C	  
for	   30	   seconds,	   94°C	   for	   20	   seconds,	   60°C	   for	   30	   seconds,	   72°C	   for	   30	  
seconds	   with	   a	   final	   extension	   at	   72°C	   for	   5	   minutes.	   The	   PCR	   products	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were	   size-­‐fractionated	   by	   2%	   agarose	   gel	   electrophoresis	   in	   a	   TAE	   buffer	  
(Invitrogen).	  Signals	  with	  gel	  red	  staining	  was	  detected	  and	  quantified	  using	  
a	  CCD	  camera-­‐based	  instrument.	  Experiments	  were	  repeated	  at	  least	  three	  
times.	  
	  
Table	  1.	  Primers	  used	  in	  standard	  and	  real	  time	  PCR.	  	  
Gene	   Sequence	  
β -­‐Actin	   QuantiItect	  Primer	  Assay	  	  
(Cat	  n°	  QT01680476)	  -­‐	  Qiagen	  
HPRT	   5’-­‐GTC	  AAG	  CAG	  CAT	  AAT	  CCA	  AAG	  ATG-­‐3’	  
5’-­‐GTC	  TGG	  TCT	  ATA	  TCC	  AAC	  ACT	  TCG-­‐3’	  (Microsynth) 
GATA4	   	   QuantiItect	  Primer	  Assay	  	  
(Cat	  n°	  QT00031997)	  -­‐	  Qiagen	  
TBX5	   QuantiItect	  Primer	  Assay	  	  
(Cat	  n°	  QT00056574)	  -­‐	  Qiagen	  
TBX18	   5’-­‐GCC	  TGC	  CTC	  GGG	  GGA	  GAC	  TT	  -­‐	  3’	  
5’-­‐TGA	  CGT	  GCA	  CTC	  GCG	  GTT	  GG	  -­‐	  3’	  (Microsynth) 
CX43	   5’-­‐AGG	  AGT	  TCA	  ATC	  ACT	  TGG	  CG	  -­‐3’	  
5’-­‐GAG	  TTT	  GCC	  TAA	  GGC	  GCT	  C	  -­‐	  3’	  (Microsynth)	  
BAF60C	   QuantiItect	  Primer	  Assay	  	  
(Cat	  n°	  QT00069181)	  -­‐	  Qiagen	  
NKX2-­‐5	   5’-­‐ACC	  TCA	  ACA	  GCT	  CCC	  TGA	  CTC-­‐3’	  
5’-­‐ATA	  ATC	  GCC	  GCC	  ACA	  AAC	  TCT	  CC-­‐3’	  (Microsynth)	  
MEF2C	   5’-­‐AGA	  TAC	  CCA	  CAA	  CAC	  ACC	  ACG	  CGC	  C-­‐3’	  
5’-­‐ATC	  CTT	  CAG	  AGA	  GTC	  GCA	  TGC-­‐3’	  (Microsynth)	  
HAND1	   5’-­‐AAC	  TCA	  AGA	  AGG	  CGG	  ATG	  G-­‐3’	  
5’-­‐TCG	  GCT	  CAC	  TGG	  TTT	  AAC	  TC-­‐3’	  (Microsynth)	  
HAND2	   5’-­‐GCA	  GGA	  CTC	  AGA	  GCA	  TCA	  AC-­‐3’	  
5’-­‐CAT	  GAG	  GTA	  GGC	  GAT	  GTA	  GC-­‐3’	  (Microsynth)	  
FOG	   5’-­‐ATG	  AAG	  ACA	  GTG	  CCC	  ATC	  AG-­‐3’	  
5’-­‐TCA	  CGG	  AAT	  CAG	  CAG	  CAG	  TGT	  AG-­‐3’	  (Microsynth)	  
CAMTA	   	   5’-­‐ACT	  TAG	  AGC	  AGG	  AGG	  TTG	  AC-­‐3’	  
5’-­‐GGA	  ATG	  AGC	  CAC	  AGA	  CAA	  TG-­‐3’	  (Microsynth)	  
CKIT	   5’-­‐GAG	  TCC	  AAG	  AGG	  GTC	  CTT	  TAG	  -­‐3’	  
5’-­‐ACT	  GAT	  GCC	  TTC	  CAC	  TTC	  C-­‐3’	  (Microsynth)	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SIRPA	   5’-­‐TAC	  TCC	  GTG	  TGG	  TTG	  TTG-­‐3’	  	  
5’-­‐CAG	  GGC	  AAGVCAG	  ATG	  TCG	  CAA	  G-­‐3’	  (Microsynth)	  
NCX	   5’-­‐GAA	  GGG	  CAA	  TCA	  TGT	  TGT	  TGG	  TG-­‐3’	  
5’-­‐AAG	  GAT	  AAG	  GAT	  GGG	  TTA	  G-­‐3’	  (Microsynth)	  
SERCA-­‐2	   5’-­‐ACC	  GAA	  GGC	  ATG	  CAT	  TAC-­‐3’	  
5’-­‐TGC	  TGC	  AAG	  AGG	  AAT	  GAG-­‐3’	  (Microsynth)	  
MHC	   5’-­‐GAA	  GCC	  CAG	  CAC	  ATC	  AAA	  AG-­‐3’	  
5’-­‐GAT	  CAC	  CAA	  CAA	  CCC	  CTA	  CG-­‐3’	  (Microsynth)	  
	  
2.7.1.1	  Cardiac	  Biopsy	  
Cardiac	   biopsy	   specimens	   were	   obtained	   with	   informed	   consent	   from	  
patients	  undergoing	  open-­‐heart	  surgery.	  In	  total	  we	  used	  the	  tissue	  from	  3	  
patients.	   Mean	   ages	   were	   67	   years.	   Atrial	   cells	   were	   obtained	   from	   the	  
atrial	   appendage.	   The	   heart	   samples	   were	   taken	   in	   conjunction	   with	   the	  
insertion	  of	  the	  cannula	  for	  venous	  drainage	  of	  the	  right	  atrium	  through	  the	  
atrial	   appendage,	   a	   necessary	   procedure	   for	   the	   institution	   of	  
cardiopulmonary	  bypass	   (extracorporeal	   circulation).	   Individual	   specimens	  
were	   immediately	   transferred	   into	   tubes	   containing	   ice-­‐cold	   Ca2+	   free	  
Krebs-­‐Ringer	  saline	  solution;	  specimens	  were	  transported	  to	  the	  cell	  culture	  
laboratory	   within	   30	   minutes.	   	   For	   total	   RNA	   extraction,	   the	   tissue	   was	  
placed	   in	  cryovial	   tubes	  and	  dipped	   into	   liquid	  nitrogen	  for	  3	  minutes	  and	  
then	   minced	   with	   sterile	   scissors.	   TRI	   Reagent	   (Sigma)	   was	   added	   and	  
mRNA	  isolated	  according	  to	  the	  manufacturer’s	  protocol.	  First-­‐strand	  cDNA	  
was	  synthesized	  from	  total	  RNA	  using	  Thermostable	  reverse	  transcriptase.	  




After	  differentiation	  induction,	  cells	  grown	  on	  coverslips,	  were	  washed	  with	  
PBS	  solution	  and	  fixed	  with	  4%	  paraformaldehyde	  (PFA)	   for	  10	  minutes	  at	  
room	   temperature.	   After	   washing	   twice	   with	   PBS,	   fixed	   cells	   were	  
permeabilized	  with	  PBS	  +	  0.1%	  Triton	  X-­‐100	  (Sigma)	  3	  times	  for	  5	  minutes	  
and	  then	  non-­‐specific	  binding	  was	  blocked	  using	  2%	  bovine	  serum	  albumin	  
(BSA)	   (Sigma)	  at	  37°C	   for	  30	  minutes.	   Then	   the	   cells	  were	   incubated	  with	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the	  primary	  antibody	  in	  0.2%	  BSA	  +	  0.2%	  Triton	  X-­‐100	  solution	  for	  1	  hour	  at	  
RT.	  The	  cells	  were	  then	  washed	  3	  times	  in	  PBS	  +	  0.1%	  Tween	  (Sigma)	  +	  0.2%	  	  
BSA	   and	   incubated	   with	   the	   secondary	   antibody.	   At	   the	   end	   they	   were	  
washed	  3	   times	   for	  5	  minutes	  with	  PBS	  +	  0.1%	  Tween	  +	  0.2	  %	  BSA	   for	  30	  
minutes	   at	   RT.	   To	   provide	   a	   quick	   assessment	   of	   cell	   distribution,	   4’,	   6-­‐
diamidino-­‐2-­‐phenylindole	  (DAPI,	  Sigma	  -­‐	  Italy)	  was	  used	  to	  stain	  cell	  nuclei.	  
Coverslips	   were	   mounted	   with	   one	   drop	   of	   Hydromount	   (National	  
Diagnostics,	   USA)	   and	   protected	   from	   light.	   Samples	  were	   analysed	   using	  
fluorescent	   microscopy	   (Olympus	   BX50).	   Cells	   incubated	   with	   only	  
secondary	  antibody	  were	  used	  as	  negative	  controls.	  
Table	  2.	  List	  of	  primary	  and	  secondary	  antibodies	  used	  in	  immunofluorescence	  analysis.	  	  
	  
	  
2.7.3	  Optical,	  transmission	  (TEM)	  and	  scanning	  (SEM)	  electron	  microscopy	  
These	   analysis	   were	   performed	   by	   Prof.	   Magda	   de	   Eguileor’s	   group	  
(Department	   of	   Biotechnology	   and	   Life	   Sciences,	   University	   of	   Insubria	   -­‐	  
Italy).	  
After	  10	  days	  or	  21	  days	  of	  induction	  the	  cells	  were	  collected	  and	  fixed	  with	  
4%	  glutaraldehyde	  in	  0.1	  M	  Na-­‐cacodylate	  buffer	  (pH	  7.2).	  	  
Pellets	  were	  washed	  in	  0.1	  M	  Na-­‐cacodylate	  buffer	  (pH	  7.2)	  and	  post-­‐fixed	  
for	   20	   minutes	   with	   1%	   osmic	   acid	   in	   cacodylate	   buffer	   (pH	   7.2).	   After	  
standard	  dehydration	   in	  an	  ethanol	   series,	   samples	  were	  embedded	   in	  an	  
Primary	  Antibody	   Secondary	  Antibody	  
Anti-­‐sarcomeric-­‐α-­‐actinin	  	  	  
(Santa	  Cruz	  Biothechnologies)	  
TRITC;	  1:200	  dilution	  (Jackson,	  Immuno	  
Research	  Laboratories,	  West	  Grove,	  Pa.	  
-­‐	  USA)	  
Anti-­‐actin	  	  
(Santa	  Cruz	  Biothechnologies)	  
TRITC;	  1:200	  dilution	  (Jackson,	  Immuno	  
Research	  Laboratories,	  West	  Grove,	  Pa.	  
-­‐	  USA)	  
Anti	  -­‐	  Myosin	  heavy	  chain	  	  
(Santa	  Cruz	  Biothechnologies)	  
TRITC;	  1:200	  dilution	  (Jackson,	  Immuno	  
Research	  Laboratories,	  West	  Grove,	  Pa.	  
-­‐	  USA)	  
NKX2-­‐5	  goat	  polyclonal	  antibodies	  	  
(Santa	  Cruz	  Biothechnologies)	  
Rabbit	   F	   (ab’)2	   –	   Anti-­‐Goat	   IgG	   (H+L)	  
Human	  FITC	  (Beckman	  Coulter)	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Epon-­‐Araldite	   812	   mixture	   and	   sectioned	   with	   a	   Reichert	   Ultracut	   S	  
ultratome	   (Leica,	   Nussloch,	   Germany).	   Semithin	   sections	   were	   stained	   by	  
conventional	  methods	  (crystal	  violet	  and	  basic	  fuchsin)	  and	  were	  observed	  
with	   a	   light	   microscope	   (eclipse	   Nikon).	   Thin	   sections	   were	   stained	   by	  
uranyl	   acetate	   and	   lead	   citrate	   and	   observed	   with	   a	   Jeol	   1010	   electron	  
microscope	  (Jeol,	  Tokyo,	  Japan).	  	  
Cells	  for	  SEM	  were	  fixed	  and	  dehydrated	  as	  described	  above,	  treated	  with	  
hexamethildisilazane	   and	   mounted	   on	   polylysinated	   slides.	   Next,	   the	  
samples	   were	   air-­‐dried	   and	   covered	   with	   a	   9	   nm	   gold	   film	   by	   flash	  
evaporation	   of	   carbon	   in	   an	   Emitech	   K	   250	   sputter	   coater	   (Emitech,	  
Baltimore,	   MD,	   USA).	   Specimens	   were	   then	   examined	   with	   a	   SEM-­‐FEG	  
Philips	  XL-­‐30	  microscope	  (Philips,	  Eindhoven,	  Netherlands).	  
2.7.4	  Characterization	  of	  induced	  cells	  by	  FACS	  Analysis	  
At	   the	   end	   of	   the	   induction	   of	   cardiac	   differentiation,	   a	   representative	  
aliquot	   of	   the	   cells	  was	   characterized	   for	   the	   expression	   of	   particular	   cell	  
surface	   cardiac	   markers	   using	   the	   following	   anti-­‐human	   monoclonal	  
antibodies:	  
	  
ü CD140a	  (PDGFR)-­‐PE	  (323505)	  BioLegend	  
ü CD184	  (CXCR4)-­‐BV	  421	  (306517)	  BioLegend	  
ü CD117	  (cKIT)-­‐PC7	  (IM3698)	  Beckman	  Coulter	  
ü CD309	  (VEGFR)-­‐AF	  647	  (338909)	  BioLegend	  
ü IgG1-­‐PC7	  (737662)	  Beckman	  Coulter	  
ü IgG1-­‐PE	  (400113)	  BioLegend	  
ü IgG2a-­‐BV	  421	  (400259)	  BioLegend	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2.8	  Tissue	  Engineering	  
	  
The	   scaffolds	   used	   in	   this	   thesis	   to	   produce	   cellularized	   matrices	   for	  
application	   in	   cardiac	   tissue	   engineering/regenerative	   medicine	   (TERM)	  
were	   developed	   and	   characterized	   by	   Prof.	   Ciardelli’s	   Research	   Group	  
(Materials	   in	   Bionanotechnology,	   Department	   of	   Mechanical	   and	  
Aerospace	  Engineering,	  Politecnico	  di	  Torino	  -­‐ITALY-­‐).	  The	  scaffold-­‐forming	  
material	   is	   an	   elastomeric	   polyester	   urethane	   developed	   and	   synthesized	  
by	   the	   same	   research	   group.	   This	   biodegradable	   polyurethane	   with	  
acronym	  K-­‐BC2000	  was	  synthesized	  as	  previously	  described	  (Rechichi	  et	  al.,	  
2008;	  Sartori	  et	  al.,	  2013)	  starting	  from	  poly(ε-­‐caprolactone)	  (PCL)	  diol,	  1,4-­‐
budandiisocyanate	  and	  L-­‐lysine	  ethyl	  ester	  dihydrochloride.	  
2.8.1	  Fabrication	  of	  PUR	  porous	  scaffolds	  	  
PUR	   porous	   scaffolds	   were	   fabricated	   by	   thermally	   induced	   phase	  
separation	   (TIPS)	   and	   subsequent	   solvent	   extraction.	   The	   applied	  method	  
was	   similar	   to	   that	   described	   by	   Guan	   et	   al.	   (Guan	   et	   al.,	   2005,	   2008).	  
Briefly,	   the	  polyurethane	  was	  first	  dissolved	  at	  60	  °C	   in	  dimethyl	  sulfoxide	  
(DMSO)	  (Sigma	  Aldrich	  -­‐ITALY-­‐)	  at	  12	  %w/v;	  then,	  the	  obtained	  solution	  was	  
poured	   in	   a	   stainless	   steel	   parallelepiped	   mold	   (50	   x	   25	   x	   30	   mm)	   and	  
cooled	   down	   at	   -­‐20	   °C	   for	   5	   hours.	   The	   quenching	  was	   performed	   under	  
application	  of	   a	   thermal	   cooling	   gradient	   to	   induce	  DMSO	  crystal	   growth,	  
i.e.	  pore	  formation,	   in	  a	  preferred	  direction.	  All	  mold	  walls	  were	   insulated	  
using	  polystyrene	  and	  cotton	  wool	  except	  one.	   In	  order	   to	  extract	  DMSO,	  
the	   frozen	   scaffold	  was	  placed	   for	   three	  days	   in	   a	  water/ethanol	   solution	  
(30/70	   v/v)	   refreshed	   twice	   a	   day.	   The	   scaffold	   was	   finally	   freeze-­‐dried	  
(Martin	  Christ	  ALPHA	  2-­‐4	  LSC)	  and	  cut	  to	  obtain	  matrices	  with	  a	  thickness	  of	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2.8.2	  Scaffold	  characterization	  
2.8.2.1	  -­‐	  Morphological	  and	  structural	  properties	  
	  
-­‐	  Scaffold	  morphology	  
The	   morphology	   of	   the	   produced	   scaffolds	   was	   evaluated	   by	   Scanning	  
Electron	  Microscopy	   (SEM;	   LEO	   1450VP).	  Micrographs	  were	   taken	  with	   a	  
beam	  voltage	  of	  20	  kV	  and	   instrument	  magnification	  of	  100x.	  All	   samples	  
were	   gold-­‐coated	   before	   analysis.	   Image	   data	   were	   analyzed	   by	   ImageJ	  
software.	  The	  average	  pore	  size	  and	  pore	  size	  distribution	  were	  obtained	  by	  
measuring	   the	   diameter	   of	   80	   pores	   chosen	   at	   random	   throughout	   the	  
central	  section	  of	  the	  samples.	  
-­‐	  Scaffold	  porosity	  
Scaffold	   porosity	   was	   determined	   using	   a	   liquid	   displacement	   method	  
similar	   to	   that	   reported	   by	   (Zhang	   and	  Ma,	   1999)	   and	   (Hsu	   et	   al.,	   1997).	  
Ethanol	   was	   used	   as	   the	   displacement	   liquid.	   A	   scaffold	   sample	   was	  
immersed	   in	   a	   glass	   cylinder	   containing	   a	   known	   volume	   of	   ethanol	   (V1).	  
The	  sample	  was	  pressed	  to	  force	  air	  out	  of	  the	  scaffold	  until	  no	  further	  air	  
bubbles	  were	  seen,	  allowing	  the	  ethanol	  to	  fill	  the	  pores.	  The	  total	  volume	  
of	  ethanol	  and	   the	  ethanol-­‐impregnated	   scaffold	  was	   recorded	  as	  V2.	   The	  
ethanol-­‐impregnated	  scaffold	  was	  then	  removed	  from	  the	  cylinder	  and	  the	  
residual	   ethanol	   volume	   was	   recorded	   as	   V3.	   The	   percentage	   of	   porosity	  
(p%)	  of	  the	  scaffold	  was	  determined	  by:	  𝑝% =    (𝑉! −   𝑉!)(𝑉! − 𝑉!)    ∙ 100	  
2.8.2.2	  Mechanical	  properties	  
	  
-­‐	  Tensile	  tests	  
Scaffold	  rectangular	  samples	  (25	  x	  7	  x	  1	  mm)	  were	  analyzed	  by	  stress-­‐strain	  
tests,	  performed	  using	  a	  MTS	  QTest/10	  Elite	  Controller	  equipped	  with	  a	  10	  
N	  load	  cell.	  The	  cross-­‐head	  speed	  was	  1	  mm/min.	  The	  samples	  were	  tested	  
in	  dry	  and	  wet	  conditions	  at	  room	  temperature.	  For	   instance,	  the	  samples	  
were	   immersed	   in	   water	   overnight	   before	   test,	   when	   analyzed	   in	   wet	  
conditions.	  Tensile	  tests	  were	  conducted	  in	  triplicate.	  
Materials and Methods 
	  
	  50	  
-­‐	  Durability	  tests	  
Durability	  tests	  were	  conducted	  to	  evaluate	  the	  capability	  of	  the	  developed	  
matrix	   to	   sustain	   the	   mechanical	   stress	   it	   will	   be	   subjected	   to	   during	  
dynamic	   cell	   culture.	   For	   this	   reason,	   these	   tests	   were	   conducted	   in	   the	  
dynamic	  cell	  culture	  system	  “Stimiote”.	  
2.8.2.3	  Statistical	  analysis	  
Tensile	  test	  results	  are	  expressed	  as	  a	  mean	  ±	  standard	  deviation	  calculated	  	  
using	   Microsoft	   Excel	   (Redmond,	   WA,	   USA)	   software.	   Statistical	   analysis	  
was	   performed	  using	  GraphPad	   Prism.	  One-­‐way	  ANOVA	   followed	  by	   post	  
hoc	  analysis	  (Bofferoni)	  was	  used	  to	  compare	  the	  results.	  A	  P	  value	  of	  less	  
than	  0.05	  was	  considered	  as	  statistically	  significant.	  
2.8.3	  Stimiote	  
Stimiote	   is	   a	   novel	   device	   (patent	   pending),	   engineered,	   developed	   and	  
built	   by	   the	   Swiss	   Stem	   Cell	   Foundation	   in	   collaboration	   with	   the	   Scuola	  
Universitaria	   della	   Svizzera	   Italiana	   (SUPSI)	   Lugano	   (Switzerland)	   for	   the	  
application	   of	   controlled	   mechanical	   and/or	   electrical	   stimuli	   that	   are	  












Figure	  10.	  Stimiote.	  Photograph	  of	  the	  dynamic	  cell	  culture	  system	  device	  engineered	  and	  
built	  for	  application	  of	  controlled	  mechanical	  and/or	  electrical	  force.	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The	  main	  components	  of	  the	  system	  [Fig.	  11]	  are:	  (i)	  a	  mechanical	  structure	  
to	   support	   an	   actuator	   that	   makes	   it	   possible	   to	   apply	   a	   controlled	  
longitudinal	   force	   to	   the	   sample,	   (ii)	   an	   endless	   screw	   actuator,	   (iii)	   two	  
displacement	   detectors	   to	   monitor	   patch	   deformation,	   (iv)	   four	   flexible	  
blades	   with	   one	   degree	   of	   freedom	   to	   limit	   friction	   and	   support	   the	  
movable	  part	  of	  the	  device,	  (v)	  a	  flask	  containing	  the	  culture	  medium,	  (vi)	  a	  
system	   of	   movable	   rigid	   beams	   to	   transmit	   movement	   to	   the	   patch	   and	  
record	  information	  about	  patch	  position	  and	  the	  applied	  force,	  (vii)	  a	  clamp	  




Figure	  11.	  The	  main	  component	  of	  Stimiote.	  Schematic	  diagram	  of	  the	  main	  components	  of	  
Stimiote	  dynamic	  cell	  culture	  system.	  
 
The	  Stimiote	  system	  is	  a	  stress-­‐controlled	  bioreactor	  that	  makes	  it	  possible	  
to	  apply	  a	  force	  up	  to	  3	  N	  to	  a	  bio	  absorbable	  patch.	  It	  is	  characterized	  by	  a	  
force	  and	  strain	  accuracy	  of	  0.66%	  and	  0.1	  mm,	  respectively.	  Moreover,	   it	  
allows	   the	   application	   of	   a	   sinusoidal	   mechanical	   stress	   with	   frequency	  
ranging	  between	  0	  and	  1	  Hz.	  In	  order	  to	  test	  durability,	  the	  patch	  (30x25x10	  
mm)	   has	   been	   subjected	   to	   the	   same	   mechanical	   pattern	   it	   will	   be	  
subjected	   during	   in	   vitro	   cell	   culture	   tests:	   applied	   force	   0.4	   ±	   0.2	   N,	  
frequency	  1	  Hz,	  wet	  conditions,	  12	  days.	  All	  samples	  were	  preconditioned	  
in	  cell	  culture	  medium	  for	  24h	  before	  analysis.	  Stimiote	  equipment	  allows	  
to	   record	   sample	   position	   and	   applied	   force	   over	   time.	   A	   specifically	  
developed	   Matlab	   routine	   makes	   possible	   to	   analyze	   data.	   Tests	   were	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conducted	  in	  triplicate.	  
2.8.4	  Seeding	  the	  scaffold	  and	  stimulation	  with	  Stimiote	  
Before	   cell	   seeding,	   scaffolds	   must	   be	   coated	   with	   collagen	   I	   (Coating	  
Matrix	   Kit,	   Gibco)	   overnight	   to	   enhance	   cell	   attachment.	   Sterilized	  
membrane	  (30	  x	  12.5	  mm)	  were	  placed	  into	  60	  mm	  petri	  culture	  dish	  and	  
seeded	  with	   1x106	   cells.	   The	   cell	   suspension	  was	   pipetted	   directly	   on	   the	  
membrane	  surface	  (6	  drops	  of	  25	  µl	  each).	  Cells	  were	  allowed	  to	  attach	  to	  
scaffold	   for	   2	   hours	   before	   adding	   the	   culture	   medium.	   Cells	   were	  
maintained	   in	  humidified	  37°C	   incubator	  containing	  5%	  CO2	   for	  5	  days.	  At	  
day	  6	  the	  scaffold	  was	  assembled	  on	  the	  device	  with	  a	  sterile	  forceps	  under	  
laminar	  flow.	  The	  device	  was	  placed	  in	  a	  sterile	  container	  and	  the	  induction	  
started	  using	  cardio	  induction	  culture	  medium	  and	  setting	  the	  device	  on	  a	  
force	  of	  0.4N,	  amplitude	  0.2N,	  frequency	  1	  Hz	  [Fig.	  12].	  In	  this	  study	  Alamar	  
Blue	  assay	  was	  used	  to	  assess	  cell	  viability	  5	  days	  after	  seeding	  and	  at	  the	  











Figure	   12.	   A	   schematic	   representation	   of	   seeding	   scaffold.	   After	   expansion	   the	   cell	  
suspension	  was	  pipetted	  directly	  on	  the	  membrane	  surface.	  Cells	  were	  maintained	  in	  SF	   in	  
incubator	   for	   5	   days.	   After	   this	   period	   the	   scaffold	   was	   assembled	   on	   the	   device	   with	   a	  
sterile	  forceps	  under	  laminar	  flow	  for	  10	  days	  with	  cardioinduction	  medium.	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2.8.5	  Alamar	  Blue	  Assay	  
Alamar	  Blue	  is	  an	  assay	  to	  monitor	  cell	  health. Plasma	  membrane	  integrity,	  
DNA	  synthesis,	  DNA	  content,	  enzyme	  activity,	  presence	  of	  ATP,	  and	  cellular	  
reducing	  conditions	  are	  known	  indicators	  of	  cell	  viability	  and	  cell	  death.	  The	  
Alamar	  Blue	  cell	  viability	  reagent	  functions	  as	  a	  cell	  health	  indicator	  and	  by	  
using	   the	   reducing	   power	   of	   living	   cells	   to	   quantify	   the	   proliferation	   of	  
MSCs.	   When	   the	   cells	   are	   alive	   they	   maintain	   a	   reducing	   environment	  
within	   the	   cytosol	   of	   the	   cell.	   Resazurin,	   the	   active	   ingredient	   of	   Alamar	  
Blue	  reagent,	  is	  a	  non-­‐toxic,	  cell	  permeable	  compound	  that	  is	  Blue	  in	  colour	  
and	   non-­‐fluorescent.	   Upon	   entering	   cells,	   Resazurin	   is	   reduced	   to	  
Resorufin,	   a	   red	   and	   fluorescent	   compound.	   Viable	   cells	   continuously	  
convert	   Resazurin	   to	   Resorufin,	   increasing	   the	   overall	   fluorescence	   and	  
color	  of	  the	  media.	  
Alamar	   Blue	   cell	   viability	   reagent	   is	   used	   to	   assess	   cell	   viability	   by	   simply	  
adding	  the	  10x	  ready-­‐to-­‐use	  solution	  to	  the	  culture	  medium	  and	  incubating	  
at	   37°C	   o/n.	   There	   is	   no	   requirement	   to	   remove	   media	   from	   cells	   or	   to	  
place	  cells	  in	  minimal	  media.	  The	  absorbance	  of	  Alamar	  Blue	  was	  read	  on	  a	  
spectrophotometer	  at	  540	  and	  630	  nm.	  Results	  were	  analysed	  by	  plotting	  






3.1	  Stromal	  Vascular	  Fraction	  (SVF)	  Extraction	  
Our	  first	  milestone	  was	  the	  preparation	  of	  the	  SVF	  from	  adipose	  tissue	  and	  
the	   subsequent	   isolation	   of	   ASCs	   fraction.	   The	   starting	   material	   for	   our	  
study	  was	  obtained,	  after	  informed	  consent	  of	  healthy	  female	  donors,	  from	  
subcutaneous	   adipose	   tissue	   collected	   during	   an	   elective	   liposuction	  
procedure.	  The	   lipoaspirate	  (generally	  70	  to	  150	  g)	  was	  transferred	  to	  the	  
lab,	   and	   SVF	   cells	   were	   then	   isolated	   by	   our	   standard	   GMP-­‐optimized	  
procedure,	   consisting	   of	   an	   initial	  washing	   step	   to	   remove	  blood	   and	   any	  
other	  contaminant	  (e.	  g.	  the	  anaesthetic	  used	  during	  sampling),	  followed	  by	  
the	  digestion	  of	  the	  adipose	  tissue	  with	  the	  enzyme	  collagenase	  (for	  details	  
see	   2.	  Materials	   and	  Methods).	   The	   enzymatic	   digestion	  was	   required	   to	  
separate	  the	  mesenchymal	  progenitors	  that	  are	  trapped	  in	  the	  extracellular	  
matrix	   and	   located	   within	   the	   tissue.	   After	   such	   enzymatic	   digestion,	   we	  
performed	   a	   series	   of	   extraction	   steps	   using	   a	   solution	   that	   blocks	   the	  
effect	   of	   the	   enzyme,	   helping	   to	   reduce	   stress	   and	   increase	   cell	   viability	  
[Fig.	   13].	   The	   SVF	  was	   analysed	   for	   cell	   count,	   vitality,	   as	   well	   as	   for	   the	  
expression	  of	  surface	  markers	  by	  flow	  cytometry.	  The	  number	  of	  nucleated	  














Figure	  13.	  Isolation	  of	  the	  Stromal	  Vascular	  Fraction	  (SVF).	  A	  schematic	  representation	  of	  
the	   isolation	   of	   the	   SVF	   from	   lipoaspirates	   using	   an	   enzymatic	   digestion	   designed	   to	  




3.2	  Characterization	  of	  the	  SVF	  
3.2.1	  Immunophenotypisation	  of	  SVF	  from	  liposuction	  aspirate	  
An	   important	   milestone	   of	   this	   project	   was	   to	   establish	   a	   detailed	  
immunophenotype	   of	   ASCs,	   a	   somewhat	   challenging	   task	   due	   to	   a	   still	  
incomplete	  knowledge	  of	   the	  cellular	  and	  developmental	  biology	  of	   these	  
cells,	  and	  the	  consequent	  difficulties	  in	  identifying	  multipotent	  stromal	  cells	  
based	  only	  on	  a	  phenotypical	  analysis.	  
As	   already	   explained	   in	   the	   introduction,	   the	   cells	   isolated	   from	   the	  
hydrophilic	   portion	   of	   adipose	   tissue	   are	   called	   Stromal	   Vascular	   Fraction	  
(SVF)	   and	   represent	   a	   heterogeneous	   population.	   The	   major	   problem	   is	  
that,	  to	  date,	  there	  is	  no	  easy	  and	  accurate	  assay	  capable	  of	  characterizing	  
and	  enumerating	  these	  cells	  after	  isolation.	  In	  fact,	  this	  problem	  represents	  
a	   major	   obstacle,	   especially	   if	   the	   SVF	   has	   to	   be	   used	   for	   clinical	  
applications	  that	  require	  a	  well-­‐defined	  composition	  of	   the	  “cell-­‐drug”.	  To	  
overcome	   this	   problem,	   we	   developed	   and	   optimized	   a	   five-­‐colour	   flow	  
cytometry	  protocol	   that	   is	   suited	   for	   the	  analysis	   of	   freshly	   extracted	   SVF	  
cells.	   Freshly	   isolated	   SVF	  was	   immediately	   analysed	  with	   a	  no-­‐wash	   flow	  
cytometer	  protocol:	   a	   small	   amount	  of	   the	   cell	   suspension	  was	   incubated	  
with	   specific	   antibodies,	   the	   erythrocytes	   were	   removed	   with	   a	   lysing	  
solution	  and	  the	  sample	  was	  immediately	  analysed	  with	  a	  cytofluorimeter.	  
In	  order	  to	  define	  the	  different	  populations	  we	  used	  three	  surface	  antigen	  
markers	   (i.e.	   CD45,	   CD34	   and	   CD146).	   CD34	   was	   used	   as	   marker	   for	  
pluripotent	   stromal	   cells,	   while	   CD146	   and	   CD45	   were	   used	   to	   label	  
endothelial	  and	  hematic	  cells,	  respectively.	  With	  this	  approach	  and	  marker	  
combination	   we	   could	   reliably	   define	   the	   ASCs	   and	   reproducibly	   identify	  
three	  distinct	  SVF	  subpopulations,	  of	  which	  ASCs	  are	  CD146/CD45	  negative	  
and	  CD34	  positive	  cells,	  representing	  10%-­‐25%	  of	  the	  total	  SVF	  cells.	  
The	   viability	   dye	   7-­‐AAD	   and	   the	   DNA	  marker	   Syto	   40	  were	   added	   to	   the	  
analysis	   to	   remove	   artefacts	   and	   improve	   separation	   of	   the	   populations.	  
The	  cell	  viability	  assay	   is	  very	   important	  since	  the	  ASCs	  cells	  are	  subjected	  
to	  a	  long	  period	  of	  stress	  starting	  with	  the	  surgical	  procedure,	  through	  the	  
extraction	   steps	   and	   finally	   to	   the	   seeding	   in	   a	   cell	   culture	   plate.	   This	  




density,	  which	  is	  a	  main	  factor	  affecting	  cell	  proliferation	  and	  maintenance	  
of	  pluripotency.	  
3.2.2	  Gating	  strategy	  
To	   ensure	   that	   no	   false-­‐positive	   results	   occur,	   we	   developed	   a	   gate	   that	  
excludes	  debris,	  cell	  doublets	  and	  dead	  cells	  [Fig.	  14].	  After	  exclusion	  from	  
the	  analysis	  of	  the	  flow	  count	  fluorospheres	  used	  for	  counting	  the	  cells,	  the	  
first	  two	  gates	  (A	  and	  B)	  allow	  to	  discriminate	  the	  nucleated	  cells	  (i.e.	  Syto	  
40	  positive)	  and	   to	  avoid	  artefacts	  due	   to	  cell	  doublets.	  The	  Boolean	  gate	  
Clean	   SVF	   (C)	   combines	   the	   gates	   A	   and	   B,	   with	   the	   exclusion	   of	   the	  
fluorospheres.	  Finally,	  before	  analysing	  the	  surface	  marker	  expression,	  we	  






















Figure	   14.	   Gating	   strategy	   to	   ensure	   no	   false-­‐positive	   results.	   To	   ensure	   that	   no	   false-­‐
positive	   results	   occur,	   a	   gate	   that	   excludes	   debris,	   cell	   doublets	   and	   death	   cells	   has	   been	  
developed.	  Data	  were	  acquired	  with	  a	  10	  color	  Navios	  (Beckman	  Coulter)	  and	  were	  analyzed	  




3.2.3	  Identification	  of	  sub-­‐populations	  in	  the	  SVF	  
In	  addition	   to	   the	  population	  of	  ASCs	  we	  were	  able	   to	   identify	  7	  different	  
sub-­‐populations	   among	   which	   we	   found	   cells	   of	   endothelial	   origin	   (i.e.	  
CD146+,	  CD34+,	  CD45-­‐)	  and	  a	  small	  and	  very	  interesting	  population	  of	  CD45	  
and	  CD34	  positive	  cells,	  called	  “hematopoietic	  stem	  cell	  like”	  which	  are	  yet	  






















Figure	  15.	  Identification	  of	  SVF	  sub-­‐populations.	  A	  five	  color	  flow	  cytometer	  strategy	  allows	  
to	  distinguish	  the	  following	  sub-­‐populations	  of	  cells	  present	  in	  the	  SVF:	  
-­‐ Adipose-­‐derived	  multipotent	  stromal	  cells	  (ASCs):	  CD34+,	  CD45-­‐	  and	  CD146-­‐	  
-­‐ Pericytes:	  CD34-­‐,	  CD45-­‐	  and	  CD146+	  
-­‐ Endothelial	  cells:	  CD34+,	  CD45-­‐	  and	  CD146+	  
-­‐ Endothelial	  progenitor	  cells	  (EPCs):	  CD34+,	  CD45+	  and	  CD146+	  
-­‐ Hematopoietic	  Stem	  Cells-­‐Like	  (HSCs):	  CD34+,	  CD45+	  and	  CD146-­‐	  
-­‐ Blood	  cells:	  CD34-­‐,	  CD45+	  AND	  CD146-­‐	  




3.2.4	  ASCs	  selection	  based	  on	  adherence	  capacity	  
The	  SVF,	  that	  included	  the	  ASCs	  sub-­‐population,	  was	  characterized	  to	  verify	  
if	   cells	   fitted	   into	   the	  classical	  profile	  of	  MSCs.	  Among	  the	  properties	   that	  
characterize	  these	  cells,	  is	  the	  adherence	  to	  plastic.	  After	  seeding	  the	  SVF	  in	  
culture	  plastic,	  only	  a	  small	  fraction	  of	  the	  total	  cells	  adheres	  to	  plastic	  and	  
grows.	  Cells	  were	  seeded	  and	  allowed	  to	  attach	   to	   the	  culture	  plate	   for	  6	  
days.	  As	  the	  aim	  was	  to	  confirm	  the	  presence	  and	  identity	  of	  adherent	  cells,	  
flow	  cytometric	  analysis	  of	  supernatant	  cells	  was	  performed.	  The	  only	  sub-­‐
population	   absent	   in	   the	   supernatant	   is	   the	   CD34+,	   CD45-­‐	   and	   CD146-­‐,	  
corresponding	  to	  the	  ASCs	  [Fig.	  16].	  
However,	  it	  is	  important	  to	  consider	  that	  not	  all	  ASCs	  adhere	  to	  plastic,	  but	  
some	   of	   them	   rather	   loose	   the	   CD34	  marker	   or	   dies,	   as	   assessed	   by	   the	  
total	  amount	  of	  cells	  counted.	  Despite	  that,	  the	  flow	  cytometric	  analysis	  is	  





















Figure	  16.	  ASCs	  selection.	  Strategy	  used	  to	  select	  ASCs	  based	  on	  their	  adhesion	  capacity	  and	  
cytofluorimetric	  analysis	  of	  SVF	  sub-­‐populations.	  After	  6	  days	  of	  culture	  the	  ASCs	  completely	  
disappeared	   from	   the	   supernatant.	   CD31	  was	   used	   in	   place	   of	   CD146,	   because	   the	   latter	  




3.2.5	  Clonogenic	  CFU-­‐F	  assay	  
To	   verify	   the	   stemness	   of	   the	   isolated	   ASCs,	   we	   further	   performed	  
clonogenic	   CFU-­‐F	   assays.	   In	   this	   assay,	   every	   colony	  derives	   from	  a	   single	  
cell	   clone,	   thus	   demonstrating	   the	   clonogenic	   ability	   of	   the	   SVF	   isolated	  
with	   our	   protocol.	   5.000	   and	   10.000	   cells	   of	   SVF	   were	   seeded	   in	   two	  
different	  culture	  plates.	  After	  14	  days	  of	  culture,	  the	  plates	  were	  fixed	  and	  
colonies	  of	  more	  than	  50	  cells	  were	  then	  counted	  as	  positive	  [Fig.	  17].	  Even	  













3.2.6	  Ability	  of	  ASCs	  to	  differentiate	  in	  the	  three	  main	  lineages	  
Finally,	   we	   questioned	   the	   ability	   of	   ASCs	   to	   differentiate	   in	   osteogenic,	  
chondrogenic	  and	  adipogenic	  cell	   lines.	  To	  do	  this	  we	  induced	  the	  cells	  by	  
means	  of	  different	  cocktails	  and	  we	  analysed	  the	  cells	  with	  classical	  staining	  
(i.e.	  Alizarin	  S,	  Oil	  Red	  O	  and	  Alcian	  Blue).	  The	  media	  and	  protocol	  used	  are	  
described	   in	   Materials	   and	   Methods	   section	   2.5.	   Results	   clearly	   showed	  
that	  ASCs	  extracted	  with	  our	  protocol	  can	  differentiate	  in	  all	  the	  expected	  
cell	  lineages	  [Fig.	  18],	  thus	  maintaining	  the	  potential	  of	  mesenchymal	  stem	  
cells.	  	  
	  
Figure	  17.	   Colony	   Forming	  Units	  Fibroblast	  Assay.	  Crystal	  Violet-­‐staining	   for	  CFU-­‐F	  assay	  
showing	  that	  the	  cultured	  SVF	  is	  composed	  of	  fibroblast-­‐like	  cells,	  a	  typical	  characteristic	  of	  

























3.2.7	  Immunophenotypisation	  of	  expanded	  cells	  
The	  remaining	  ASCs	  were	  expanded	   for	  6	  passages	  and	  at	  each	  passage	  a	  
fraction	   of	   the	   cells	  was	   used	   for	   immunophenotypic	   analysis,	   to	   confirm	  
the	   mesenchymal	   phenotype.	   The	   expansion	   was	   carried	   out	   in	   a	   serum	  
free	   medium.	   SVF	   cells	   were	   seeded	   onto	   plates	   that	   were	   coated	   with	  
collagen	  I	  in	  order	  to	  allow	  their	  adhesion	  and	  promote	  growth.	  In	  contrast	  
to	   freshly	   isolated	   SVF,	   in	   vitro	   expanded	   cells	   have	   been	   extensively	  
characterized	  in	  the	  literature	  using	  different	  markers,	  and	  are	  described	  as	  
CD90+,	   CD73+,	   CD105+,	   CD34-­‐	   and	   CD45-­‐	   (Dominici	   et	   al.,	   2006).	   The	  
citofluorimetric	   analysis	   of	   expanded	   ASCs	   showed	   a	   concordant	   pattern	  
[Fig.	  19].	  At	  this	  stage	  we	  can	  therefore	  conclude	  that	  the	  isolated	  cells	  fit	  
with	   the	  accepted	  definition	  of	  mesenchymal	   stem	  cell.	  With	   this	   in	  mind	  
Figure	  18.	  Differentiation	  potential	  of	  ASCs	  toward	  adipogenic,	  osteogenic	  and	  chondrogenic	  
cell	   lines.	  A:	  non	   induced	   control	  ASCs	  at	  10x	  magnification;	  B:	  Alizarin	  S	  staining	   to	  underline	  
the	  extracellular	  calcium	  deposits;	  C:	  adipogenic-­‐induced	  ASCs	  stained	  with	  Oil	  Red	  O,	  aimed	  to	  


















Figure	  19.	  FACS	  analysis	  of	  expanded	  ASCs	  using	  different	  known	  cellular	  markers	  for	  MSC.	  
First	   panel	   (A):	   gated	   population.	   Other	   panels:	   comparison	   of	   signal	   intensity	   of	   a	   given	  
marker	   (orange)	  compared	   to	  unstained	  cells	   (red).	  The	  markers	  are	   indicated	  above	  each	  
panel.	  	  
	  
3.3	  Expression	  of	  some	  cardiac-­‐specific	  transcription	  markers	  in	  non	  
induced	  human	  ASCs	  
	  
After	  the	  selection	  of	  cardiac-­‐specific	   transcription	  factors,	  as	  described	   in	  
the	   introduction,	   total	   mRNA	   was	   extracted	   from	   passage	   2	   of	   ASCs	  
cultivated	   in	   serum	   free	   medium.	   As	   positive	   control,	   RNA	   from	   a	   heart	  
biopsy	  was	  used.	  Indeed,	  heart	  biopsy	  showed	  the	  expected	  expression	  of	  
the	   selected	   transcription	   factors.	   Unexpectedly,	   however,	   non-­‐induced	  
ASCs	   also	   showed	   the	   expression	   of	   nearly	   half	   of	   the	   selected	   cardiac	  






















3.4	  Formulation	  of	  a	  cardio	  inducing	  cocktail	  for	  ASCs	  	  
	  
Our	   next	   goal	   was	   to	   select	   the	   most	   effective	   combination	   of	   growth	  
factors	   and	   cytokines,	   their	   time	   of	   application	   and	   the	   best	   culture	  
conditions	   in	   order	   to	   obtain	   differentiation	  of	  ASCs	   into	   cardiomyocytes.	  
An	   extensive	   literature	   search	   allowed	   to	   select	   28	   growth	   factors	  
potentially	   involved	   in	   induction	   of	   cardiomyogenic	   differentiation	   (see	  
introduction)	  that	  were	  combined	  in	  16	  different	  cocktails,	  as	  summarized	  
in	  Table	  4.	  
Legend	  
Green:	  presence	  of	  gene	  expression	  
Red:	  Absence	  of	  gene	  expression	  
Table	   3.	   Expression	   of	   selected	   cardiac	   genes	   in	   heart	   biopsy	   (control)	   and	  







































Table	  4.	  Cardiogenic	  differentiation	  cocktails.	  	  
	  
Detailed	  composition	  of	   the	  16	  cocktails	   tested	  for	   the	   cardiac	  differentiation	  of	  ASCs.	  
Cocktail	  number	  14	  was	  chosen	  on	  the	  basis	  of	  the	  up-­‐regulated	  cardiac-­‐marker	  gene’s	  
panel.	  
Legend:	  
Red:	  fixed	  component	  





All	  of	  them	  were	  tested	  for	  their	  cardiogenic	  potential.	  Because	  one	  of	  the	  
aims	  of	   this	   study	   is	   to	   contribute	   to	   the	  development	  of	   stem	  cell-­‐based	  
therapies	  for	  the	  cure	  of	  cardiovascular	  diseases	  (CVDs),	  our	  efforts	  focused	  
on	   the	   formulation	   of	   cocktails	   in	   defined	   serum	   free	   culture	   induction	  
medium	  as	  simple	  as	  possible.	  In	  a	  first	  instance,	  medium	  containing	  serum	  
was	  used	  to	  test	  the	  different	  cocktails	  and	  was	  substituted	  with	  serum	  free	  
after	  the	  selection	  of	  the	  best	  cocktail.	  	  The	  time	  of	  each	  induction	  was	  kept	  
constant	   to	   three	   weeks.	   However,	   in	   certain	   cases	   two	   distinct	   culture	  
media	   were	   prepared:	   one	   used	   for	   the	   first	   10	   days	   of	   culture	   and	   the	  
second	  for	  the	  next	  11	  days.	  
In	  this	  screening	  phase,	  the	  presence	  of	  differentiated	  cells	  was	  monitored	  
by	   standard	   and	   quantitative	   RT-­‐PCR	   for	   the	   expression	   of	   cardio-­‐specific	  
genes	  described	  in	  the	  previous	  section.	  The	  most	  informative	  genes	  were	  
those	  not	  expressed	  in	  non-­‐induced	  ASCs,	  like	  NKX2-­‐5	  and	  MEF2C	  [Tab.	  3].	  
Cocktail	  no.	  14	  was	  selected	  because	   it	  was	  the	  most	  effective	  capacity	   in	  
inducing	   cardiogenic	  phenotype	  compared	   to	  other	   cocktails,	   as	  observed	  
by	   the	   up-­‐regulation	   of	   NKX2-­‐5	   and	  MEF2C	   cardiospecific	   genes	   by	   qPCR	  
firstly	  [Fig.	  20]	  and	  by	  the	  induction	  of	  HAND2,	  FOG	  and	  CAMTA	  genes	  for	  





















Figure	  20.	  Expression	  of	  cardiac	  specific	  markers	   in	  cells	   induced	  with	  different	  cocktails.	  
qPCR	  was	  used	  to	  establish	  the	  optimal	  cocktail	  to	  induce	  cardiomyogenic	  differentiation	  of	  
ASCs.	  A.	  Expression	  of	  NKX2-­‐5	  was	  used	  to	  verify	  the	  best	  cocktail	  out	  of	  4	  representatives	  
(Cocktails	  13-­‐16).	  
Cocktails	   14	   and	  16	  were	   selected	  due	   to	   induction	  of	   higher	   expression	   levels	  of	  Nkx2.5	  




























In	  a	  second	  phase,	  whose	  aim	  was	  to	  obtain	  a	  serum-­‐	  and	  xeno-­‐free	  culture	  
medium,	   the	   previously	   identified	   cocktail	   no.	   14	  was	   tested	  without	   any	  
serum	   but	   with	   the	   addition	   of	   5%	   of	   human	   albumin	   instead,	   keeping	  
constant	  all	  other	  culture	  conditions.	  Cocktail	  no.	  14	  was	  very	  effective	   in	  
inducing	   cardiomyogenic	   conditions	   also	   in	   these	   conditions.	   Culture	  
medium	  no.	  14-­‐SF	  was	  then	  challenged	  for	  the	  up-­‐regulation	  of	  a	  panel	  of	  
cardiogenic	   genes:	   NKX2-­‐5,	  MEF2C,	   HAND2	   and	   FOG.	   The	   results	   showed	  
the	  up-­‐regulation	  of	  all	   tested	  genes	   in	   induced	  cells	  also	   in	   these	  culture	  




Figure	   21.	   Expression	   of	   cardiospecific	   genes	   in	   induced	   ASCs	   and	   control	   cells.	   Up-­‐
regulation	   of	   selected	   transcripts	   that	   represent	   markers	   of	   cardiac	   differentiation	   was	  
tested	  by	  RT-­‐	  PCR	  in	  ASCs	  grown	  in	  culture	  medium	  containing	  cocktail	  no.14	  after	  21	  days	  
of	  culture.	  Beta-­‐actin	  is	  used	  as	  positive	  control.	  Non-­‐induced	  ASCs	  (N.I.),	  induced	  ASCs	  (I)	  
and	   heart	   biopsy	   (H).	   NKX2-­‐5,	  MEF2C,	   HAND2,	   FOG	   and	   CAMTA	   are	   clearly	   up-­‐regulated	  































	   Legend	  
Green:	  presence	  of	  gene	  expression	  
Red:	  Absence	  of	  gene	  expression	  
	  
	  
Figure	   22.	   Expression	   of	   cardiospecific	   genes	   in	  
induced	   ASCs	   and	   control	   cells.	   Gene	   up-­‐regulation	  
tested	  by	  reverse	  transcription	  PCR	  of	  culture	  medium	  
composed	  of	  cocktail	  no.14	  after	  21	  days	  of	  culture	  of	  
ASCs	   without	   any	   serum	   component.	   Beta-­‐actin	  
represent	  the	  positive	  control	  and	  appears	  in	  all	  three	  
lanes,	  non-­‐induced	  (N.I.),	   induced	  (I)	  and	  heart	  biopsy	  
(H).	  NKX2-­‐5,	  MEF2C,	  HAND2,	  and	  FOG	  are	   clearly	  up-­‐







We	   further	   investigated	   the	   presence	   of	   functional	   genes	   in	   induced	   and	  
non-­‐induced	   cells.	   For	   instance,	   we	   evaluated	   the	   expression	   of	   SERCA-­‐2	  
(Sarco/Endoplasmic	   Reticulum	   Ca2+-­‐ATPase)	   and	   NCX	   (Sodium-­‐Calcium	  
Exchanger).	   Both	   genes	   are	   expressed	   in	   induced	   cells	   after	   21	   days	   of	  
culture	  using	  cardiogenic	  cocktail	  nr	  14.	  Only	  a	  faint	  signal	  is	  present	  in	  NCX	  
in	  non-­‐induced	  cells	  [Fig.	  23].	  The	  ability	  of	  cocktail	  14-­‐SF	  to	  induce	  cardiac	  
















Figure	   23.	   Expression	   of	   functional	   genes.	   Expression	   of	   functional	   genes	   (SERCA-­‐2	   and	  
NCX)	  in	  non	  induced	  (NI),	  induced	  (I)	  and	  heart	  biopsy	  (H).	  
Figure	  24.	  Reproducibility	   of	   the	  differentiating	  ability	  of	   cocktail	   14-­‐SF.	  Expression	  of	  
Nkx2.5	   and	  Mef2C	   genes	   in	   non	   induced	   (NI),	   induced	   (I)	   and	   heart	   biopsy	   (H)	   in	   two	  
further	   inducing	   treatments	   of	   ASCs	   preparations.	   This	   image	   shows	   the	   high	  




3.5	  Morphological	  Characterization	  of	  induced	  ASCs	  
	  
When	  ASCs	  were	  induced	  toward	  the	  cardiac	  lineage	  during	  three	  weeks	  of	  
differentiation	   in	   the	   cardiogenic	   cocktail	   no.	   14,	   they	   showed	   clear	  
macroscopical	  morphological	  changes	  [Fig.	  25].	  In	  particular,	  when	  induced,	  
the	   cells	   became	  more	   fusiform	  or	   spindle-­‐like,	  whereas	   the	   non-­‐induced	  
ones	   remained	  more	   round-­‐shaped.	   Results	   were	   highly	   reproducible,	   as	  
found	  after	  studying	  cells	  obtained	  from	  10	  different	  patients	  (not	  shown),	  



















Figure	   25.	   Morphological	   changes	   after	   cardiac	   induction	   of	   ASCs.	   A.	   non	   induced	  
undifferentiated	  ASCs	  grown	  in	  serum	  free	  medium,	  4x	  magnification;	  B.	  cardio-­‐induced	  ASCs,	  







Further	   analysis	   of	   semi-­‐thin	   sections	   of	   ASCs	   stained	   with	   Crystal	   Violet	  
and	   Fuchsin	   and	   observed	   under	   light	   microscope,	   showed	   big	   cells	   and	  
presence	   of	   autophagosomes	   in	   non-­‐induced	   cells,	   whereas	   induced	   cells	  
appeared	  smaller	  and	  had	  less	  autophagosomes,	  as	  depicted	  in	  Figure	  26.	  
Interestingly,	   further	   analysis	   by	   transmission	   electron	   microscopy	   (TEM)	  
revealed	   the	   presence	   of	   unorganized	   tubular	   structures	   in	   the	   cell	  
cytoplasm	  of	  induced	  cells,	  as	  shown	  in	  Figure	  28.	  In	  contrast,	  non-­‐induced	  
cells	   displayed	   cytoplasm	   vacuolization	   confirming	   the	   presence	   of	  









Figure	  26.	  Light	  microscope	  images	  of	  non	  induced	  and	  induced	  cells	  after	  staining	  with	  
Crystal	   Violet	   and	   Fuchsin.	  Non	   induced	   cells	   (left)	   show	   a	   regular	   shape	   and	   display	  
similar	  size,	  whereas	  induced	  cells	  (right)	  are	  less	  regular	  in	  shape	  and	  uneven,	  generally	  


























Figure	  27.	  Transmission	  Electron	  Microscope	  (TEM)	  images	  of	  non	  induced	  cells.	  Non	  induced	  





































Figure	  28.	  Transmission	  Electron	  Microscope	  (TEM)	  images	  of	   induced	  cells.	  Induced	  cells	  





3.6	  Detection	  of	  protein	  markers	  of	  cardiac	  differentiation	  
	  
Finally,	   the	   presence	   of	   specific	   structural	   and	   functional	   proteins	  
characteristic	   of	   cardiac	   tissue	   (i.e.	  α-­‐actin,	   cardiac	  α-­‐actinin	   and	  myosin	  
light	  chain)	  and	  of	  a	  cardiac	  transcription	  factor	  (i.e.	  NKX2-­‐5)	  was	  assessed	  
by	  immunocytochemical	  analysis	  of	  induced	  and	  non-­‐induced	  cells.	  Results	  
highlight	  the	  differentiated	  status	  of	  the	  ASCs	  and	  are	  presented	   in	  Figure	  
29.	  The	  induction	  of	  α−actin	  is	  evident	  by	  a	  more	  prominent	  red	  staining	  in	  
induced	   cells.	   Similarly,	   α-­‐actinin,	   a	   more	   specific	   marker	   of	   cardiogenic	  
differentiation	  was	  markedly	   increased	   in	   induced	  cells	   compared	   to	  non-­‐
induced	   cells,	   where	   a	   less	   intense	   non-­‐specific	   staining	   is	   visible	   around	  
the	  DAPI-­‐stained	  nuclei.	  Myosin,	   another	  muscle-­‐specific	  marker	   for	  myo-­‐
differentiation,	   could	   be	   seen	   in	   a	   small	   fraction	   of	   the	   induced	   cells,	  
whereas	   it	   could	   not	   be	   seen	   in	   any	   other	   non-­‐induced	   cells.	   The	  master	  
regulator	  of	  cardiac	  differentiation	  and	  nuclear	  transcription	  factor,	  NKX2-­‐
5,	  was	  evidenced	  by	  fluorescent	  signal	  in	  the	  nucleus	  of	  all	  induced	  cells,	  as	  
expected.	  	  






	   	  
Figure	  29.	  Immunohistochemical	  analysis	  of	  different	  markers	  of	  cardiac	  differentiation	  in	  
induced	  ASCs	  versus	  controls.	  Non	  induced	  (NI)	  and	  induced	  cells	  (I)	  were	  stained	  either	  for	  
Actin	  (red),	  for	  Cardiac	  α-­‐actinin	  (red),	  for	  Myosin	  light	  chain	  (red)	  (Courtesy	  of	  Prof.	  Magda	  
de	   Eguileor’s	   group	   -­‐	   University	   of	   Insubria	   -­‐	   Italy)	   or	   for	   NKX2-­‐5	   (green)	   (from	   top	   to	  
bottom).	  Nuclei	  were	  counterstained	  with	  DAPI,	  excepted	  for	  the	  NKX2-­‐5	  pictures,	  because	  





3.7	  Immunophenotypical	  characterization	  of	  cardio	  induced	  ASCs	  
	  
To	  confirm	  whether	  the	  cardiac	  differentiation	  of	  the	  ASCs	  took	  place	  by	  a	  
different	   mean	   than	   the	   ones	   described	   before,	   we	   developed	   an	  
immunophenotypic	   citofluorimetric	   analysis.	   For	   this,	   after	   21	   days	   of	  
induction,	  a	  part	  of	  the	  culture	  was	  dissociated	  into	  single	  cells	  and	  stained	  
for	   four	   different	   cardiogenic	   markers:	   CD184	   (CXCR4),	   CD309	   (VEGFR2),	  
CD117	   (cKIT)	   and	   CD172A	   (SIRPA).	   As	   shown	   the	   preliminary	   results	   in	  
Figure	  30,	   flow	  cytometric	  analysis	   revealed	   that	  17.70%	  of	   the	   total	   cells	  
expressed	   detectable	   levels	   of	   CD184,	   7.39%	   expressed	   CD309,	   3.50%	  
expressed	   cKIT	   and	  more	   than	   90%	   the	  marker	   CD172A.	   In	   contrast,	   non	  














Figure	  30.	  FACS	  analysis	  of	  induced	  cells.	  	  
After	   induction,	   cells	   were	   stained	   respectively	   for:	   CD184-­‐CXCR4	   (A),	   CD309-­‐VEGFR	   (B),	  
CD117-­‐cKIT	   (C)	   and	   CD172A-­‐SIRPA	   (D).	   In	   E,	   the	   comparison	   of	   signal	   intensity	   of	   CD172	  




3.8	  Tissue	  Engineering	  
	  
The	  last	  important	  milestone	  of	  this	  work	  was	  to	  use	  the	  newly	  formulated	  
cardiogenic	   cocktail	   in	   combination	   with	   mechanical	   and	   eventually	  
electrical	   stimuli.	   It	   is	   a	   common	  belief	   that	   these	   stimuli	   should	  enhance	  
the	  differentiation	  status	  of	  the	  cells	  by	  mimicking	  the	  natural	  niche	  where	  
the	  cells	  are	  located	  (see	  introductory	  part).	  It	  was	  therefore	  interesting	  to	  
test	  whether	   the	   combination	   of	   the	   two	  with	   our	   cocktail	  would	   further	  
enhance	  the	  differentiation	  of	  the	  ASCs.	  	  
To	   achieve	   this,	   a	   device	   has	   been	   developed	   by	   the	   Swiss	   Stem	   Cell	  
Foundation	   in	   collaboration	   with	   Scuola	   Universitaria	   Professionale	   della	  
Svizzera	  Italiana	  (SUPSI)	  for	  the	  application	  of	  controlled	  mechanical	  and/or	  
electrical	   stimuli	   to	   a	   scaffold	   over	   a	   desired	   lap	   of	   time	   (see	   2.8.3).	   The	  
scaffolds	   used	   were	   developed	   and	   characterized	   by	   Prof.	   Ciardelli’s	  
Research	   Group	   (Materials	   in	   Bionanotechnology,	   Department	   of	  
Mechanical	  and	  Aerospace	  Engineering,	  Politecnico	  di	  Torino,	  see	  material	  
and	   methods	   section	   2.8	   for	   further	   details).	   Below,	   preliminary	  
experiments	  and	  results	  are	  presented.	  
	  
3.8.1	  Morphological	  and	  structural	  properties	  of	  the	  scaffold	  
We	  asked	  the	  researchers	  at	  the	  Politecnico	  di	  Torino	  to	  produce	  a	  scaffold	  
that	  could	  be	  close	   in	  morphology	  to	  the	  human	  heart.	  As	  an	  example	  we	  
looked	   for	   pictures	   from	   de-­‐cellularized	   human	   hearts	   taken	   at	   the	  
electronic	  microscope	  and	  compared	  with	   the	  scaffolds	  produced	  by	  Prof.	  
Ciardelli’s	  group	  [Fig.	  31].	  
Scanning	  Electron	  Microscopy	  (SEM)	  micrograph	  of	  the	  produced	  scaffold	  is	  
reported	   in	   Figure	   31A	   and	   it	   is	   compared	   to	   the	   structure	   of	   a	  
decellularized	  heart	  [Fig.	  31B].	  Despite	  the	  application	  of	  a	  thermal	  gradient	  
to	   allow	   pore	   orientation	   in	   a	   preferred	   direction,	   the	   proposed	   scaffold	  
does	   not	   show	   a	   highly	   organized	   microstructure.	   This	   behavior	   can	   be	  
correlated	  to	  the	  concurrent	  effects	  of	  both	  the	  freezing	  conditions	  (-­‐20°C	  
for	  5h)	  and	  the	  concentration	  of	  the	  starting	  DMSO	  solution	  (12%	  w/v),	  that	  
do	  not	  allow	  solvent	  crystal	  growth	  in	  a	  preferred	  direction.	  The	  produced	  




promote	  scaffold	  colonization.	  In	  detail,	  scaffold	  pore	  size	  was	  75	  ±	  57	  μm	  
and	   its	  porosity	  was	  about	  82%	  (82	  ±2	  %).	  Figure	  32	  reports	   the	  pore	  size	  
distribution.	  The	  proposed	  scaffold	  showed	  a	  pore	  size	  ranging	  from	  tens	  to	  
hundreds	   μm,	   thus	   allowing	   both	   cell	   colonization	   and	   vascularization:	  
small	   pores	   favor	   vascularization	   since	   endothelial	   cells	   are	   unable	   to	   fill	  
pores	   larger	   than	   their	   diameter	   (8-­‐12	   μm	   (Christenson	   and	   Stouffer,	  
1996)),	  while	  larger	  pores	  are	  necessary	  to	  allow	  cell	  homing	  and	  migration	  
deep	  in	  the	  scaffold.	  
	  
Figure	   31.	  Morphological	   properties	   of	   the	   scaffold.	   Scanning	   Electron	  Microscopy	   (SEM)	  









Figure	   32.	   Structural	   properties	   of	   the	   scaffold.	   Pore	   size	   distribution	   of	   the	   scaffold	   as	  
evaluated	  with	  Image	  J	  software.	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3.8.2	  Mechanical	  properties	  
3.8.2.1	  Tensile	  tests	  
The	  fabricated	  scaffolds	  are	  characterized	  from	  a	  mechanical	  point	  of	  view	  
by	   stress-­‐strain	   tests	   in	   dry	   and	  wet	   conditions	   at	   room	   temperature	   and	  
results	   are	   collected	   in	   Table	   6.	   The	   typical	   stress-­‐strain	   curve	   of	   the	  
scaffold	  in	  dry	  and	  wet	  conditions	  is	  reported	  in	  figure	  33.	  	  
	  


























The	  amplitude	  of	  the	  initial	  elastic	  region	  increases	  from	  about	  10%	  to	  20%,	  
in	   wet	   compared	   to	   dry	   conditions,	   thus	   making	   the	   proposed	   scaffold	  
suitable	   for	   cardiac	   TERM	   application	   (strain	   <	   10	   %	   at	   diastole	   initial	  
stages:	   strain	  ≈	  15-­‐22	  %	  at	   the	  diastole	  end	   (Chen	  et	  al.,	   2008;	  Enderlein,	  
1975;	  Hidalgo-­‐Bastida	  et	  al.,	  2007;	  Silvestri	  et	  al.,	  2013).	  Moreover,	  stress	  at	  
break	  and	  young	  modulus	  in	  wet	  conditions	  is	   lower	  than	  in	  the	  dry	  state,	  
while	  a	  significant	  (P<0.05)	  increase	  in	  strain	  at	  break	  was	  observed	  in	  wet	  
conditions	   with	   respect	   to	   the	   dry	   ones.	   The	   changes	   in	   mechanical	  
properties	   we	   observed	   in	   wet	   conditions	   compared	   to	   the	   dry	   state,	   as	  
observed	   by	   (Klouda	   et	   al.,	   2008)	   and	   (Pan	   and	   Ding,	   2012)	   for	   different	  
polymer	   substrates,	   can	   be	   correlated	   to	   the	   plasticizing	   effect	   of	   the	  
aqueous	  environment	  (Klouda	  et	  al.,	  2008;	  Pan	  and	  Ding,	  2012;	  Zhou	  et	  al.,	  
2005).	   The	   scaffold	   showed	   a	   young	   modulus	   of	   about	   1	   MPa	   in	   wet	  
conditions.	   This	   value	   is	   in	   accordance	   with	   the	   stiffness	   required	   for	  
scaffold	   application	   in	   cardiac	   tissue	   engineering/regenerative	   medicine	  
(Boffito	   et	   al.,	   2013;	   Silvestri	   et	   al.,	   2013).	  Moreover,	   stress	   and	   strain	   at	  
break	  are	  significantly	  higher	  than	  stress	  and	  strain	  at	  break	  of	  myocardial	  
tissue	  (3-­‐15	  KPa	  and	  22-­‐90%,	  respectively)	  (AYGEN	  and	  BRAUNWALD,	  1962;	  
Boffito	   et	   al.,	   2013;	   Hidalgo-­‐Bastida	   et	   al.,	   2007;	   Silvestri	   et	   al.,	   2013;	  
Yamada	  and	  Evans,	  1970).	  
3.8.2.2	  Durability	  tests	  
Durability	  tests	  were	  conducted	  to	  evaluate	  the	  suitability	  of	  the	  proposed	  
scaffolds	   for	   the	   intended	  application,	   i.e.	   the	  development	  of	  cellularized	  
matrices	  to	  be	  applied	  in	  cardiac	  tissue	  engineering/regenerative	  medicine	  
through	  mechanical	  stimulation	  in	  a	  bioreactor.	  As	  an	  example,	  the	  results	  
of	   one	   of	   the	   three	   conducted	   analysis	   are	   reported.	   Figure	   34	   reports	  
clamp	   position	   as	   a	   function	   of	   time.	   The	   specifically	   developed	   Matlab	  
routine	   made	   it	   possible	   to	   chart	   the	   maximum	   and	   minimum	   clamp	  



















Figure	  34.	  Durability	  tests	  1.	  Clamp	  position	  as	  a	  function	  of	  time.	  
 
	  






	  	  	  	  	  	  	  	  	  
Figure	  36.	  Durability	  tests	  3.	  Patch	  deformation	  (delta	  position)	  as	  a	  function	  of	  time.	  
	  
	  
Due	   to	   the	   application	   of	   a	   sinusoidal	   (frequency	   1	   Hz)	   stress	   with	  
amplitude	  0.4	  ±	  0.2	  N,	  the	  patch	  underwent	  a	  cyclic	  deformation	  of	  about	  
0.2	   mm	   (i.e.	   1%).	   None	   of	   the	   analyzed	   samples	   showed	   macroscopic	  
damage	  or	  broke	  during	  the	  analysis.	  A	  plastic	  deformation	  was	  observed	  at	  
the	   end	   of	   the	   experiment;	   each	   sample,	   indeed,	   showed	   an	   initial	  
deformation	  followed	  by	  an	  elastic	  behavior.	  
	  
3.8.3	  Scaffold	  seeding	  
Before	   cell	   seeding,	   scaffolds	  were	   coated	  with	   collagen	   I	   to	   enhance	   cell	  
attachment,	   then	   the	   scaffold	   was	   placed	   into	   a	   petri	   culture	   dish	   and	  
seeded	  with	   1x106	   cells.	   The	   cell	   suspension	  was	   pipetted	   directly	   on	   the	  
membrane	  surface	  (6	  drops	  of	  25	  µl	  each).	  Cells	  were	  allowed	  to	  attach	  to	  
the	   scaffold	   for	   2	   hours	   before	   adding	   the	   culture	   medium.	   Cells	   were	  
maintained	   in	  humidified	  37°C	   incubator	  containing	  5%	  CO2	   for	  5	  days.	  At	  




laminar	  flow.	  The	  device	  was	  placed	  in	  a	  sterile	  container	  and	  the	  induction	  
started	  using	  cardio	  induction	  culture	  medium	  and	  setting	  the	  device	  on	  a	  
force	   of	   0.4N,	   amplitude	   0.2N,	   frequency	   1	   Hz.	   The	   duration	   of	   the	  





















Figure	  37.	  Scanning	  Electron	  Microscope	  (SEM)	  of	  the	  scaffold.	  The	  pictures	  (A-­‐C)	  show	  a	  
clear	  surface	  distribution	  of	  the	  cells	  on	  the	  scaffold.	  





3.8.4	  Alamar	  Blue	  assay	  for	  the	  assessment	  of	  viability	  of	  ASCs	  in	  the	  scaffold	  
Due	  to	  the	  fact	  that	   it	   is	  extremely	  stable	  and	  more	   importantly	  non-­‐toxic	  
to	  the	  cells,	  Alamar	  Blue	  allows	  for	  continuous	  monitoring	  of	  cultures	  over	  
time.	  We	  performed	  the	  assay	  5	  days	  after	  seeding	  (before	  assembling	  on	  
the	   device)	   and	   at	   the	   end	   of	  mechanical	   stimulation.	   The	   percentage	   of	  
reduction	  appears	  to	  be	  about	  90%	  5	  days	  after	  seeding	  and	  decreases	  to	  
approximately	  70%	  at	  the	  end	  of	  the	  ten	  days	  of	  the	  mechanical	  stimulation	  
[Fig.	  38].	  
	   	  
Figure	  38.	  Cell	  viability	  assays	  (Alamar	  Blue	  proliferation	  assay)	  5	  days	  after	  seeding	  and	  at	  
the	   end	   of	  mechanical	   stimulation.	   The	   graph	   shows	   the	  %	  of	   reduction	  of	  Alamar	  Blue	  of	  
three	  different	  scaffolds	  compared	  with	  scaffold	  without	  cells	  5	  days	  after	  seeding	  (left)	  and	  at	  





3.8.5	  Comparison	  between	  2D	  Induction	  and	  Induction	  on	  scaffold	  
The	   final	   goal	   was	   to	   understand	   if	   the	   combination	   of	   cardiac	   induction	  
with	   cocktail	   nr	   14	   and	   the	   mechanical	   stimulation	   on	   a	   scaffold	   would	  
increase	   the	   expression	   of	   the	   most	   important	   cardiogenic	   transcription	  
factors	   if	   compared	   to	   the	   induction	  with	   cardiogenic	   cocktail	   alone	   on	   a	  
simple	   2D	   culture	   condition.	   Therefore,	   at	   the	   end	   of	   the	   ten	   days	   of	  
mechanical	  stimulation,	  qPCR	  was	  performed	  to	  confirm	  the	  expression	  of	  
cardiac	  markers	  in	  2D	  induction	  (on	  plate)	  and	  to	  make	  a	  comparison	  with	  
the	   induction	   on	   scaffold	   subjected	   to	   mechanical	   stimuli.	   The	   Figure	   39	  
shows	   the	   preliminary	   results:	   indeed	   the	   combination	   of	   growth	   factors,	  
cytokines	  and	  mechanical	   stimulation	   for	  10	  days	   led	   to	  an	  at	   least	  2	   fold	  








Figure	  39.	  Evaluation	  of	  the	  expression	  
of	   cardiogenic	   transcription	   factors	  
after	   different	   treatments	   by	   qPCR.	  
Comparison	  of	  relative	  gene	  expression	  
of	   several	   cardiogenic	   factors	   after	  
induction	   in	   2D	   (I	   2D)	   or	   on	   scaffold	   (I	  
scaffold),	  in	  heart	  biopsy	  (H)	  and	  in	  non	  
induced	  cells	  (N.I.).	  	  
mRNA	  expression	  is	  relative	  to	  β-­‐actin.	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cKIT	  HAND2	  
Discussion and Outlook 
	  
	  85	  
4.	  Discussion	  and	  Outlook	  
	  
The	   aim	   of	   the	   present	   thesis	   was	   to	   evaluate	   the	   differentiation	   of	  
multipotent	   stromal	   cells	   to	   cardiomyocytes	   and	   to	   characterize	   the	  
differentiated	   cells.	   Due	   to	   the	   many	   aspects	   covered	   in	   this	   thesis,	   the	  
present	   discussion	   has	   been	   divided	   accordingly	   to	   the	   topic	   into	   three	  
main	   sections:	   extraction	   and	   characterization	   of	   the	   SVF,	   evaluation	   of	  
cardiac	  differentiation	  capability	  of	  ASCs	  and	  tissue	  engineering.	  
	  
4.1	  Extraction	  and	  characterization	  of	  SVF	  
Our	   first	   milestone	   was	   focused	   on	   developing	   protocols	   for	   the	  
preparation	  of	  the	  SVF	  from	  adipose	  tissue	  and	  the	  subsequent	  isolation	  of	  
ASCs	   fraction	   as	   more	   extensively	   described	   in	   our	   submitted	   paper	  
(Minonzio	  et	  al.,	  submitted).	  The	  cells	  have	  been	  extensively	  characterized	  
by	   flow	  cytometry,	   and	  genetically	  profiled	  by	  a	   reverse-­‐transcription	  and	  
PCR-­‐based	  approach.	  In	  the	  SVF	  we	  identified	  three	  distinct	  subpopulations	  
of	  cells	  in	  which	  the	  ASCs	  were	  defined	  as	  CD146/CD45	  negative	  and	  CD34	  
positive,	   representing	   10%-­‐25%	   of	   the	   total	   SVF	   cells.	   CD34	   was	   used	   as	  
marker	   for	  pluripotent	  stromal	  cells,	  while	  CD146	  and	  CD45	  were	  used	   to	  
label	  endothelial	   and	  hematic	   cells,	   respectively.	  Dominici	  and	  co-­‐workers	  
extensively	  characterized	  in	  vitro	  the	  expanded	  cells	  with	  different	  markers	  
describing	  them	  as	  CD90+,	  CD73+,	  CD105+,	  CD34-­‐	  and	  CD45-­‐	  (Dominici	  et	  al.,	  
2006).	   Therefore,	   our	   citofluorimetric	   analysis	   showed	   a	   concordant	  
pattern.	  At	  this	  stage	  one	  can	  conclude	  that	  the	  isolated	  cells	  fit	  with	  the	  so	  
far	  accepted	  definition	  of	  mesenchymal	  stem	  cell.	  	  
The	  isolated	  ASCs	  were	  then	  tested	  for	  presence	  of	  features	  that	  stem	  cells	  
usually	  display,	  such	  as	  ability	  to	  adhere	  to	  plastic,	  CFU-­‐F	  clonogenic	  assay	  
for	   their	   stemness,	   and	   for	   their	   ability	   to	   differentiate	   in	   osteogenic,	  
chondrogenic	  and	  adipogenic	  and	  finally	  cardiogenic	  cell	  lines.	  	  
Interestingly,	   all	   these	   features	   did	   attract	   the	   attention	   of	   researchers	  
interested	   in	   regenerative	   medicine,	   in	   particular	   in	   the	   field	   devoted	   to	  
restore	   the	   functionality	   of	   a	   damaged	   heart.	   In	   comparison	   to	   bone	  
marrow,	  the	  main	  advantage	  in	  using	  adipose	  tissue	  is	  that	  the	  latter	  can	  be	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obtained	   in	   much	   larger	   amounts	   and	   with	   a	   far	   less-­‐invasive	   surgical	  
operation.	   Furthermore	   the	   number	   of	   ASCs	   in	   harvested	   fat	   is	  
approximately	  40-­‐times	  higher	  than	  that	  of	  bone	  marrow	  MSCs.	  
	  
4.2	  Evaluation	  of	  cardiac	  differentiation	  capability	  of	  ASCs.	  
	  
The	  most	  important	  milestone	  and	  goal	  of	  this	  work	  was	  to	  investigate	  the	  
cardiogenic	  potential	  of	  the	  ASCs.	  
Cardiovascular	  disease	  remains	  one	  of	   the	  most	  deadly	  diseases	   (Roger	  et	  
al.,	   2012).	   One	   of	   the	   causes	   is	   that	   after	   a	   myocardial	   infarction,	   an	  
extensive	   tissue	   damage	   leads	   to	   the	   development	   of	   congestive	   heart	  
failure	  in	  many	  survivors.	  Heart	  transplantation	  is	  nowadays	  the	  only	  viable	  
treatment	  for	  end-­‐stage	  congestive	  heart	  failure,	  but	  unfortunately	  lack	  of	  
available	   donors	   has	   remained	   an	   insurmountable	   problem	   (Vono	   et	   al.,	  
2012).	  Therefore,	  in	  the	  search	  for	  alternative	  therapies,	  myocardial	  repair	  
via	   cell	   therapy,	   that	   is	   the	   injection	   of	   cell	   suspension	   directly	   in	   a	  
damaged	  cardiac	  area,	  has	  generated	  a	  great	  deal	  of	  enthusiasm	  (Vono	  et	  
al.,	   2012).	   Obviously,	   which	   type	   of	   cell	   has	   to	   be	   used	   to	   generate	   an	  
artificial	  heart	  tissue	  represents	  a	  relevant	  issue,	  since	  this	  heavily	  impacts	  
on	   the	   final	   properties	   of	   the	   graft.	   Nevertheless,	   some	   minimal	  
requirement	  must	  be	  fulfilled:	  the	  cells	  should	  at	  least	  be	  highly	  viable,	  be	  
able	   to	   electromechanically	   integrate	   into	   the	   resident	   healthy	  
cardiomyocytes	  and	  possibly	  be	  histocompatible.	  In	  this	  regard,	  the	  use	  of	  
autologous	   stem	   cells	   into	   the	   damaged	  heart	   seems	   therefore	   on	   of	   the	  
best	   solutions.	   It	   is	  well	   established	   that	   embryonic	   stem	   cells	   (ESCs)	   can	  
generate	   cardiomyocytes,	   but	   ethical	   issues	   limit	   their	   clinical	   potential	  
(Doetschman	  et	  al.,	  1985).	  The	  ability	  to	  generate	  induced	  pluripotent	  stem	  
cells	   (iPSCs)	   provides	   another	   approach	   for	   the	   generation	   of	   autologous	  
grafts.	  Nevertheless,	  their	  main	  limitations	  for	  the	  clinical	  use	  are	  the	  time	  
that	   is	  required	  for	  the	  reprogramming	  procedure	  and	  the	  need	  to	  ensure	  
that	  they	  are	  non	  tumorigenic	  (Mauritz	  et	  al.,	  2008).	  Resident	  cardiac	  stem	  
cells	   are	  another	  promising	   candidate	   for	   cell	   therapies	   since	   they	   can	  be	  
isolated	   from	   identifiable	   cardiac	   niches	   and	   expanded	   ex	   vivo.	  
Nonetheless,	  the	  high	  invasiveness	  of	  the	  harvesting	  technique	  limits	  their	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clinical	   suitability.	   Thus	  ASCs	   have	   been	   identified	   as	   the	  most	   suited	   cell	  
type	  and	  investigated	  for	  their	  use	  in	  biological	  grafts	  for	  cardiac	  repair	  due	  
to	   their	   relative	   ease	   and	   safeness	   of	   their	   obtainment	   (Beltrami	   et	   al.,	  
2003).	  	  
In	  this	  work,	  after	  the	  in	  vitro	  expansion	  of	  ASCs	  in	  serum	  free	  medium	  that	  
has	  been	  developed	  in	  our	  laboratory,	  we	  followed	  an	  innovative	  approach	  
for	   the	   cardiogenic	   differentiation:	   the	   use	   of	   human	   growth	   factors	   in	   a	  
defined	   serum-­‐free	   culture	   induction	  medium.	   For	   this,	   different	   cocktails	  
of	   growth	   factors	   and	   cytokines	   and	   different	   culture	   conditions	   were	  
tested	  for	  their	  ability	  to	  induce	  cardiomyogenesis.	  
In	   the	   past	   years,	   different	   approaches	   have	   been	   used	   to	   induce	   the	  
differentiation	  of	  ASCs	  toward	  the	  cardiac	  lineage.	  Gaustad	  and	  co-­‐workers	  
in	   2004	   investigated	   the	   possibility	   to	   use	   cell	   extracts	   to	   promote	  
differentiation	  of	  ASCs	   (Gaustad	   et	   al.,	   2004).	   In	   particular,	   they	   reported	  
the	  induction	  of	  cardiomyocyte	  properties	  in	  human	  ASCs	  after	  exposure	  to	  
a	  nuclear	  and	  cytoplasmic	  extract	  of	  rat	  cardiomyocytes.	  The	  induced	  cells	  
showed	  evidence	  of	  differentiation	  in	  vitro,	  they	  expressed	  cardiomyocytes	  
markers	  and	  were	  induced	  to	  beat	  in	  culture.	  These	  results	  support	  the	  use	  
of	   somatic	  cell	  extracts	   to	  elicit	  differentiation	  of	  MSCs	   towards	  a	   specific	  
target	  cell	  lineage.	  	  
Several	   other	   groups	   (Makino	   et	   al.,	   1999;	   Rangappa	   et	   al.,	   2003)	   have	  
found	  that	  mesenchymal	  stem	  cells	  can	  be	  transformed	  into	  cardiomycytes	  
after	   the	   exposure	   to	   5-­‐azacytidine	   (5-­‐aza).	   The	   latter	   was	   originally	  
developed	   and	   tested	   as	   a	   nucleoside	   anti-­‐metabolite	   for	   treatment	   of	  
acute	  myelogenous	   leukemia	   (Wilhelm	  et	   al.,	   1999).	   This	   compound	   is	   an	  
effective	   DNA	   hypomethylating	   agent	   and	   it	   is	   capable	   of	   altering	   the	  
expression	   of	   certain	   genes	   and	   of	   regulating	   the	   differentiation.	   In	  
addition,	   human	   ES	   cells	   and	   stem	   cell	   antigen-­‐1	   (Sca-­‐1	   positive)	   cardiac	  
progenitor	  cells	  were	  differentiated	   into	  cardiomyocytes	   in	  response	  to	  5-­‐
aza	  treatments.	  Another	  group	  (Zhu	  et	  al.,	  2009)	  investigated	  the	  role	  that	  
cardiac	  microenvironment	   plays	   in	   directing	   the	   progression	   of	   stem	   cells	  
into	   differentiated	   cells.	   Adipose	   tissue	   derived	   stem	   cells	   (ASCs)	   were	  
cultured	   with	   cardiomyocytes	   directly	   (“direct	   co-­‐culture	   directly”)	   or	   by	  
cell	  culture	  insert	  (“indirect	  co-­‐culture	  indirectly”).	  Differentiated	  ASCs	  that	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experienced	  the	  co-­‐culture	  presented	  cardiac	  ultrastructure	  and	  expressed	  
cardiac	   specific	   genes,	   suggesting	   that	   cell-­‐to-­‐cell	   contact	   is	   important	   in	  
relaying	   the	  external	   cues	  of	   the	  microenvironment	  and	   in	  controlling	   the	  
differentiation	  of	  ASCs	  toward	  cardiomyocytes.	  
Because	   of	   the	   use	   of	   animal	   derivatives	   or	   of	   chemical	   agents	   that	  may	  
affect	  the	  genomic	  stability	  of	  the	  cells	  (i.e.	  5-­‐AZA),	  none	  of	  the	  above	  cited	  
methods	   are	   compatible	   with	   the	   use	   of	   ASCs	   in	   the	   clinical	   practice.	  
Therefore,	   in	  this	  work,	  different	  cocktails	  of	  growth	  factors	  and	  cytokines	  
and	  different	   culture	   conditions	  have	   thus	  been	   tested	   for	   their	   ability	   to	  
induce	   cardiomyogenesis,	   with	   the	   goal	   of	   being	   compatible	   with	   a	  
potential	  clinical	  application.	  
On	  the	  basis	  of	  the	  crucial	  biochemical	  pathways	  involved	  in	  cardiac	  muscle	  
formation	   during	   embryogenesis	   and	   stem	   cell	   differentiation,	   we	   were	  
able	   to	   identify	   and	   select	   growth	   factors	   and	   cytokines	   that	   were	  more	  
effective	  in	  the	  induction	  cocktail.	  Other	  studies	  have	  identified	  three	  main	  
families	  of	  peptide	  growth	  factors	  that	  are	  essential	  for	  heart	  development	  
and	   speciation:	   the	   bone	   morphogenetic	   proteins	   (BMPs),	   that	   are	  
members	   of	   the	   transforming	   growth	   factors	   β	   superfamily	   (TGF-­‐β),	   the	  
wingless-­‐related	   proteins	   (Wnt)	   and	   the	   fibroblast	   growth	   factors	   (FGFs)	  
(Behfar	   et	   al.,	   2010).	   All	   of	   them	   have	   been	   proven	   to	   be	   of	   similar	  
importance	   in	   the	   mammalian	   heart	   as	   either	   positive	   or	   negative	  
regulators.	   In	   our	   cocktails	   we	   tested	   several	   components	   of	   the	   TGF-­‐
β family	   for	   their	   ability	   to	   promote	   expression	   of	   the	   principal	   cardiac	  
transcription	  factors.	  In	  particular,	  we	  demonstrated	  that	  BMPs	  are	  needed	  
during	   mesodermal	   patterning	   but	   not	   later	   for	   the	   differentiation	   of	  
committed	  precursors.	  The	  combination	  of	  BMP4	  and	  Activin	  A	  induces	  the	  
formation	   of	   primitive	   streak-­‐like	   population	   (Yang	   et	   al.,	   2008)	   and	  
promotes	  mesodermal	  fate	  determination	  (Kattman	  et	  al.,	  2011;	  Teo	  et	  al.,	  
2012).	   Indeed	   extracellular	   inhibitors	   of	   BMP	   and	  Wnts	   are	   the	   principal	  
inducers	   that	   commit	  multipotent	  progenitors	   to	   cardiac	   fate	   (Mercola	   et	  
al.,	   2011;	   Noseda	   et	   al.,	   2011).	   For	   this	   reason	   after	   testing	   16	   different	  
cocktails	   combining	   the	   28	   growth	   factors	   potentially	   involved	   in	  
cardiogenic	   differentiation,	   we	   decided	   to	   produce	   two	   different	  
cardiogenic	  media:	  the	  first	  was	  applied	  for	  10	  days	  to	  allow	  the	  creation	  of	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mesodermal	  patterning	  and	  the	  second	  for	  the	  following	  11	  days	  to	  commit	  
the	  mesodermal	  cells	  into	  cardiac	  fate.	  
It	   was	   also	   important	   to	   investigate	   the	   role	   of	   Wnt	   pathway	   in	   the	  
emergence	   of	   cardiac	   lineage.	   Willens	   and	   co-­‐workers	   (Willems	   et	   al.,	  
2011b)	   identified	   small-­‐molecule	   inhibitor	   of	   b-­‐catenin	   dependent	  
canonical	   Wnt	   pathway	   that	   drove	   ESCs-­‐derived	   mesoderm	   to	   a	   cardiac	  
fate.	   On	   the	   basis	   of	   these	   experiments,	   in	   our	   study	   we	   tested	   several	  
molecules	   and	   we	   observed	   that	   only	   IWR	   was	   able	   to	   switch	   on	   the	  
expression	  of	  the	  principle	  cardiogenic	  factors.	  Cardiogenol	  C	  turned	  out	  to	  
be	   a	   crucial	   component	   of	   our	   cocktail,	   in	   fact	   it	   is	  well	   known	   to	   be	   the	  
most	   potent	   inducer	   of	   MHC	   expression	   (Wu	   et	   al.,	   2004).	   Similarly	   also	  
ascorbic	  acid	  and	  retinoic	  acid,	  a	  derivative	  of	  vitamin	  A,	  have	  been	  shown	  
to	   promote	   cardiomyogenic	   differentiation	   of	   ES	   cells	   (Takahashi	   et	   al.,	  
2003;	  Wobus	  et	  al.,	  1997).	  
The	   presence	   of	   differentiated	   cells	   was	   assessed	   by	   standard	   and	  
quantitative	  RT-­‐PCR	  for	  the	  expression	  of	  cardio-­‐specific	  genes.	  Intriguingly,	  
non-­‐induced	   human	   ASCs	   unexpectedly	   expresses	   some	   of	   the	   cardio-­‐
specific	  transcription	  factors	  (GATA4,	  TBX5	  and	  BAF60C)	  that	  were	  chosen	  
for	   this	   first	   screening	   phase.	   Interestingly,	   a	   recent	   work	   demonstrates	  
that	   a	   combination	   of	   the	   cardiogenic	   transcription	   factors	   GATA4,	   TBX5	  
and	   BAF60C	   can	   reprogram	   and	   drive	   cardiogenesis	   and	   that	   GATA4	   and	  
TBX5	   are	   part	   of	   the	   combination	   that	   directs	   the	   differentiation	   of	  
mesoderm	  into	  cardiomyocytes	  (Turbendian	  et	  al.,	  2013).	  These	  results	  are	  
therefore	   very	   relevant	   because	   they	   suggest	   for	   the	   first	   time	   that,	  
because	  of	   their	  particular	  molecular	  pattern,	   the	  ASCs	  not	  only	  have	   the	  
potential	  but	  are	  inherently	  prone	  to	  differentiate	  into	  cardiac	  precursors.	  	  
Among	   all,	   Cocktail	   no.	   14	  was	   selected,	   because	   of	   its	   ability	   to	   strongly	  
induce	  a	  cardiogenic	  phenotype	  by	  up-­‐regulating	  the	  most	  important	  cardio	  
specific	  genes	   (i.e.	  NKX2-­‐5),	  a	   transcriptional	   factor	  crucial	   for	   the	  general	  
myocardial	   development,	   and	   specifically	   required	   for	   left	   ventricular	  
chamber	   formation.	   Since	   these	   protocols	   are	   ultimately	   aimed	   at	  
producing	  cells	  for	  applications	  in	  humans,	  the	  second	  step	  was	  to	  develop	  
a	   protocol	   compliant	  with	   the	   strict	   European	   regulations	   concerning	   the	  
Advanced	   Therapy	   Medicinal	   Product	   obtaining	   a	   serum-­‐	   and	   xeno-­‐free	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“clinical	  grade”	  culture	  medium.	  For	   this	   reason	  the	   identified	  cardiogenic	  
cocktail	   has	   been	   tested	   without	   the	   addition	   of	   any	   serum	   components	  
but	  with	  5%	  human	  albumin	  instead.	  The	  results	  proved	  that	  Cocktail	  no.	  14	  
with	  human	  albumin	   (patent	  pending)	  was	   capable	  of	  producing	  a	   similar	  
induction	  also	  without	   the	  1%	  horse	   serum	  supplement.	  During	   testing	  of	  
the	  chosen	  cocktail,	  the	  expression	  of	  two	  functional	  genes	  in	  induced	  cells	  
was	   also	   evaluated:	   SERCA-­‐2	   and	   NCX.	   SERCA-­‐2	   or	   sarco/endoplasmic	  
reticulum	   Ca2+-­‐ATPase	   resides	   in	   the	   sarcoplasmic	   reticulum	   (SR)	   within	  
muscle	  cells	  and	   it	   is	  a	  Ca2+-­‐ATPase	  that	  transfers	  Ca2+	   from	  the	  cytosol	  of	  
the	   cell	   to	   the	   lumen	   of	   the	   SR	   at	   the	   expense	   of	   ATP	   hydrolysis	   during	  
muscle	   relaxation	   (Arruda	   et	   al.,	   2007).	   The	   sodium-­‐calcium	   exchanger	  
(NCX)	   is	   instead	   an	   antiporter	  membrane	   protein	   that	   removes	   a	   calcium	  
ion	  from	  the	  cell	   in	  exchange	  for	  the	   import	  of	  three	  sodium	  ions.	   In	   fact,	  
NCX	   is	  considered	  one	  of	   the	  most	   important	  cellular	  mechanisms	   for	   the	  
removal	  of	  Ca2+.	  This	  exchanger	  is	  usually	  found	  in	  the	  plasma	  membrane,	  
mitochondria	   and	   endoplasmatic	   reticulum	   of	   excitable	   cells	   (Dipolo	   and	  
Beaugé,	   2006).	   Both	   genes	   were	   found	   to	   be	   expressed	   exclusively	   in	  
induced	  cells	  further	  underlining	  the	  cardiac	  commitment	  of	  induced	  ASCs.	  	  
After	   completion	   of	   the	   molecular	   analysis,	   we	   focused	   on	   the	  
morphological	  characterization	  of	  differentiated	  ASCs.	  After	  three	  weeks	  of	  
differentiation	   in	   cardiogenic	   cocktail	   the	   cells	   showed	   a	   clear	  
macroscopical	   changes	   in	   their	   morphology	   becoming	   more	   fusiform	   or	  
spindle-­‐like	  and	  were	  arranged	  in	  the	  same	  orientation,	  forming	  an	  ordered	  
array.	   Further	   analysis	   of	   semi-­‐thin	   sections	   of	   non-­‐induced	   ASCs	   stained	  
with	  Crystal	  Violet	  and	  Fuchsin	  showed	  a	  bigger	  shape	  and	  the	  presence	  of	  
autophagosomes,	  whereas	   induced	   cells	   appeared	   smaller	   and	   had	   fewer	  
autophagosomes.	  Transmission	  electron	  microscopy	   (TEM)	  analysis	  at	  day	  
10	   of	   differentiation	   revealed	   the	   presence	   of	   unorganized	   tubular	  
structures	  in	  the	  cell	  cytoplasm	  of	  induced	  cells,	  whereas	  non-­‐induced	  cells	  
displayed	   cytoplasm	   vacuolization	   due	   to	   the	   presence	   of	   numerous	  
autophagosomes.	  Finally,	  the	  presence	  of	  specific	  structural	  and	  functional	  
proteins	   characteristic	   of	   cardiac	   tissue	   (i.e.	   actin,	   cardiac	   actinin	   and	  
myosin	   light	   chain)	   and	  of	   a	   cardiac	   transcription	   factor	   (i.e.	   NKX2-­‐5)	  was	  
assessed	   by	   immunohistochemical	   analysis	   in	   induced	   and	   non-­‐induced	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cells.	  Results	   further	  highlight	  and	  confirm	   the	  differentiation	  potential	  of	  
ASCs.	  	  
In	   conclusion,	   the	   observation	   that	   ASCs	   differentiation	   has	   not	   reached	  
completely	  could	  be	  beneficial	  for	  future	  cell	  therapy	  applications,	  since	  the	  
immature,	  but	  already	  committed	  cells	  might	  better	  survive,	  could	  still	  have	  
the	  capacity	  to	  further	  divide	  and	  be	  influenced	  by	  the	  surroundings	  in	  the	  
recipient	  heart	  (Mummery,	  2007).	  Therefore	   it	  would	  be	  of	  big	   interest	  to	  
test	   the	   survival	   rate	   and	   healing	   potential	   of	   the	   ASCs	   induced	  with	   our	  
serum	  free	  based	  cocktail	  no.	  14	  in	  an	  in	  vivo	  trial.	  
4.3	  Tissue	  engineering	  
Scientific	   studies	   have	   shown	   how	   cell	   therapies	   are	   generally	   hampered	  
and	  limited	  by	  a	  poor	  survival	  of	  the	  injected	  cells.	  In	  fact,	  most	  of	  them	  die	  
after	   grafting	   into	   the	   injured	   heart	   mainly	   for	   hypoxia	   and	   nutrient	  
deprivation.	   The	   generation	   of	   a	   tissue	   with	   complex	   structures	   and	  
functions	   is	   not	   feasible	   by	   simply	   culturing	   the	   cells	   within	   Petri	   dish	  
systems:	   without	   the	   appropriate	   chemo-­‐physical	   stimuli	   and	   a	   3D	  
environment,	  cells	  cannot	  maintain	  their	  shapes,	  phenotypes	  and	  roles	  and	  
lose	   their	   ability	   to	   proliferate	   and	   form	   organized	   tissues.	   As	   already	  
discussed,	  the	  human	  heart	  has	  a	   limited	  capacity	  of	  self-­‐regeneration.	  To	  
investigate	  and	  guide	  cellular	  growth,	  differentiation	  and	   functional	   tissue	  
organization,	   it	   is	   fundamental	   to	  recreate	  environments	   for	   the	  cells	   that	  
mimic	   physiological	   conditions.	   Therefore,	   the	   generation	   of	   a	   3D-­‐
engineered	   cardiac	   scaffold	   to	  be	   implanted	   into	   the	   injured	  myocardium	  
was	  proposed	  as	  a	  more	  suitable	  approach	  than	  the	  direct	  injection	  of	  cells	  
(Geuss	  and	  Suggs,	  2013).	  This	  represents	  a	  challenging	  but	  probably	  also	  an	  
effective	  and	  promising	  therapeutic	  strategy.	  
Therefore,	   the	   last	   important	  milestone	   of	   this	  work	  was	   to	   combine	   the	  
newly	   formulated	   cardiogenic	   cocktail	   to	   mechanical	   and/or	   electrical	  
stimuli.	   It	   is	   a	   common	   belief	   that	   those	   stimuli	   should	   enhance	   the	  
differentiation	  status	  of	  the	  cells	  by	  mimicking	  the	  natural	  niche	  where	  the	  
cells	   are	   located.	   In	   fact,	  mechanical	   stress	   has	   been	  observed	   to	   play	   an	  
important	   role	   in	   determining	   cell	   fate	   during	   embryogenesis	   (Geuss	   and	  
Suggs,	  2013).	  It	  was	  therefore	  interesting	  to	  test	  whether	  the	  combination	  
of	   these	   stimuli	   with	   our	   selected	   cocktail	   would	   further	   enhance	   the	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differentiation	  of	  the	  ASCs.	  To	  achieve	  this,	  a	  device	  was	  developed	  by	  the	  
Swiss	   Stem	   Cell	   Foundation	   in	   collaboration	  with	   the	   Scuola	   Universitaria	  
della	   Svizzera	   Italiana	   (SUPSI)	   for	   the	  application	  of	   controlled	  mechanical	  
and/or	  electrical	  stimuli	  that	  are	  applied	  on	  a	  scaffold	  over	  a	  desired	  lap	  of	  
time.	  The	  scaffold	  was	  prepared	  for	  us	  at	  the	  Politecnico	  di	  Torino	  such	  that	  
it	   closely	   resembled	   the	   morphology	   of	   the	   human	   heart.	   However,	   the	  
proposed	  scaffold	  did	  not	  show	  a	  highly	  organized	  microstructure,	  despite	  
the	   application	   of	   a	   thermal	   gradient	   to	   allow	   the	   pore	   orientation.	   This	  
behavior	  can	  be	  correlated	  to	  the	  concurrent	  effects	  of	  freezing	  conditions	  
and	   the	   concentration	   of	   the	   starting	   DMSO	   solution.	   Such	   result	   is	   in	  
agreement	  with	  the	  data	  reported	  by	  Guan	  and	  co-­‐workers,	  who	  observed	  
that	   if	   the	   polymer	   solution	   concentration	   is	   high,	   the	   viscosity	   of	   the	  
polymer/DMSO	  system	  might	  lead	  to	  slow	  crystal	  growth	  during	  quenching,	  
minimizing	  the	  impact	  of	  the	  transient	  temperature	  gradient	  and	  resulting	  
in	   random	  pore	   structures	   (Guan	  et	  al.,	  2005).	   In	  general,	   a	  good	  scaffold	  
should	   provide	   a	   structured	   environment	   with	   tissue-­‐specific	   mechanical	  
properties	  and	  the	  ability	  to	  integrate	  with	  surrounding	  tissue.	  The	  Torino’s	  
scaffold	  showed	  a	  pore	  size	  ranging	  from	  tens	  to	  hundreds	  of	  microns,	  thus	  
allowing	   both	   cell	   colonization	   and	   vascularization.	   It	   was	   characterized	  
from	   the	   mechanical	   point	   of	   view	   by	   stress-­‐strain	   tests	   in	   dry	   and	   wet	  
conditions	  and	  durability	  tests	  ensuring	  for	  good	  stretch	  properties.	  
The	   concept	   of	   using	   a	   strain	   to	   induce	   differentiation	   is	   based	   on	   the	  
biological	   function	   of	   cardiomyocytes.	   Experimental	   evidences	   underlines	  
the	   importance	   of	   this	   strategy	   for	   cardiogenic	   differentiation:	   cell	  
stretching	   promoted	   the	   elongation	   of	   the	   cell	   membrane	   and	   the	  
rearrangement	   and	   orientation	   of	   actin	   filaments,	   which	   facilitates	   the	  
connections	   made	   between	   cells	   that	   are	   necessary	   to	   promote	  
intracellular	   communication	   (Salameh	   et	   al.,	   2010);	   Vandenburgh	   and	   co-­‐
workers	   showed	   that	   unidirectional	  mechanical	   stretch	   in	   vitro	   initiated	   a	  
number	  of	  morphological	  alterations	  in	  a	  confluent	  cardiomyocyte	  culture,	  
which	   were	   similar	   to	   those	   occurring	   in	   vivo	   during	   the	   heart	   growth	  
(Vandenburgh	   et	   al.,	   1996).	   Other	   experiments	   demonstrated	   that,	  
compared	   to	   unstretched	   controls,	   six	   days	   of	   unidirectional	   stretch	   of	  
engineered	   heart	   tissue	   (made	   out	   from	   neonatal	   rat	   or	   embryonic	   chick	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cardiomyocytes	  mixed	  with	  collagen	   I)	   in	  a	  custom-­‐made	  device	   improved	  
the	   cellular	  organization	  and	   increased	  expression	  of	   the	  atrial	   natriuretic	  
factor	   (ANF)	   and	  α-­‐sarcomeric	   actin	   (Fink	   et	   al.,	   2000).	   Another	   German	  
group	   showed	   that	   after	   seven	   days	   of	   unidirectional	   cyclic	   stretch	   (10%,	  
2Hz),	   the	   engineered	   heart	   tissue	   displayed	   structural	   and	   functional	  
features	   of	   a	   native	   differentiated	   myocardium	   and	   were	   proposed	   as	   a	  
promising	   material	   for	   in	   vitro	   studies	   of	   cardiac	   function	   and	   tissue	  
replacement	   therapy	   (Zimmermann	   et	   al.,	   2006).	   In	   2008,	   Gwak	   and	   co-­‐
workers,	   reported	   that	   cyclic	   mechanical	   strain	   (10%,	   1	   Hz,	   for	   2	   weeks)	  
promotes	  cardiomyogenesis	  in	  mouse	  embryonic	  stem	  cell	  (ESCs)	  as	  shown	  
by	   cardiac-­‐specific	   gene	   expression	   and	   in	   vivo	   tests,	   that	   showed	   a	  
significant	   increase	   of	   grafting	   efficiency	   and	   cardiomyogenic	   potential	   of	  
the	  implanted	  cells	  (Gwak	  et	  al.,	  2008).	  
In	  our	  preliminary	  experiments,	  we	  chose	  to	  apply	  a	  sinusoidal	  (frequency	  1	  
Hz)	   stress	  with	   an	   amplitude	   of	   0.4	   N.	  With	   these	   parameters,	   the	   patch	  
underwent	   a	   cyclic	   deformation	   of	   about	   0.2	  mm	   (i.e.	   1%).	   All	   the	   cyclic	  
deformations	  proposed	   in	  other	  mentioned	  studies	  were	  higher	   than	   that	  
produced	  in	  our	  tests.	  This	  was	  due	  to	  a	  different	  approach	  that	  was	  based	  
on	  mimicking	  the	  physiological	  conditions:	  the	  ASCs	  were	  in	  fact	  subjected	  
to	  a	  mechanical	  force	  that	  is	  equivalent	  to	  the	  diastolic	  strains	  of	  the	  native	  
heart	   as	   described	   by	   Hess	   and	   co-­‐workers	   (Hess	   et	   al.,	   1979).	   The	  
frequency	   of	   1	   Hz	   or	   60	   pulsations	   per	  minutes	   reflects	   the	   usual	   resting	  
heart	   rate.	   Presence	   of	   macroscopic	   damage	   was	   monitored	   during	   our	  
analysis.	  However,	  each	  sample	  underwent	  an	  initial	  deformation	  followed	  
by	  an	  elastic	  behavior.	  These	  results	  can	  be	  correlated	  to	  the	  polymer	  chain	  
reorganization	  upon	  the	  application	  of	  the	  mechanical	  stress.	  In	  fact,	  due	  to	  
the	  viscoelastic	  nature	  of	   the	  polyurethane	  used	   to	   fabricate	   the	  scaffold,	  
when	  a	  cyclic	  stress	   is	  applied,	  polymer	  chains	  tend	  to	  gradually	   lose	  their	  
random	   coil	   configuration	   and	   orient	   themselves	   in	   the	   direction	   of	   the	  
applied	  mechanical	  stress,	  as	  reported	  before	  (Guan	  et	  al.,	  2005).	  
The	   scaffolds	   were	   seeded	   with	   ASCs	   and	   cell	   viability	   was	   assessed	   by	  
Alamar	   Blue	   Assay:	   5	   days	   after	   seeding	   the	   reduction	   in	   Alamar	   Blue	  
staining	  was	   decreased	   by	   only	   10%	   and	   reached	   30%	   by	   the	   end	   of	   the	  
mechanical	  stimulation.	  This	  underlines	  the	  high	  viability	  of	  the	  cells	  within	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the	   scaffold	   after	   the	   stimulation.	   The	   final	   goal	  was	   to	  understand	   if	   the	  
combination	   of	   the	   selected	   cardiac	   induction	   cocktail,	   the	   3D	   scaffold	  
conformation	   and	   the	   mechanical	   stimulation	   would	   enhance	   the	  
expression	   of	   the	   most	   important	   cardiogenic	   transcription	   factors	   if	  
compared	  to	  the	   induction	  with	  cardiogenic	  cocktail	  alone	  on	  a	  simple	  2D	  
culture	   condition.	   Our	   preliminary	   results	   suggest	   that	   indeed	   the	  
combination	  of	  growth	  factors,	  cytokines	  and	  mechanical	  stimulation	  for	  10	  
days	   led	   to	   an	   at	   least	   2	   fold	   increase	   in	   all	   mRNAs	   tested	   (i.e.	   NKX2-­‐5,	  
MEF2C,	  HAND2	  and	  MHC).	  It	  would	  be	  of	  great	  interest	  to	  test	  whether	  the	  
addition	  of	  the	  electrical	  stimuli	  would	  further	  enhance	  these	  effects.	  
	  
Taken	   together	   our	   data	   strongly	   support	   the	   use	   of	   ASCs	   in	   heart	  
regenerative	   medicine	   and	   underline	   their	   intrinsic	   propensity	   to	  
differentiate	   into	   cardiomyocytes.	   Furthermore,	   as	   demonstrated	   by	   the	  
molecular	  analyses,	   the	  entire	  population	  of	  cells	   responded	  to	  our	  newly	  
selected	  cardiogenic	  induction	  cocktail	  at	  the	  level	  of	  specific	  expression	  of	  
cardiac	   transcription	   factors.	   In	   contrast,	   only	   a	   small	   fraction	   of	   cells	  
resulted	   positive	   for	   cardiac	   specific	   structural	   proteins.	   These	   findings	  
therefore	   support	   the	   theory	   that	   the	   heart	   is	   a	   dynamic	   and	   complex	  
organ,	  subjected	  to	  various	  mechanical	  signals,	  such	  as	  those	  produced	  by	  
the	   normal	   contraction	   of	   heart	   muscle.	   These	   mechanical	   signals	   are	  
fundamental	   and	   trigger	   various	   transduction	   pathways	   leading	   to	   gene	  
reprogramming	   and	   enhancing	   synthesis	   of	   specific	   proteins,	   that	  
determine	   the	   final	   cell	   fate.	   For	   this	   reason,	   use	   of	   a	   customized	   device	  
and	   of	   scaffolds	   for	   cell	   seeding,	   become	   of	   crucial	   importance	   for	   tissue	  
engineering:	   it	   is	   a	   more	   suitable	   approach	   that	   provides	   a	   structural	  
environment	  with	   tissue-­‐specific	  mechanical	   properties	   and	   the	   ability	   to	  
integrate	   with	   the	   surrounding	   tissue.	   In	   this	   contest,	   our	   preliminary	  
results	   demonstrate	   that	   the	   mechanical	   stimulation	   increases	   the	  
expression	   of	   cardiac	   genes.	   Further	   research	   should	   first	   confirm	   these	  
results	  and	  then	   investigate	  the	  effect	  caused	  by	  the	  addition	  of	  electrical	  
stimuli.	  The	  final	  aim	  should	  be	  to	  obtain	  functional	  cardiac	  precursors	  in	  a	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